Compositions and methods for oncology precision assays

ABSTRACT

Provided are methods and compositions for preparing a library of target nucleic acid sequences that are useful for assessing gene mutations for oncology biomarker profiling of samples. In particular, a target-specific primer panel is provided that allows for selective amplification of oncology biomarker target sequences in a sample. In one aspect, the invention relates to target-specific primers useful for selective amplification of one or more target sequences associated with oncology biomarkers from two or more sample types. In some aspects, amplified target sequences obtained using the disclosed methods, and compositions can be used in various processes including nucleic acid sequencing and used to detect the presence of genetic variants of one or more targeted sequences associated with oncology.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/948,046, filed Aug. 28, 2020, which claims priority to and the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/894,576, filed Aug. 30, 2019, each of which are incorporated herein by reference in their entirety.

SEQUENCE LISTING

The material in the electronic Sequence Listing is submitted as an XML file entitled 9748-107215-02_Sequence_Listing.xml created on Oct. 6, 2022, which has a file size of 11,734,191 bytes, and is herein incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to compositions and methods of preparing a library of target nucleic acid sequences and uses therefor.

BACKGROUND OF THE INVENTION

Advances in cancer therapies have started to provide promising results across oncology. Targeted therapies, immune checkpoint inhibitors, cancer vaccines and T-cell therapies have shown sustainable results in responsive populations over conventional chemotherapies. However, effective identification of responsive candidates and/or monitoring response has proven challenging. The need of a better understanding of the tumor microenvironment, tumor evolution and drug response biomarkers is immediate. Higher-throughput, systematic and standardized assay solutions that can efficiently and effectively detect multiple relevant biomarkers in a variety of sample types are desirable.

BRIEF SUMMARY OF THE INVENTION

In one aspect of the invention compositions are provided for a single stream multiplex determination of actionable oncology biomarkers in a sample. In some embodiments the composition consists of a plurality of primer reagents directed to a plurality of target sequences to rapidly and effectively detect low level targets in the sample. Provided compositions target oncology gene sequences wherein the plurality of gene sequences are selected from targets among DNA hotspot mutation genes, copy number variation (CNV) genes, inter-genetic fusion genes, and intra-genetic fusion genes. Provided compositions maximize detection of key biomarkers, e.g., EGFR, ALK, BRAF, ROS1, HER2, MET, NTRK, and RET from a variety of samples (e.g., FFPE tissue, plasma) in a single-day in an integrated and automated workflow.

In some embodiments the plurality of actionable target genes in a sample determines a change in oncology activity in the sample indicative of a potential diagnosis, prognosis, candidate therapeutic regimen, and/or adverse event. In particular embodiments, provided compositions include a plurality of primer reagents selected from Table A. In some embodiments a multiplex assay comprising compositions of the invention is provided. In some embodiments a test kit comprising compositions of the invention is provided.

In another aspect of the invention, methods are provided for determining actionable oncology biomarkers in a biological sample. Such methods comprise performing multiplex amplification of a plurality of target sequences from a biological sample containing target sequences. Amplification comprises contacting at least a portion of the sample comprising multiple target sequences of interest using a plurality of target-specific primers in the presence of a polymerase under amplification conditions to produce a plurality of amplified target sequences. The methods further comprise detecting the presence of each of the plurality of target oncology sequences, wherein detection of one or more actionable oncology biomarkers as compared with a control sample determines a change in oncology activity in the sample indicative of a potential diagnosis, prognosis, candidate therapeutic regimen, and/or adverse event. The methods described herein utilize compositions of the invention provided herein. In some embodiments target genes are selected from the group consisting of DNA hotspot mutation genes, copy number variation (CNV) genes, inter-genetic fusion genes, and intra-genetic fusion genes. In certain embodiments target genes are selected from the genes of Table 1. In particular embodiments the target genes consist of the genes of Table 1.

Still further, uses of provided compositions and kits comprising provided compositions for analysis of sequences of the nucleic acid libraries are additional aspects of the invention. In some embodiments, analysis of the sequences of the resulting libraries enables detection of low frequency alleles, improved detection of gene fusions and novel fusions, and/or detection of genetic mutations in a sample of interest and/or multiple samples of interest is provided. In certain embodiments, manual, partially automated and fully automated implementations of uses of provided compositions and methods are contemplated. In a particular embodiment, use of provide compositions is implemented in a fully integrated library preparation, templating and sequencing system for genetic analysis of samples. In certain embodiments, uses of provided compositions and method of the invention provide benefit for research and clinical applications including first line testing of tissue and/or plasma specimens as well as ongoing monitoring of specimens for recurrence and/or resistance detection of biomarkers.

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

Efficient methods for production of targeted libraries encompassing actionable oncology biomarkers from complex samples is desirable for a variety of nucleic acid analyses. The present invention provides, inter alia, methods of preparing libraries of target nucleic acid sequences, allowing for rapid production of highly multiplexed targeted libraries, including unique tag sequences; and resulting library compositions are useful for a variety of applications, including sequencing applications. Provided compositions are designed for the detection of mutations, copy number variations (CNVs), and gene fusions in tissue and plasma derived samples. Provided compositions comprise targeted primer panels and reagents for use in high throughput sample to results next generation workflows for genetic analysis. In particular embodiments, use is implemented on a completely integrated sample to analysis system. Novel features of the invention are set forth with particularity in the appended claims; and a complete understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized.

DESCRIPTION OF THE INVENTION

Section headings used herein are for organizational purposes only and are not to be construed as limiting the described subject matter in any way. All literature and similar materials cited in this application, including but not limited to, patents, patent applications, articles, books, treatises, and internet web pages are expressly incorporated by reference in their entirety for any purpose. When definitions of terms in incorporated references appear to differ from the definitions provided in the present teachings, the definition provided in the present teachings shall control. It will be appreciated that there is an implied “about” prior to the temperatures, concentrations, times, etc discussed in the present teachings, such that slight and insubstantial deviations are within the scope of the present teachings herein. In this application, the use of the singular includes the plural unless specifically stated otherwise. It is noted that, as used in this specification, singular forms “a,” “an,” and “the,” and any singular use of a word, include plural referents unless expressly and unequivocally limited to one referent. Also, the use of “comprise”, “comprises”, “comprising”, “contain”, “contains”, “containing”, “include”, “includes”, and “including” are not intended to be limiting. It is to be understood that both the general description is exemplary and explanatory only and not restrictive of the invention.

Unless otherwise defined, scientific and technical terms used in connection with the invention described herein shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligo- or polynucleotide chemistry and hybridization used herein are those well-known and commonly used in the art. The practice of the present subject matter may employ, unless otherwise indicated, conventional techniques and descriptions of organic chemistry, molecular biology (including recombinant techniques), cell biology, and biochemistry, which are within the skill of the art. Such conventional techniques include, but are not limited to, preparation of synthetic polynucleotides, polymerization techniques, chemical and physical analysis of polymer particles, preparation of nucleic acid libraries, nucleic acid sequencing and analysis, and the like. Specific illustrations of suitable techniques can be used by reference to the examples provided herein. Other equivalent conventional procedures can also be used. Such conventional techniques and descriptions can be found in standard laboratory manuals such as Genome Analysis: A Laboratory Manual Series (Vols. I-IV), PCR Primer: A Laboratory Manual, and Molecular Cloning: A Laboratory Manual (all from Cold Spring Harbor Laboratory Press), Hermanson, Bioconjugate Techniques, Second Edition (Academic Press, 2008); Merkus, Particle Size Measurements (Springer, 2009); Rubinstein and Colby, Polymer Physics (Oxford University Press, 2003); and the like. As utilized in accordance with embodiments provided herein, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

As used herein, “amplify”, “amplifying” or “amplification reaction” and their derivatives, refer generally to an action or process whereby at least a portion of a nucleic acid molecule (referred to as a template nucleic acid molecule) is replicated or copied into at least one additional nucleic acid molecule. The additional nucleic acid molecule optionally includes sequence that is substantially identical or substantially complementary to at least some portion of the template nucleic acid molecule. A template target nucleic acid molecule may be single-stranded or double-stranded. The additional resulting replicated nucleic acid molecule may independently be single-stranded or double-stranded. In some embodiments, amplification includes a template-dependent in vitro enzyme-catalyzed reaction for the production of at least one copy of at least some portion of a target nucleic acid molecule or the production of at least one copy of a target nucleic acid sequence that is complementary to at least some portion of a target nucleic acid molecule. Amplification optionally includes linear or exponential replication of a nucleic acid molecule. In some embodiments, such amplification is performed using isothermal conditions; in other embodiments, such amplification can include thermocycling. In some embodiments, the amplification is a multiplex amplification that includes simultaneous amplification of a plurality of target sequences in a single amplification reaction. At least some target sequences can be situated on the same nucleic acid molecule or on different target nucleic acid molecules included in a single amplification reaction. In some embodiments, “amplification” includes amplification of at least some portion of DNA- and/or RNA-based nucleic acids, whether alone, or in combination. An amplification reaction can include single or double-stranded nucleic acid substrates and can further include any amplification processes known to one of ordinary skill in the art. In some embodiments, an amplification reaction includes polymerase chain reaction (PCR). In some embodiments, an amplification reaction includes isothermal amplification.

As used herein, “amplification conditions” and derivatives (e.g., conditions for amplification, etc.) generally refers to conditions suitable for amplifying one or more nucleic acid sequences. Amplification can be linear or exponential. In some embodiments, amplification conditions include isothermal conditions or alternatively include thermocyling conditions, or a combination of isothermal and themocycling conditions. In some embodiments, conditions suitable for amplifying one or more target nucleic acid sequences includes polymerase chain reaction (PCR) conditions. Typically, amplification conditions refer to a reaction mixture that is sufficient to amplify nucleic acids such as one or more target sequences, or to amplify an amplified target sequence ligated to one or more adaptors, e.g., an adaptor-ligated amplified target sequence. Generally, amplification conditions include a catalyst for amplification or for nucleic acid synthesis, for example a polymerase; a primer that possesses some degree of complementarity to the nucleic acid to be amplified; and nucleotides, such as deoxyribonucleoside triphosphates (dNTPs) to promote extension of a primer once hybridized to a nucleic acid. Amplification conditions can require hybridization or annealing of a primer to a nucleic acid, extension of the primer and a denaturing step in which the extended primer is separated from the nucleic acid sequence undergoing amplification. Typically, though not necessarily, amplification conditions can include thermocycling. In some embodiments, amplification conditions include a plurality of cycles wherein steps of annealing, extending and separating are repeated. Typically, amplification conditions include cations such as Mg⁺⁺ or Mn⁺⁺ (e.g., MgCl₂, etc.) and can also optionally include various modifiers of ionic strength.

As used herein, “target sequence” “target nucleic acid sequence” or “target sequence of interest” and derivatives, refers generally to any single or double-stranded nucleic acid sequence that can be amplified or synthesized according to the disclosure, including any nucleic acid sequence suspected or expected to be present in a sample. In some embodiments, the target sequence is present in double-stranded form and includes at least a portion of the particular nucleotide sequence to be amplified or synthesized, or its complement, prior to the addition of target-specific primers or appended adaptors. Target sequences can include the nucleic acids to which primers useful in the amplification or synthesis reaction can hybridize prior to extension by a polymerase. In some embodiments, the term refers to a nucleic acid sequence whose sequence identity, ordering or location of nucleotides is determined by one or more of the methods of the disclosure.

The term “portion” and its variants, as used herein, when used in reference to a given nucleic acid molecule, for example a primer or a template nucleic acid molecule, comprises any number of contiguous nucleotides within the length of the nucleic acid molecule, including the partial or entire length of the nucleic acid molecule.

As used herein, “contacting” and its derivatives, when used in reference to two or more components, refers generally to any process whereby the approach, proximity, mixture or commingling of the referenced components is promoted or achieved without necessarily requiring physical contact of such components, and includes mixing of solutions containing any one or more of the referenced components with each other. The referenced components may be contacted in any particular order or combination and the particular order of recitation of components is not limiting. For example, “contacting A with B and C” encompasses embodiments where A is first contacted with B then C, as well as embodiments where C is contacted with A then B, as well as embodiments where a mixture of A and C is contacted with B, and the like. Furthermore, such contacting does not necessarily require that the end result of the contacting process be a mixture including all of the referenced components, as long as at some point during the contacting process all of the referenced components are simultaneously present or simultaneously included in the same mixture or solution. For example, “contacting A with B and C” can include embodiments wherein C is first contacted with A to form a first mixture, which first mixture is then contacted with B to form a second mixture, following which C is removed from the second mixture; optionally A can then also be removed, leaving only B. Where one or more of the referenced components to be contacted includes a plurality (e.g., “contacting a target sequence with a plurality of target-specific primers and a polymerase”), then each member of the plurality can be viewed as an individual component of the contacting process, such that the contacting can include contacting of any one or more members of the plurality with any other member of the plurality and/or with any other referenced component (e.g., some but not all of the plurality of target specific primers can be contacted with a target sequence, then a polymerase, and then with other members of the plurality of target-specific primers) in any order or combination.

As used herein, the term “primer” and its derivatives refer generally to any polynucleotide that can hybridize to a target sequence of interest. In some embodiments, the primer can also serve to prime nucleic acid synthesis. Typically, a primer functions as a substrate onto which nucleotides can be polymerized by a polymerase; in some embodiments, however, a primer can become incorporated into a synthesized nucleic acid strand and provide a site to which another primer can hybridize to prime synthesis of a new strand that is complementary to the synthesized nucleic acid molecule. A primer may be comprised of any combination of nucleotides or analogs thereof, which may be optionally linked to form a linear polymer of any suitable length. In some embodiments, a primer is a single-stranded oligonucleotide or polynucleotide. (For purposes of this disclosure, the terms ‘polynucleotide” and “oligonucleotide” are used interchangeably herein and do not necessarily indicate any difference in length between the two). In some embodiments, a primer is double-stranded. If double stranded, a primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. A primer must be sufficiently long to prime the synthesis of extension products. Lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method. In some embodiments, a primer acts as a point of initiation for amplification or synthesis when exposed to amplification or synthesis conditions; such amplification or synthesis can occur in a template-dependent fashion and optionally results in formation of a primer extension product that is complementary to at least a portion of the target sequence. Exemplary amplification or synthesis conditions can include contacting the primer with a polynucleotide template (e.g., a template including a target sequence), nucleotides and an inducing agent such as a polymerase at a suitable temperature and pH to induce polymerization of nucleotides onto an end of the target-specific primer. If double-stranded, the primer can optionally be treated to separate its strands before being used to prepare primer extension products. In some embodiments, the primer is an oligodeoxyribonucleotide or an oligoribonucleotide. In some embodiments, the primer can include one or more nucleotide analogs. The exact length and/or composition, including sequence, of the target-specific primer can influence many properties, including melting temperature (Tm), GC content, formation of secondary structures, repeat nucleotide motifs, length of predicted primer extension products, extent of coverage across a nucleic acid molecule of interest, number of primers present in a single amplification or synthesis reaction, presence of nucleotide analogs or modified nucleotides within the primers, and the like. In some embodiments, a primer can be paired with a compatible primer within an amplification or synthesis reaction to form a primer pair consisting or a forward primer and a reverse primer. In some embodiments, the forward primer of the primer pair includes a sequence that is substantially complementary to at least a portion of a strand of a nucleic acid molecule, and the reverse primer of the primer of the primer pair includes a sequence that is substantially identical to at least of portion of the strand. In some embodiments, the forward primer and the reverse primer are capable of hybridizing to opposite strands of a nucleic acid duplex. Optionally, the forward primer primes synthesis of a first nucleic acid strand, and the reverse primer primes synthesis of a second nucleic acid strand, wherein the first and second strands are substantially complementary to each other, or can hybridize to form a double-stranded nucleic acid molecule. In some embodiments, one end of an amplification or synthesis product is defined by the forward primer and the other end of the amplification or synthesis product is defined by the reverse primer. In some embodiments, where the amplification or synthesis of lengthy primer extension products is required, such as amplifying an exon, coding region, or gene, several primer pairs can be created than span the desired length to enable sufficient amplification of the region. In some embodiments, a primer can include one or more cleavable groups. In some embodiments, primer lengths are in the range of about 10 to about 60 nucleotides, about 12 to about 50 nucleotides and about 15 to about 40 nucleotides in length. Typically, a primer is capable of hybridizing to a corresponding target sequence and undergoing primer extension when exposed to amplification conditions in the presence of dNTPS and a polymerase. In some instances, the particular nucleotide sequence or a portion of the primer is known at the outset of the amplification reaction or can be determined by one or more of the methods disclosed herein. In some embodiments, the primer includes one or more cleavable groups at one or more locations within the primer.

As used herein, “target-specific primer” and its derivatives, refers generally to a single stranded or double-stranded polynucleotide, typically an oligonucleotide, that includes at least one sequence that is at least 50% complementary, typically at least 75% complementary or at least 85% complementary, more typically at least 90% complementary, more typically at least 95% complementary, more typically at least 98% or at least 99% complementary, or identical, to at least a portion of a nucleic acid molecule that includes a target sequence. In such instances, the target-specific primer and target sequence are described as “corresponding” to each other. In some embodiments, the target-specific primer is capable of hybridizing to at least a portion of its corresponding target sequence (or to a complement of the target sequence); such hybridization can optionally be performed under standard hybridization conditions or under stringent hybridization conditions. In some embodiments, the target-specific primer is not capable of hybridizing to the target sequence, or to its complement, but is capable of hybridizing to a portion of a nucleic acid strand including the target sequence, or to its complement. In some embodiments, the target-specific primer includes at least one sequence that is at least 75% complementary, typically at least 85% complementary, more typically at least 90% complementary, more typically at least 95% complementary, more typically at least 98% complementary, or more typically at least 99% complementary, to at least a portion of the target sequence itself; in other embodiments, the target-specific primer includes at least one sequence that is at least 75% complementary, typically at least 85% complementary, more typically at least 90% complementary, more typically at least 95% complementary, more typically at least 98% complementary, or more typically at least 99% complementary, to at least a portion of the nucleic acid molecule other than the target sequence. In some embodiments, the target-specific primer is substantially non-complementary to other target sequences present in the sample; optionally, the target-specific primer is substantially non-complementary to other nucleic acid molecules present in the sample. In some embodiments, nucleic acid molecules present in the sample that do not include or correspond to a target sequence (or to a complement of the target sequence) are referred to as “non-specific” sequences or “non-specific nucleic acids”. In some embodiments, the target-specific primer is designed to include a nucleotide sequence that is substantially complementary to at least a portion of its corresponding target sequence. In some embodiments, a target-specific primer is at least 95% complementary, or at least 99% complementary, or identical, across its entire length to at least a portion of a nucleic acid molecule that includes its corresponding target sequence. In some embodiments, a target-specific primer can be at least 90%, at least 95% complementary, at least 98% complementary or at least 99% complementary, or identical, across its entire length to at least a portion of its corresponding target sequence. In some embodiments, a forward target-specific primer and a reverse target-specific primer define a target-specific primer pair that can be used to amplify the target sequence via template-dependent primer extension. Typically, each primer of a target-specific primer pair includes at least one sequence that is substantially complementary to at least a portion of a nucleic acid molecule including a corresponding target sequence but that is less than 50% complementary to at least one other target sequence in the sample. In some embodiments, amplification can be performed using multiple target-specific primer pairs in a single amplification reaction, wherein each primer pair includes a forward target-specific primer and a reverse target-specific primer, each including at least one sequence that substantially complementary or substantially identical to a corresponding target sequence in the sample, and each primer pair having a different corresponding target sequence. In some embodiments, the target-specific primer can be substantially non-complementary at its 3′ end or its 5′ end to any other target-specific primer present in an amplification reaction. In some embodiments, the target-specific primer can include minimal cross hybridization to other target-specific primers in the amplification reaction. In some embodiments, target-specific primers include minimal cross-hybridization to non-specific sequences in the amplification reaction mixture. In some embodiments, the target-specific primers include minimal self-complementarity. In some embodiments, the target-specific primers can include one or more cleavable groups located at the 3′ end. In some embodiments, the target-specific primers can include one or more cleavable groups located near or about a central nucleotide of the target-specific primer. In some embodiments, one of more targets-specific primers includes only non-cleavable nucleotides at the 5′ end of the target-specific primer. In some embodiments, a target specific primer includes minimal nucleotide sequence overlap at the 3′end or the 5′ end of the primer as compared to one or more different target-specific primers, optionally in the same amplification reaction. In some embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, target-specific primers in a single reaction mixture include one or more of the above embodiments. In some embodiments, substantially all of the plurality of target-specific primers in a single reaction mixture includes one or more of the above embodiments.

As used herein, the term “adaptor” denotes a nucleic acid molecule that can be used for manipulation of a polynucleotide of interest. In some embodiments, adaptors are used for amplification of one or more target nucleic acids. In some embodiments, the adaptors are used in reactions for sequencing. In some embodiments, an adaptor has one or more ends that lack a 5′ phosphate residue. In some embodiments, an adaptor comprises, consists of, or consist essentially of at least one priming site. Such priming site containing adaptors can be referred to as “primer” adaptors. In some embodiments, the adaptor priming site can be useful in PCR processes. In some embodiments an adaptor includes a nucleic acid sequence that is substantially complementary to the 3′ end or the 5′ end of at least one target sequences within the sample, referred to herein as a gene specific target sequence, a target specific sequence, or target specific primer. In some embodiments, the adaptor includes nucleic acid sequence that is substantially non-complementary to the 3′ end or the 5′ end of any target sequence present in the sample. In some embodiments, the adaptor includes single stranded or double-stranded linear oligonucleotide that is not substantially complementary to an target nucleic acid sequence. In some embodiments, the adaptor includes nucleic acid sequence that is substantially non-complementary to at least one, and preferably some or all of the nucleic acid molecules of the sample. In some embodiments, suitable adaptor lengths are in the range of about 10-75 nucleotides, about 12-50 nucleotides and about 15-40 nucleotides in length. Generally, an adaptor can include any combination of nucleotides and/or nucleic acids. In some aspects, adaptors include one or more cleavable groups at one or more locations. In some embodiments, the adaptor includes sequence that is substantially identical, or substantially complementary, to at least a portion of a primer, for example a universal primer. In some embodiments, adaptors include a tag sequence to assist with cataloguing, identification or sequencing. In some embodiments, an adaptor acts as a substrate for amplification of a target sequence, particularly in the presence of a polymerase and dNTPs under suitable temperature and pH.

As used herein, “polymerase” and its derivatives, generally refers to any enzyme that can catalyze the polymerization of nucleotides (including analogs thereof) into a nucleic acid strand. Typically but not necessarily, such nucleotide polymerization can occur in a template-dependent fashion. Such polymerases can include without limitation naturally occurring polymerases and any subunits and truncations thereof, mutant polymerases, variant polymerases, recombinant, fusion or otherwise engineered polymerases, chemically modified polymerases, synthetic molecules or assemblies, and any analogs, derivatives or fragments thereof that retain the ability to catalyze such polymerization. Optionally, the polymerase can be a mutant polymerase comprising one or more mutations involving the replacement of one or more amino acids with other amino acids, the insertion or deletion of one or more amino acids from the polymerase, or the linkage of parts of two or more polymerases. Typically, the polymerase comprises one or more active sites at which nucleotide binding and/or catalysis of nucleotide polymerization can occur. Some exemplary polymerases include without limitation DNA polymerases and RNA polymerases. The term “polymerase” and its variants, as used herein, also refers to fusion proteins comprising at least two portions linked to each other, where the first portion comprises a peptide that can catalyze the polymerization of nucleotides into a nucleic acid strand and is linked to a second portion that comprises a second polypeptide. In some embodiments, the second polypeptide can include a reporter enzyme or a processivity-enhancing domain. Optionally, the polymerase can possess 5′ exonuclease activity or terminal transferase activity. In some embodiments, the polymerase can be optionally reactivated, for example through the use of heat, chemicals or re-addition of new amounts of polymerase into a reaction mixture. In some embodiments, the polymerase can include a hot-start polymerase and/or an aptamer based polymerase that optionally can be reactivated.

The terms “identity” and “identical” and their variants, as used herein, when used in reference to two or more nucleic acid sequences, refer to similarity in sequence of the two or more sequences (e.g., nucleotide or polypeptide sequences). In the context of two or more homologous sequences, the percent identity or homology of the sequences or subsequences thereof indicates the percentage of all monomeric units (e.g., nucleotides or amino acids) that are the same (i.e., about 70% identity, preferably 75%, 80%, 85%, 90%, 95%, 98% or 99% identity). The percent identity can be over a specified region, when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection. Sequences are said to be “substantially identical” when there is at least 85% identity at the amino acid level or at the nucleotide level. Preferably, the identity exists over a region that is at least about 25, 50, or 100 residues in length, or across the entire length of at least one compared sequence. A typical algorithm for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al, Nuc. Acids Res. 25:3389-3402 (1977). Other methods include the algorithms of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), and Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), etc. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent hybridization conditions.

The terms “complementary” and “complement” and their variants, as used herein, refer to any two or more nucleic acid sequences (e.g., portions or entireties of template nucleic acid molecules, target sequences and/or primers) that can undergo cumulative base pairing at two or more individual corresponding positions in antiparallel orientation, as in a hybridized duplex. Such base pairing can proceed according to any set of established rules, for example according to Watson-Crick base pairing rules or according to some other base pairing paradigm. Optionally there can be “complete” or “total” complementarity between a first and second nucleic acid sequence where each nucleotide in the first nucleic acid sequence can undergo a stabilizing base pairing interaction with a nucleotide in the corresponding antiparallel position on the second nucleic acid sequence. “Partial” complementarity describes nucleic acid sequences in which at least 20%, but less than 100%, of the residues of one nucleic acid sequence are complementary to residues in the other nucleic acid sequence. In some embodiments, at least 50%, but less than 100%, of the residues of one nucleic acid sequence are complementary to residues in the other nucleic acid sequence. In some embodiments, at least 70%, 80%, 90%, 95% or 98%, but less than 100%, of the residues of one nucleic acid sequence are complementary to residues in the other nucleic acid sequence. Sequences are said to be “substantially complementary” when at least 85% of the residues of one nucleic acid sequence are complementary to residues in the other nucleic acid sequence. In some embodiments, two complementary or substantially complementary sequences are capable of hybridizing to each other under standard or stringent hybridization conditions. “Non-complementary” describes nucleic acid sequences in which less than 20% of the residues of one nucleic acid sequence are complementary to residues in the other nucleic acid sequence. Sequences are said to be “substantially non-complementary” when less than 15% of the residues of one nucleic acid sequence are complementary to residues in the other nucleic acid sequence. In some embodiments, two non-complementary or substantially non-complementary sequences cannot hybridize to each other under standard or stringent hybridization conditions. A “mismatch” is present at any position in the two opposed nucleotides are not complementary. Complementary nucleotides include nucleotides that are efficiently incorporated by DNA polymerases opposite each other during DNA replication under physiological conditions. In a typical embodiment, complementary nucleotides can form base pairs with each other, such as the A-T/U and G-C base pairs formed through specific Watson-Crick type hydrogen bonding, or base pairs formed through some other type of base pairing paradigm, between the nucleobases of nucleotides and/or polynucleotides in positions antiparallel to each other. The complementarity of other artificial base pairs can be based on other types of hydrogen bonding and/or hydrophobicity of bases and/or shape complementarity between bases.

As used herein, “amplified target sequences” and its derivatives, refers generally to a nucleic acid sequence produced by the amplification of/amplifying the target sequences using target-specific primers and the methods provided herein. The amplified target sequences may be either of the same sense (the positive strand produced in the second round and subsequent even-numbered rounds of amplification) or antisense (i.e., the negative strand produced during the first and subsequent odd-numbered rounds of amplification) with respect to the target sequences. For the purposes of this disclosure, amplified target sequences are typically less than 50% complementary to any portion of another amplified target sequence in the reaction.

As used herein, terms “ligating”, “ligation” and derivatives refer generally to the act or process for covalently linking two or more molecules together, for example, covalently linking two or more nucleic acid molecules to each other. In some embodiments, ligation includes joining nicks between adjacent nucleotides of nucleic acids. In some embodiments, ligation includes forming a covalent bond between an end of a first and an end of a second nucleic acid molecule. In some embodiments, for example embodiments wherein the nucleic acid molecules to be ligated include conventional nucleotide residues, the ligation can include forming a covalent bond between a 5′ phosphate group of one nucleic acid and a 3′ hydroxyl group of a second nucleic acid thereby forming a ligated nucleic acid molecule. In some embodiments, any means for joining nicks or bonding a 5′phosphate to a 3′ hydroxyl between adjacent nucleotides can be employed. In an exemplary embodiment, an enzyme such as a ligase can be used.

As used herein, “ligase” and its derivatives, refers generally to any agent capable of catalyzing the ligation of two substrate molecules. In some embodiments, the ligase includes an enzyme capable of catalyzing the joining of nicks between adjacent nucleotides of a nucleic acid. In some embodiments, a ligase includes an enzyme capable of catalyzing the formation of a covalent bond between a 5′ phosphate of one nucleic acid molecule to a 3′ hydroxyl of another nucleic acid molecule thereby forming a ligated nucleic acid molecule. Suitable ligases may include, but not limited to, T4 DNA ligase; T7 DNA ligase; Taq DNA ligase, and E. coli DNA ligase.

As defined herein, a “cleavable group” generally refers to any moiety that once incorporated into a nucleic acid can be cleaved under appropriate conditions. For example, a cleavable group can be incorporated into a target-specific primer, an amplified sequence, an adaptor or a nucleic acid molecule of the sample. In an exemplary embodiment, a target-specific primer can include a cleavable group that becomes incorporated into the amplified product and is subsequently cleaved after amplification, thereby removing a portion, or all, of the target-specific primer from the amplified product. The cleavable group can be cleaved or otherwise removed from a target-specific primer, an amplified sequence, an adaptor or a nucleic acid molecule of the sample by any acceptable means. For example, a cleavable group can be removed from a target-specific primer, an amplified sequence, an adaptor or a nucleic acid molecule of the sample by enzymatic, thermal, photo-oxidative or chemical treatment. In one aspect, a cleavable group can include a nucleobase that is not naturally occurring. For example, an oligodeoxyribonucleotide can include one or more RNA nucleobases, such as uracil that can be removed by a uracil glycosylase. In some embodiments, a cleavable group can include one or more modified nucleobases (such as 7-methylguanine, 8-oxo-guanine, xanthine, hypoxanthine, 5,6-dihydrouracil or 5-methylcytosine) or one or more modified nucleosides (i.e., 7-methylguanosine, 8-oxo-deoxyguanosine, xanthosine, inosine, dihydrouridine or 5-methylcytidine). The modified nucleobases or nucleotides can be removed from the nucleic acid by enzymatic, chemical or thermal means. In one embodiment, a cleavable group can include a moiety that can be removed from a primer after amplification (or synthesis) upon exposure to ultraviolet light (i.e., bromodeoxyuridine). In another embodiment, a cleavable group can include methylated cytosine. Typically, methylated cytosine can be cleaved from a primer for example, after induction of amplification (or synthesis), upon sodium bisulfite treatment. In some embodiments, a cleavable moiety can include a restriction site. For example, a primer or target sequence can include a nucleic acid sequence that is specific to one or more restriction enzymes, and following amplification (or synthesis), the primer or target sequence can be treated with the one or more restriction enzymes such that the cleavable group is removed. Typically, one or more cleavable groups can be included at one or more locations with a target-specific primer, an amplified sequence, an adaptor or a nucleic acid molecule of the sample.

As used herein, “digestion”, “digestion step” and its derivatives, generally refers to any process by which a cleavable group is cleaved or otherwise removed from a target-specific primer, an amplified sequence, an adaptor or a nucleic acid molecule of the sample. In some embodiments, the digestion step involves a chemical, thermal, photo-oxidative or digestive process.

As used herein, the term “hybridization” is consistent with its use in the art, and generally refers to the process whereby two nucleic acid molecules undergo base pairing interactions. Two nucleic acid molecule molecules are said to be hybridized when any portion of one nucleic acid molecule is base paired with any portion of the other nucleic acid molecule; it is not necessarily required that the two nucleic acid molecules be hybridized across their entire respective lengths and in some embodiments, at least one of the nucleic acid molecules can include portions that are not hybridized to the other nucleic acid molecule. The phrase “hybridizing under stringent conditions” and its variants refers generally to conditions under which hybridization of a target-specific primer to a target sequence occurs in the presence of high hybridization temperature and low ionic strength. As used herein, the phrase “standard hybridization conditions” and its variants refers generally to conditions under which hybridization of a primer to an oligonucleotide (i.e., a target sequence), occurs in the presence of low hybridization temperature and high ionic strength. In one exemplary embodiment, standard hybridization conditions include an aqueous environment containing about 100 mm magnesium sulfate, about 500 mM Tris-sulfate at pH 8.9, and about 200 mM ammonium sulfate at about 50-55° C., or equivalents thereof.

As used herein, the term “end” and its variants, when used in reference to a nucleic acid molecule, for example a target sequence or amplified target sequence, can include the terminal 30 nucleotides, the terminal 20 and even more typically the terminal 15 nucleotides of the nucleic acid molecule. A linear nucleic acid molecule comprised of linked series of contiguous nucleotides typically includes at least two ends. In some embodiments, one end of the nucleic acid molecule can include a 3′ hydroxyl group or its equivalent, and can be referred to as the “3′ end” and its derivatives. Optionally, the 3′ end includes a 3′ hydroxyl group that is not linked to a 5′ phosphate group of a mononucleotide pentose ring. Typically, the 3′ end includes one or more 5′ linked nucleotides located adjacent to the nucleotide including the unlinked 3′ hydroxyl group, typically the 30 nucleotides located adjacent to the 3′ hydroxyl, typically the terminal 20 and even more typically the terminal 15 nucleotides. Generally, the one or more linked nucleotides can be represented as a percentage of the nucleotides present in the oligonucleotide or can be provided as a number of linked nucleotides adjacent to the unlinked 3′ hydroxyl. For example, the 3′ end can include less than 50% of the nucleotide length of the oligonucleotide. In some embodiments, the 3′ end does not include any unlinked 3′ hydroxyl group but can include any moiety capable of serving as a site for attachment of nucleotides via primer extension and/or nucleotide polymerization. In some embodiments, the term “3′ end” for example when referring to a target-specific primer, can include the terminal 10 nucleotides, the terminal 5 nucleotides, the terminal 4, 3, 2 or fewer nucleotides at the 3′end. In some embodiments, the term “3′ end” when referring to a target-specific primer can include nucleotides located at nucleotide positions 10 or fewer from the 3′ terminus. As used herein, “5′ end”, and its derivatives, generally refers to an end of a nucleic acid molecule, for example a target sequence or amplified target sequence, which includes a free 5′ phosphate group or its equivalent. In some embodiments, the 5′ end includes a 5′ phosphate group that is not linked to a 3′ hydroxyl of a neighboring mononucleotide pentose ring. Typically, the 5′ end includes to one or more linked nucleotides located adjacent to the 5′ phosphate, typically the 30 nucleotides located adjacent to the nucleotide including the 5′ phosphate group, typically the terminal 20 and even more typically the terminal 15 nucleotides. Generally, the one or more linked nucleotides can be represented as a percentage of the nucleotides present in the oligonucleotide or can be provided as a number of linked nucleotides adjacent to the 5′ phosphate. For example, the 5′ end can be less than 50% of the nucleotide length of an oligonucleotide. In another exemplary embodiment, the 5′ end can include about 15 nucleotides adjacent to the nucleotide including the terminal 5′ phosphate. In some embodiments, the 5′ end does not include any unlinked 5′ phosphate group but can include any moiety capable of serving as a site of attachment to a 3′ hydroxyl group, or to the 3′end of another nucleic acid molecule. In some embodiments, the term “5′ end” for example when referring to a target-specific primer, can include the terminal 10 nucleotides, the terminal 5 nucleotides, the terminal 4, 3, 2 or fewer nucleotides at the 5′end. In some embodiments, the term “5′ end” when referring to a target-specific primer can include nucleotides located at positions 10 or fewer from the 5′ terminus. In some embodiments, the 5′ end of a target-specific primer can include only non-cleavable nucleotides, for example nucleotides that do not contain one or more cleavable groups as disclosed herein, or a cleavable nucleotide as would be readily determined by one of ordinary skill in the art. A “first end” and a “second end” of a polynucleotide refer to the 5′ end or the 3′end of the polynucleotide. Either the first end or second end of a polynucleotide can be the 5′ end or the 3′ end of the polynucleotide; the terms “first” and “second” are not meant to denote that the end is specifically the 5′ end or the 3′ end.

As used herein “tag,” “barcode,” “unique tag” or “tag sequence” and its derivatives, refers generally to a unique short (6-14 nucleotide) nucleic acid sequence within an adaptor or primer that can act as a ‘key’ to distinguish or separate a plurality of amplified target sequences in a sample. For the purposes of this disclosure, a barcode or unique tag sequence is incorporated into the nucleotide sequence of an adaptor or primer. As used herein, “barcode sequence” denotes a nucleic acid fixed sequence that is sufficient to allow for the identification of a sample or source of nucleic acid sequences of interest. A barcode sequence can be, but need not be, a small section of the original nucleic acid sequence on which the identification is to be based. In some embodiments a barcode is 5-20 nucleic acids long. In some embodiments, the barcode is comprised of analog nucleotides, such as L-DNA, LNA, PNA, etc. As used herein, “unique tag sequence” denotes a nucleic acid sequence having at least one random sequence and at least one fixed sequence. A unique tag sequence, alone or in conjunction with a second unique tag sequence, is sufficient to allow for the identification of a single target nucleic acid molecule in a sample. A unique tag sequence can, but need not, comprise a small section of the original target nucleic acid sequence. In some embodiments a unique tag sequence is 2-50 nucleotides or base-pairs, or 2-25 nucleotides or base-pairs, or 2-10 nucleotides or base-pairs in length. A unique tag sequence can comprise at least one random sequence interspersed with a fixed sequence.

As used herein, “comparable maximal minimum melting temperatures” and its derivatives, refers generally to the melting temperature (Tm) of each nucleic acid fragment for a single adaptor or target-specific primer after digestion of a cleavable groups. The hybridization temperature of each nucleic acid fragment generated by an adaptor or target-specific primer is compared to determine the maximal minimum temperature required preventing hybridization of a nucleic acid sequence from the target-specific primer or adaptor or fragment or portion thereof to a respective target sequence. Once the maximal hybridization temperature is known, it is possible to manipulate the adaptor or target-specific primer, for example by moving the location of one or more cleavable group(s) along the length of the primer, to achieve a comparable maximal minimum melting temperature with respect to each nucleic acid fragment to thereby optimize digestion and repair steps of library preparation.

As used herein, “addition only” and its derivatives, refers generally to a series of steps in which reagents and components are added to a first or single reaction mixture. Typically, the series of steps excludes the removal of the reaction mixture from a first vessel to a second vessel in order to complete the series of steps. Generally, an addition only process excludes the manipulation of the reaction mixture outside the vessel containing the reaction mixture. Typically, an addition-only process is amenable to automation and high-throughput.

As used herein, “polymerizing conditions” and its derivatives, refers generally to conditions suitable for nucleotide polymerization. In typical embodiments, such nucleotide polymerization is catalyzed by a polymerase. In some embodiments, polymerizing conditions include conditions for primer extension, optionally in a template-dependent manner, resulting in the generation of a synthesized nucleic acid sequence. In some embodiments, the polymerizing conditions include polymerase chain reaction (PCR). Typically, the polymerizing conditions include use of a reaction mixture that is sufficient to synthesize nucleic acids and includes a polymerase and nucleotides. The polymerizing conditions can include conditions for annealing of a target-specific primer to a target sequence and extension of the primer in a template dependent manner in the presence of a polymerase. In some embodiments, polymerizing conditions can be practiced using thermocycling. Additionally, polymerizing conditions can include a plurality of cycles where the steps of annealing, extending, and separating the two nucleic strands are repeated. Typically, the polymerizing conditions include a cation such as MgCl₂. Generally, polymerization of one or more nucleotides to form a nucleic acid strand includes that the nucleotides be linked to each other via phosphodiester bonds, however, alternative linkages may be possible in the context of particular nucleotide analogs.

As used herein, the term “nucleic acid” refers to natural nucleic acids, artificial nucleic acids, analogs thereof, or combinations thereof, including polynucleotides and oligonucleotides. As used herein, the terms “polynucleotide” and “oligonucleotide” are used interchangeably and mean single-stranded and double-stranded polymers of nucleotides including, but not limited to, 2′-deoxyribonucleotides (nucleic acid) and ribonucleotides (RNA) linked by internucleotide phosphodiester bond linkages, e.g. 3′-5′ and 2′-5′, inverted linkages, e.g. 3′-3′ and 5′-5′, branched structures, or analog nucleic acids. Polynucleotides have associated counter ions, such as H⁺, NH₄ ⁺, trialkylammonium, Mg²⁺, Na⁺ and the like. An oligonucleotide can be composed entirely of deoxyribonucleotides, entirely of ribonucleotides, or chimeric mixtures thereof. Oligonucleotides can be comprised of nucleobase and sugar analogs. Polynucleotides typically range in size from a few monomeric units, e.g. 5-40, when they are more commonly frequently referred to in the art as oligonucleotides, to several thousands of monomeric nucleotide units, when they are more commonly referred to in the art as polynucleotides; for purposes of this disclosure, however, both oligonucleotides and polynucleotides may be of any suitable length. Unless denoted otherwise, whenever a oligonucleotide sequence is represented, it will be understood that the nucleotides are in 5′ to 3′ order from left to right and that “A” denotes deoxyadenosine, “C” denotes deoxycytidine, “G” denotes deoxyguanosine, “T” denotes thymidine, and “U’ denotes deoxyuridine. As discussed herein and known in the art, oligonucleotides and polynucleotides are said to have “5′ ends” and “3′ ends” because mononucleotides are typically reacted to form oligonucleotides via attachment of the 5′ phosphate or equivalent group of one nucleotide to the 3′ hydroxyl or equivalent group of its neighboring nucleotide, optionally via a phosphodiester or other suitable linkage.

As used herein, the term “polymerase chain reaction” (“PCR”) refers to the method of K. B. Mullis U.S. Pat. Nos. 4,683,195 and 4,683,202, hereby incorporated by reference, which describe a method for increasing the concentration of a segment of a polynucleotide of interest in a mixture of genomic DNA without cloning or purification. This process for amplifying the polynucleotide of interest consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired polynucleotide of interest, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded polynucleotide of interest. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the polynucleotide of interest molecule. Following annealing, the primers are extended with a polymerase to form a new pair of complementary strands. The steps of denaturation, primer annealing and polymerase extension can be repeated many times (i.e., denaturation, annealing and extension constitute one “cycle”; there can be numerous “cycles”) to obtain a high concentration of an amplified segment of the desired polynucleotide of interest. The length of the amplified segment of the desired polynucleotide of interest (amplicon) is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of repeating the process, the method is referred to as the “polymerase chain reaction” (hereinafter “PCR”). Because the desired amplified segments of the polynucleotide of interest become the predominant nucleic acid sequences (in terms of concentration) in the mixture, they are said to be “PCR amplified”. As defined herein, target nucleic acid molecules within a sample including a plurality of target nucleic acid molecules are amplified via PCR. In a modification to the method discussed above, the target nucleic acid molecules can be PCR amplified using a plurality of different primer pairs, in some cases, one or more primer pairs per target nucleic acid molecule of interest, thereby forming a multiplex PCR reaction. Using multiplex PCR, it is possible to simultaneously amplify multiple nucleic acid molecules of interest from a sample to form amplified target sequences. It is also possible to detect the amplified target sequences by several different methodologies (e.g., quantitation with a bioanalyzer or qPCR, hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of ³²P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified target sequence). Any oligonucleotide sequence can be amplified with the appropriate set of primers, thereby allowing for the amplification of target nucleic acid molecules from genomic DNA, cDNA, formalin-fixed paraffin-embedded DNA, fine-needle biopsies and various other sources. In particular, the amplified target sequences created by the multiplex PCR process as disclosed herein, are themselves efficient substrates for subsequent PCR amplification or various downstream assays or manipulations.

As defined herein “multiplex amplification” refers to selective and non-random amplification of two or more target sequences within a sample using at least one target-specific primer. In some embodiments, multiplex amplification is performed such that some or all of the target sequences are amplified within a single reaction vessel. The “plexy” or “plex” of a given multiplex amplification refers generally to the number of different target-specific sequences that are amplified during that single multiplex amplification. In some embodiments, the plexy can be about 12-plex, 24-plex, 48-plex, 96-plex, 192-plex, 384-plex, 768-plex, 1536-plex, 3072-plex, 6144-plex or higher.

Compositions

We have developed a single stream multiplex next generation sequencing workflow for determination of actionable oncology tumor biomarkers in a sample, in order to determine oncology status in a sample. The oncology precision assay compositions and methods of the invention offer a specific and robust solution for biomarker screening for understanding mechanisms involved with tumor immune response. Thus, provided are compositions for multiplex library preparation and use in conjunction with next generation sequencing technologies and workflow solutions (e.g., Ion Torrent™ NGS workflow), manual or automated, to evaluate low level biomarker targets in a variety of sample types to assess oncology status.

Thus, provided are compositions for a single stream multiplex determination of actionable oncology biomarkers in a sample. In some embodiments, the composition consists of a plurality of sets of primer pair reagents directed to a plurality of target sequences to detect low level targets in the sample, wherein the target genes are selected from oncology response genes consisting of the following function: DNA hotspot mutation genes, copy number variation (CNV) genes, inter-genetic fusion genes, and intra-genetic fusion genes. In some embodiments, the target genes are selected from oncology genes consisting of one or more function of Table 1. In some embodiments, the target genes are selected from one or more actionable target genes in a sample that determines a change in oncology activity in the sample indicative of a potential diagnosis, prognosis, candidate therapeutic regimen, and/or adverse event likelihood. In total, the various functions of genes comprising the provided multiplex panel of the invention provide a comprehensive picture recommending actionable approaches to cancer therapy.

In certain embodiments, target oncology sequences are directed to sequences having mutations associated with cancer. In some embodiments, the target sequences or amplified target sequences are directed to sequences having mutations associated with one or more solid tumor cancers selected from the group consisting of head and neck cancers (e.g., HNSCC, nasopharyngeal, salivary gland), brain cancer (e.g., glioblastoma, glioma, gliosarcoma, glioblastoma multiforme, neuroblastoma), breast cancer (e.g., TNBC, trastuzumab resistant HER2+ breast cancer, ER+/HER− breast cancer), gynecological (e.g., uterine, ovarian cancer, cervical cancer, endometrial cancer, fallopian cancer), colorectal cancer, gallbladder cancer, esophageal cancer, gastrointestinal cancer, gastric cancer, bladder cancer, prostate cancer, testicular cancer, urothelial cancer, liver cancer (e.g., hepatocellular, HCC), lung cancer (e.g., non-small cell lung, small cell lung), kidney (renal cell) cancer, pancreatic cancer (e.g., adenocarcinoma, ductal), thyroid cancer, bile duct cancer, pituitary tumor, wilms tumor, kaposi sarcoma, hairy cell carcinoma, osteosarcoma, thymus cancer, skin cancer, melanoma, heart cancer, oral and larynx cancer, neuroblastoma, mesothelioma, and other solid tumors (thymic, bone, soft tissue, oral SCC, myelofibrosis, synovial sarcoma). In one embodiment, the mutations can include substitutions, insertions, inversions, point mutations, deletions, mismatches and translocations. In some embodiments, the target sequences or amplified target sequences are directed to sequences having mutations associated with one or more blood/hematologic cancers selected from the group consisting of multiple myeloma, diffuse large B cell lymphoma (DLBCL), lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, follicular lymphoma, leukemia, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), myelodisplastic syndrome. In one embodiment, the mutant biomarker associated with cancer is located in at least one of the genes provided in Table 1.

In some embodiments, one or more mutant oncology sequences are located in at least one of the genes selected from, Table 1. In some embodiments the one or more mutant sequences indicate cancer activity.

In some embodiments the one or more mutant sequences indicate a patient's likelihood to response to a therapeutic agent. In some embodiments, the one or more mutant oncology biomarker sequences indication a patient's likelihood to not be responsive to a therapeutic agent. In certain embodiments, relevant therapeutic agents can be oncology therapies including but not limited to kinase inhibitors, cell signaling inhibitors, checkpoint blockades, T cell therapies, and therapeutic vaccines.

In some embodiments, target sequences or mutant target sequences are directed to mutations associated with cancer. In some embodiments, the target sequences or mutant target sequences are directed to mutations associated with one or more solid tumor cancers selected from the group consisting of head and neck cancers (e.g., HNSCC, nasopharyngeal, salivary gland), brain cancer (e.g., glioblastoma, glioma, gliosarcoma, glioblastoma multiforme, neuroblastoma), breast cancer (e.g., TNBC, trastuzumab resistant HER2+ breast cancer, ER+/HER− breast cancer), gynecological (e.g., uterine, ovarian cancer, cervical cancer, endometrial cancer, fallopian cancer), colorectal cancer, gallbladder cancer, esophageal cancer, gastrointestinal cancer, gastric cancer, bladder cancer, prostate cancer, testicular cancer, urothelial cancer, liver cancer (e.g., hepatocellular, HCC), lung cancer (e.g., non-small cell lung, small cell lung), kidney (renal cell) cancer, pancreatic cancer (e.g., adenocarcinoma, ductal), thyroid cancer, bile duct cancer, pituitary tumor, wilms tumor, kaposi sarcoma, hairy cell carcinoma, osteosarcoma, thymus cancer, skin cancer, melanoma, heart cancer, oral and larynx cancer, neuroblastoma, mesothelioma, and other solid tumors (thymic, bone, soft tissue, oral SCC, myelofibrosis, synovial sarcoma). In one embodiment, the mutations can include substitutions, insertions, inversions, point mutations, deletions, mismatches and translocations. In one embodiment, the mutations can include variation in copy number. In one embodiment, the mutations can include germline or somatic mutations. In some embodiments, the target sequences or amplified target sequences are directed to sequences having mutations associated with one or more blood/hematologic cancers selected from the group consisting of multiple myeloma, diffuse large B cell lymphoma (DLBCL), lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, follicular lymphoma, leukemia, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), myelodisplastic syndrome.

In one embodiment, the mutations associated with cancer are located in at least one of the genes provided in Table 1. In some embodiments, mutant target sequences are directed to any one of more of the genes provided in Table 1. In some embodiments, mutant target sequences comprise any one or more amplicon sequences of the genes provided in Table 1. In some embodiments, mutant target sequences consist of any one or more amplicon sequences of the genes provided in Table 1. In some embodiments, mutant target sequences include amplicon sequences of each of the genes provided in Table 1.

In some embodiments, compositions comprise any one or more of oncology target-specific primer pairs provided in Table A. In some embodiments, compositions comprise all of the oncology target-specific primer pairs provided in Table A. In some embodiments, any one or more of the oncology target-specific primer pairs provided in Table A can be used to amplify a target sequence present in a sample as disclosed by the methods described herein.

In some embodiments, the oncology target-specific primers from Table A include 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600 or more, target-specific primer pairs. In some embodiments, the amplified target sequences can include any one or more of the amplified target sequences produced using target-specific primers provided in Table A. In some embodiments, at least one of the target-specific primers associated with cancer is at least 90% identical to at least one nucleic acid sequence produced using target specific primers selected from SEQ ID NOs: 1-1563. In some embodiments, at least one of the target-specific primers associated with oncology is complementary across its entire length to at least one target sequence in a sample. In some embodiments, at least one of the target-specific primers associated with immune response includes a non-cleavable nucleotide at the 3′ end. In some embodiments, the non-cleavable nucleotide at the 3′ end includes the terminal 3′ nucleotide. In one embodiment, the amplified target sequences are directed to one or more individual exons having mutations associated with cancer. In one embodiment, the amplified target sequences are directed to individual exons having a mutation associated with cancer.

Methods

Provided methods of the invention comprise efficient procedures which enable rapid preparation of highly multiplexed libraries suitable for downstream analysis. The methods optionally allow for incorporation of one or more unique tag sequences. Certain methods comprise streamlined, addition-only procedures conveying highly rapid library generation.

Provided herein are methods for determining oncology activity in a sample. In some embodiments, the method comprises multiplex amplification of a plurality of oncology sequences from a biological sample, wherein amplifying comprises contacting at least a portion of the sample with a plurality of sets of primer pair reagents directed to the plurality of target sequences, and a polymerase under amplification conditions, to thereby produce amplified target expression sequences. The method further comprises detecting the presence of a mutation of the one or more target sequences in the sample, wherein a mutation of one or more oncology markers as compared with a control determines a change in oncology activity in the sample. In some embodiments the oncology sequences of the methods are selected from oncology response genes consisting of the following function: DNA hotspot mutation genes, copy number variation (CNV) genes, inter-genetic fusion genes, and intra-genetic fusion genes. In some embodiments, the target genes are selected from oncology genes consisting of one or more function of Table 1. In some embodiments, the target genes are selected from one or more actionable target genes in a sample that determines a change in oncology activity in the sample indicative of a potential diagnosis, prognosis, candidate therapeutic regimen, and/or adverse event likelihood. In total, the various functions of genes comprising the provided multiplex panel of the invention provide a comprehensive picture recommending actionable approaches to cancer therapy.

In certain embodiments, target oncology sequences of the methods are directed to sequences having mutations associated with cancer. In some embodiments, the target sequences or amplified target sequences are directed to sequences having mutations associated with one or more solid tumor cancers selected from the group consisting of head and neck cancers (e.g., HNSCC, nasopharyngeal, salivary gland), brain cancer (e.g., glioblastoma, glioma, gliosarcoma, glioblastoma multiforme, neuroblastoma), breast cancer (e.g., TNBC, trastuzumab resistant HER2+ breast cancer, ER+/HER− breast cancer), gynecological (e.g., uterine, ovarian cancer, cervical cancer, endometrial cancer, fallopian cancer), colorectal cancer, gallbladder cancer, esophageal cancer, gastrointestinal cancer, gastric cancer, bladder cancer, prostate cancer, testicular cancer, urothelial cancer, liver cancer (e.g., hepatocellular, HCC), lung cancer (e.g., non-small cell lung, small cell lung), kidney (renal cell) cancer, pancreatic cancer (e.g., adenocarcinoma, ductal), thyroid cancer, bile duct cancer, pituitary tumor, wilms tumor, kaposi sarcoma, hairy cell carcinoma, osteosarcoma, thymus cancer, skin cancer, melanoma, heart cancer, oral and larynx cancer, neuroblastoma, mesothelioma, and other solid tumors (thymic, bone, soft tissue, oral SCC, myelofibrosis, synovial sarcoma). In one embodiment, the mutations can include substitutions, insertions, inversions, point mutations, deletions, mismatches and translocations. In some embodiments, the target sequences or amplified target sequences are directed to sequences having mutations associated with one or more blood/hematologic cancers selected from the group consisting of multiple myeloma, diffuse large B cell lymphoma (DLBCL), lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, follicular lymphoma, leukemia, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), myelodisplastic syndrome. In one embodiment, the mutant biomarker associated with cancer is located in at least one of the genes provided in Table 1.

In some embodiments, one or more mutant oncology sequences of the methods are located in at least one of the genes selected from, Table 1. In some embodiments the one or more mutant sequences indicate cancer activity.

In some embodiments the one or more mutant sequences of the methods indicate a patient's likelihood to response to a therapeutic agent. In some embodiments, the one or more mutant oncology biomarker sequences indication a patient's likelihood to not be responsive to a therapeutic agent. In certain embodiments, relevant therapeutic agents can be oncology therapies including but not limited to kinase inhibitors, cell signaling inhibitors, checkpoint blockades, T cell therapies, and therapeutic vaccines.

In some embodiments, target sequences or mutant target sequences of the methods are directed to mutations associated with cancer. In some embodiments, the target sequences or mutant target sequences of the methods are directed to mutations associated with one or more solid tumor cancers selected from the group consisting of head and neck cancers (e.g., HNSCC, nasopharyngeal, salivary gland), brain cancer (e.g., glioblastoma, glioma, gliosarcoma, glioblastoma multiforme, neuroblastoma), breast cancer (e.g., TNBC, trastuzumab resistant HER2+ breast cancer, ER+/HER− breast cancer), gynecological (e.g., uterine, ovarian cancer, cervical cancer, endometrial cancer, fallopian cancer), colorectal cancer, gallbladder cancer, esophageal cancer, gastrointestinal cancer, gastric cancer, bladder cancer, prostate cancer, testicular cancer, urothelial cancer, liver cancer (e.g., hepatocellular, HCC), lung cancer (e.g., non-small cell lung, small cell lung), kidney (renal cell) cancer, pancreatic cancer (e.g., adenocarcinoma, ductal), thyroid cancer, bile duct cancer, pituitary tumor, wilms tumor, kaposi sarcoma, hairy cell carcinoma, osteosarcoma, thymus cancer, skin cancer, melanoma, heart cancer, oral and larynx cancer, neuroblastoma, mesothelioma, and other solid tumors (thymic, bone, soft tissue, oral SCC, myelofibrosis, synovial sarcoma). In one embodiment, the mutations can include substitutions, insertions, inversions, point mutations, deletions, mismatches and translocations. In one embodiment, the mutations can include variation in copy number. In one embodiment, the mutations can include germline or somatic mutations. In some embodiments, the target sequences or amplified target sequences are directed to sequences having mutations associated with one or more blood/hematologic cancers selected from the group consisting of multiple myeloma, diffuse large B cell lymphoma (DLBCL), lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, follicular lymphoma, leukemia, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), myelodisplastic syndrome.

In one embodiment, the mutations associated with cancer are located in at least one of the genes provided in Table 1. In some embodiments, mutant target sequences are directed to any one of more of the genes provided in Table 1. In some embodiments, mutant target sequences comprise any one or more amplicon sequences of the genes provided in Table 1. In some embodiments, mutant target sequences consist of any one or more amplicon sequences of the genes provided in Table 1. In some embodiments, mutant target sequences include amplicon sequences of each of the genes provided in Table 1.

In some embodiments, methods comprise use of any one or more of oncology target-specific primer pairs provided in Table A. In some embodiments, methods comprise use of all of the oncology target-specific primer pairs provided in Table A. In some embodiments, use of any one or more of the oncology target-specific primer pairs provided in Table A can be used to amplify a target sequence present in a sample as disclosed by the methods described herein.

In some embodiments, methods comprise use of the oncology target-specific primers from Table A include 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 40, 60, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600 or more, target-specific primer pairs. In some embodiments, methods comprising detection of amplified target sequences can include any one or more of the amplified target sequences produced using target-specific primers provided in Table A. In some embodiments, methods comprise use of at least one of the target-specific primers associated with cancer is at least 90% identical to at least one nucleic acid sequence produced using target specific primers selected from SEQ ID NOs: 1-1563. In some embodiments, at least one of the target-specific primers associated with oncology is complementary across its entire length to at least one target sequence in a sample. In some embodiments, at least one of the target-specific primers associated with immune response includes a non-cleavable nucleotide at the 3′ end. In some embodiments, the non-cleavable nucleotide at the 3′ end includes the terminal 3′ nucleotide. In one embodiment, the amplified target sequences are directed to one or more individual exons having mutations associated with cancer. In one embodiment, the amplified target sequences are of the methods are directed to individual exons having a mutation associated with cancer.

In some embodiments, methods comprise detection and optionally, the identification of clinically actionable markers. As defined herein, the term “clinically actionable marker” includes clinically actionable mutations and/or clinically actionable expression patterns that are known or can be associated by one of ordinary skill in the art with, but not limited to, prognosis for the treatment of cancer. In one embodiment, prognosis for the treatment of cancer includes the identification of mutations and/or expression patterns associated with responsiveness or non-responsiveness of a cancer to a drug, drug combination, or treatment regime. In one embodiment, methods comprise amplification of a plurality of target sequences from a population of nucleic acid molecules linked to, or correlated with, the onset, progression or remission of cancer. In some embodiments, provided methods comprise selective amplification of more than one target sequences in a sample and the detection and/or identification of mutations associated with cancer. In some embodiments, the amplified target sequences include two or more nucleotide sequences of the genes provided in Table 1. In some embodiments, the amplified target sequences can include any one or more the amplified target sequences generated using the target-specific primers provided in Table A. In one embodiment, the amplified target sequences include 10, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600 or more amplicons of the genes from Table 1.

In one aspect of the invention, methods for preparing a library of target nucleic acid sequences are provided. In some embodiments, methods comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and optionally one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety and the universal handle sequence does not include the cleavable moiety. In some embodiments where an optional tag sequence is included in at least one adaptor, the cleavable moieties are included in the adaptor sequence flanking either end of the tag sequence.

In one aspect of the invention, methods for preparing a tagged library of target nucleic acid sequences are provided. In some embodiments, methods comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety, the universal handle sequence does not include the cleavable moiety, and the cleavable moieties are included flanking either end of the tag sequence.

In certain embodiments, the comparable maximal minimum melting temperature of each universal sequence is higher than the comparable maximal minimum melting temperature of each target nucleic acid sequence and each tag sequence present in an adaptor.

In some embodiments, each of the adaptors comprise unique tag sequences as further described herein and each further comprise cleavable groups flanking either end of the tag sequence in each adaptor. In some embodiments wherein unique taq sequences are employed, each generated target specific amplicon sequence includes at least 1 different sequence and up to 10⁷ different sequences. In certain embodiments each target specific pair of the plurality of adaptors includes up to 16,777,216 different adaptor combinations comprising different tag sequences.

In some embodiments, methods comprise contacting the plurality of gapped polynucleotide products with digestion and repair reagents simultaneously. In some embodiments, methods comprise contacting the plurality of gapped polynucleotide products sequentially with the digestion then repair reagents.

A digestion reagent useful in the methods provided herein comprises any reagent capable of cleaving the cleavable site present in adaptors, and in some embodiments includes, but is not limited to, one or a combination of uracil DNA glycosylase (UDG). apurinic endonuclease (e.g., APE1), RecJf, formamidopyrimidine [fapy]-DNA glycosylase (fpg), Nth endonuclease III, endonuclease VIII, polynucleotide kinase (PNK), Taq DNA polymerase, DNA polymerase I and/or human DNA polymerase beta.

A repair reagent useful in the methods provided herein comprises any reagent capable of repair of the gapped amplicons, and in some embodiments includes, but is not limited to, any one or a combination of Phusion DNA polymerase, Phusion U DNA polymerase, SuperFi DNA polymerase, Taq DNA polymerase, Human DNA polymerase beta, T4 DNA polymerase and/or T7 DNA polymerase, SuperFiU DNA polymerase, E. coli DNA ligase, T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, Taq DNA ligase, and/or 9° N DNA ligase.

Thus, in certain embodiments, a digestion and repair reagent comprises any one or a combination of one or a combination of uracil DNA glycosylase (UDG). apurinic endonuclease (e.g., APE1), RecJf, formamidopyrimidine [fapy]-DNA glycosylase (fpg), Nth endonuclease II, endonuclease VIII, polynucleotide kinase (PNK), Taq DNA polymerase, DNA polymerase I and/or human DNA polymerase beta; and any one or a combination of Phusion DNA polymerase, Phusion U DNA polymerase, SuperFi DNA polymerase, Taq DNA polymerase, Human DNA polymerase beta, T4 DNA polymerase and/or T7 DNA polymerase, SuperFiU DNA polymerase, E. coli DNA ligase, T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, Taq DNA ligase, and/or 9° N DNA ligase. In certain embodiments, a digestion and repair reagent comprises any one or a combination of uracil DNA glycosylase (UDG), apurinic endonuclease (e.g., APE1), Taq DNA polymerase, Phusion U DNA polymerase, SuperFiU DNA polymerase, T7 DNA ligase. In certain embodiments, a digestion and repair reagent comprises any one or a combination of uracil DNA glycosylase (UDG), formamidopyrimidine [fapy]-DNA glycosylase (fpg), Phusion U DNA polymerase, Taq DNA polymerase, SuperFiU DNA polymerase, T4 PNK and T7 DNA ligase.

In some embodiments, methods comprise the digestion and repair steps carried out in a single step. In other embodiments, methods comprise the digestion and repair of steps carried out in a temporally separate manner at different temperatures.

In some embodiments methods of the invention are carried out wherein one or more of the method steps is conducted in manual mode. In particular embodiments, methods of the invention are carried out wherein each of the method steps is conducted manually. In some embodiments methods of the invention are carried out wherein one or more of the method steps is conducted in an automated mode. In particular embodiments, methods of the invention are carried wherein each of the method steps is automated. In some embodiments methods of the invention are carried out wherein one or more of the method steps is conducted in a combination of manual and automated modes.

In some embodiments, methods of the invention comprise at least one purification step. For example, in certain embodiments a purification step is carried out only after the second amplification of repaired amplicons. In some embodiments two purification steps are utilized, wherein a first purification step is carried out after the digestion and repair and a second purification step is carried out after the second amplification of repaired amplicons.

In some embodiments a purification step comprises conducting a solid phase adherence reaction, solid phase immobilization reaction or gel electrophoresis. In certain embodiments a purification step comprises separation conducted using Solid Phase Reversible Immobilization (SPRI) beads. In particular embodiments a purification step comprises separation conducted using SPRI beads wherein the SPRI beads comprise paramagnetic beads.

In some embodiments, methods comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons, then purifying repaired amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences; and then purifying resulting library. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and optionally one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety and the universal handle sequence does not include the cleavable moiety. In some embodiments where an optional tag sequence is included in at least one adaptor, the cleavable moieties are included in the adaptor sequence flanking either end of the tag sequence.

In some embodiments, methods comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons, and purifying repaired amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences; and then purifying resulting library. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety, the universal handle sequence does not include the cleavable moiety, and cleavable moieties are included in the flanking either end of the tag sequence.

In some embodiments, methods comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons, then purifying repaired amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences; and then purifying resulting library. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and optionally one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety and the universal handle sequence does not include the cleavable moiety. In some embodiments where an optional tag sequence is included in at least one adaptor, the cleavable moieties are included in the adaptor sequence flanking either end of the tag sequence. In some embodiments a digestion and repair reagent comprises any one or a combination of one or a combination of uracil DNA glycosylase (UDG). apurinic endonuclease (e.g., APE1), RecJf, formamidopyrimidine [fapy]-DNA glycosylase (fpg), Nth endonuclease III, endonuclease VIII, polynucleotide kinase (PNK), Taq DNA polymerase, DNA polymerase I and/or human DNA polymerase beta; and any one or a combination of Phusion DNA polymerase, Phusion U DNA polymerase, SuperFi DNA polymerase, Taq DNA polymerase, Human DNA polymerase beta, T4 DNA polymerase and/or T7 DNA polymerase, SuperFiU DNA polymerase, E. coli DNA ligase, T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, Taq DNA ligase, and/or 9° N DNA ligase. In certain embodiments, a digestion and repair reagent comprises any one or a combination of uracil DNA glycosylase (UDG), apurinic endonuclease (e.g., APE1), Taq DNA polymerase, Phusion U DNA polymerase, SuperFiU DNA polymerase, T7 DNA ligase. In certain embodiments, a digestion and repair reagent comprises any one or a combination of uracil DNA glycosylase (UDG), formamidopyrimidine [fapy]-DNA glycosylase (fpg), Phusion U DNA polymerase, Taq DNA polymerase, SuperFiU DNA polymerase, T4 PNK and T7 DNA ligase.

In some embodiments, methods comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons, and purifying repaired amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences; and then purifying resulting library. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety, the universal handle sequence does not include the cleavable moiety, and cleavable moieties are included in the flanking either end of the tag sequence. In some embodiments a digestion and repair reagent comprises any one or a combination of one or a combination of uracil DNA glycosylase (UDG). apurinic endonuclease (e.g., APE1), RecJf, formamidopyrimidine [fapy]-DNA glycosylase (fpg), Nth endonuclease III, endonuclease VIII, polynucleotide kinase (PNK), Taq DNA polymerase, DNA polymerase I and/or human DNA polymerase beta; and any one or a combination of Phusion DNA polymerase, Phusion U DNA polymerase, SuperFi DNA polymerase, Taq DNA polymerase, Human DNA polymerase beta, T4 DNA polymerase and/or T7 DNA polymerase, SuperFiU DNA polymerase, E. coli DNA ligase, T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, Taq DNA ligase, and/or 9° N DNA ligase. In certain embodiments, a digestion and repair reagent comprises any one or a combination of uracil DNA glycosylase (UDG), apurinic endonuclease (e.g., APE1), Taq DNA polymerase, Phusion U DNA polymerase, SuperFiU DNA polymerase, T7 DNA ligase. In certain embodiments, a digestion and repair reagent comprises any one or a combination of uracil DNA glycosylase (UDG), formamidopyrimidine [fapy]-DNA glycosylase (fpg), Phusion U DNA polymerase, Taq DNA polymerase, SuperFiU DNA polymerase, T4 PNK and T7 DNA ligase.

In certain embodiments methods of the invention are carried out in a single, addition only workflow reaction, allowing for rapid production of highly multiplexed targeted libraries. For example, in one embodiment, methods for preparing a library of target nucleic acid sequences comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences, and purifying the resulting library. In certain embodiments the purification comprises a single or repeated separating step that is carried out following production of the library following the second amplification; and wherein the other method steps are conducted in a single reaction vessel without requisite transferring of a portion (aliquot) of any of the products generated in steps to another reaction vessel. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and optionally one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety and the universal handle sequence does not include the cleavable moiety. In some embodiments where an optional tag sequence is included in at least one adaptor, the cleavable moieties are included in the adaptor sequence flanking either end of the tag sequence.

In another embodiment, methods for preparing a tagged library of target nucleic acid sequences are provided comprising contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences, and purifying the resulting library. In certain embodiments the purification comprises a single or repeated separating step; and wherein the other method steps are optionally conducted in a single reaction vessel without requisite transferring of a portion of any of the products generated in steps to another reaction vessel. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety, the universal handle sequence does not include the cleavable moiety, and the cleavable moieties are included flanking either end of the tag sequence.

In one embodiment, methods for preparing a library of target nucleic acid sequences comprise contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicon; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences, and purifying the resulting library.

In some embodiments a digestion reagent comprises any one or any combination of: uracil DNA glycosylase (UDG). AP endonuclease (APE1), RecJf, formamidopyrimidine [fapy]-DNA glycosylase (fpg), Nth endonuclease III, endonuclease VIII, polynucleotide kinase, Taq DNA polymerase, DNA polymerase I and/or human DNA polymerase beta. In certain embodiments a digestion reagent comprises any one or any combination of: uracil DNA glycosylase (UDG). AP endonuclease (APE1), RecJf, formamidopyrimidine [fapy]-DNA glycosylase (fpg), Nth endonuclease III, endonuclease VIII, polynucleotide kinase, Taq DNA polymerase, DNA polymerase I and/or human DNA polymerase beta wherein the digestion reagent lacks formamidopyrimidine [fapy]-DNA glycosylase (fpg).

In some embodiments a digestion reagent comprises a single-stranded DNA exonuclease that degrades in a 5′-3′ direction. In some embodiments a cleavage reagent comprises a single-stranded DNA exonuclease that degrades abasic sites. In some embodiments herein the digestions reagent comprises an RecJf exonuclease. In particular embodiments a digestion reagent comprises APE1 and RecJf, wherein the cleavage reagent comprises an apurinic/apyrimidinic endonuclease. In certain embodiments the digestion reagent comprises an AP endonuclease (APE1).

In some embodiments a repair reagent comprises at least one DNA polymerase; wherein the gap-filling reagent comprises: any one or any combination of: Phusion DNA polymerase, Phusion U DNA polymerase, SuperFi DNA polymerase, Taq DNA polymerase, Human DNA polymerase beta, T4 DNA polymerase and/or T7 DNA polymerase and/or SuperFi U DNA polymerase. In some embodiments a repair reagent further comprises a plurality of nucleotides.

In some embodiment a repair reagent comprises an ATP-dependent or an ATP-independent ligase; wherein the repair reagent comprises any one or any combination of: E. coli DNA ligase, T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, Taq DNA ligase, 9° N DNA ligase

In certain embodiments a digestion and repair reagent comprises any one or a combination of one or a combination of uracil DNA glycosylase (UDG). apurinic endonuclease (e.g., APE1), RecJf, formamidopyrimidine [fapy]-DNA glycosylase (fpg), Nth endonuclease II, endonuclease VIII, polynucleotide kinase (PNK), Taq DNA polymerase, DNA polymerase I and/or human DNA polymerase beta; and any one or a combination of Phusion DNA polymerase, Phusion U DNA polymerase, SuperFi DNA polymerase, Taq DNA polymerase, Human DNA polymerase beta, T4 DNA polymerase and/or T7 DNA polymerase, SuperFiU DNA polymerase, E. coli DNA ligase, T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, Taq DNA ligase, and/or 9° N DNA ligase. In particular embodiments, a digestion and repair reagent comprises any one or a combination of uracil DNA glycosylase (UDG), apurinic endonuclease (e.g., APE1), Taq DNA polymerase, Phusion U DNA polymerase, SuperFiU DNA polymerase, T7 DNA ligase. In certain embodiments a purification comprises a single or repeated separating step that is carried out following production of the library following the second amplification; and wherein method steps are conducted in a single reaction vessel without requisite transferring of a portion of any of the products generated in steps to another reaction vessel until a first purification. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and optionally one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety and the universal handle sequence does not include the cleavable moiety. In some embodiments where an optional tag sequence is included in at least one adaptor, the cleavable moieties are included in the adaptor sequence flanking either end of the tag sequence.

In another embodiment, methods for preparing a tagged library of target nucleic acid sequences are provided comprising contacting a nucleic acid sample with a plurality of adaptors capable of amplification of one or more target nucleic acid sequences in the sample under conditions wherein the target nucleic acid(s) undergo a first amplification; digesting resulting first amplification products to reduce or eliminate resulting primer dimers and prepare partially digested target amplicons, thereby producing gapped, double stranded amplicons. The methods further comprise repairing the partially digested target amplicons; then amplifying the repaired target amplicons in a second amplification using universal primers, thereby producing a library of target nucleic acid sequences, and purifying the resulting library. In certain embodiments a digestion and repair reagent comprises any one or a combination of one or a combination of uracil DNA glycosylase (UDG). apurinic endonuclease (e.g., APE1), RecJf, formamidopyrimidine [fapy]-DNA glycosylase (fpg), Nth endonuclease III, endonuclease VIII, polynucleotide kinase (PNK), Taq DNA polymerase, DNA polymerase I and/or human DNA polymerase beta; and any one or a combination of Phusion DNA polymerase, Phusion U DNA polymerase, SuperFi DNA polymerase, Taq DNA polymerase, Human DNA polymerase beta, T4 DNA polymerase and/or T7 DNA polymerase, SuperFiU DNA polymerase, E. coli DNA ligase, T3 DNA ligase, T4 DNA ligase, T7 DNA ligase, Taq DNA ligase, and/or 9° N DNA ligase. In particular embodiments, a digestion and repair reagent comprises any one or a combination of uracil DNA glycosylase (UDG), apurinic endonuclease (e.g., APE1), Taq DNA polymerase, Phusion U DNA polymerase, SuperFiU DNA polymerase, T7 DNA ligase. In certain embodiments the purification comprises a single or repeated separating step that is carried out following production of the library following the second amplification; and wherein steps the other method steps are conducted in a single reaction vessel without requisite transferring of a portion (aliquot) of any of the products generated in steps to another reaction vessel. Each of the plurality of adaptors used in the methods herein comprise a universal handle sequence and a target nucleic acid sequence and a cleavable moiety and one or more tag sequences. At least two and up to one hundred thousand target specific adaptor pairs are included in the provided methods, wherein the target nucleic acid sequence of each adaptor includes at least one cleavable moiety, the universal handle sequence does not include the cleavable moiety, and the cleavable moieties are included flanking either end of the tag sequence.

In some embodiments, adaptor-dimer byproducts resulting from the first amplification of step of the methods are largely removed from the resulting library. In certain embodiments the enriched population of amplified target nucleic acids contains a reduced amount of adaptor-dimer byproduct. In particular embodiments adaptor dimer byproducts are eliminated.

In some embodiments, the library is prepared in less than 4 hours. In some embodiments, the library is prepared, enriched and sequenced in less than 3 hours. In some embodiments, the library is prepared, enriched and sequenced in 2 to 3 hours. In some embodiments, the library is prepared in approximately 2.5 hours. In some embodiments, the library is prepared in approximately 2.75 hours. In some embodiments, the library is prepared in approximately 3 hours.

Compositions

Additional aspects of the invention comprise composition comprising a plurality of nucleic acid adaptors, as well as library compositions prepared according to the methods of the invention. Provided compositions are useful in conjunction with the methods described herein as well as for additional analysis and applications known in the art.

Thus, provided are composition comprising a plurality of nucleic acid adaptors, wherein each of the plurality of adaptors comprises a 5′ universal handle sequence, optionally one or more tag sequences, and a 3′ target nucleic acid sequence wherein each adaptor comprises a cleavable moiety, wherein the target nucleic acid sequence of the adaptor includes at least one cleavable moiety, and when tag sequences are present cleavable moieties are included flanking either end of the tag sequence and wherein the universal handle sequence does not include the cleavable moiety. At least two and up to one hundred thousand target specific adaptor pairs are included in provided compositions. Provided composition allow for rapid production of highly multiplexed targeted libraries.

In some embodiments, provided compositions comprise plurality of nucleic acid adaptors, wherein each of the plurality of adaptors comprise a 5′ universal handle sequence, one or more tag sequences, and a 3′ target nucleic acid sequence wherein each adaptor comprises a cleavable moiety; wherein the target nucleic acid sequence of the adaptor includes at least one cleavable moiety, cleavable moieties are included flanking either end of the tag sequence and the universal handle sequence does not include the cleavable moiety. At least two and up to one hundred thousand target specific adaptor pairs are included in provided compositions. Provided composition allow for rapid production of highly multiplexed, tagged, targeted libraries.

Primer/adaptor compositions may be single stranded or double stranded. In some embodiments adaptor compositions comprise are single stranded adaptors. In some embodiments adaptor compositions comprise double stranded adaptors. In some embodiments adaptor compositions comprise a mixture of single stranded and double stranded adaptors.

In some embodiments, compositions include a plurality of adaptors capable of amplification of one or more target nucleic acid sequences comprising a multiplex of adaptor pairs capable of amplification of at least two different target nucleic acid sequences wherein the target-specific primer sequence is substantially non-complementary to other target specific primer sequences in the composition. In some embodiments, the composition comprises at least 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 2750, 3000, 3250, 3500, 3750, 4000, 4500, 5000, 5500, 6000, 7000, 8000, 9000, 10000, 11000, or 12000, or more target-specific adaptor pairs. In some embodiments, target-specific adpator pairs comprise about 15 nucleotides to about 40 nucleotides in length, wherein at least one nucleotide is replaced with a cleavable group. In some embodiments the cleavable group is a uridine nucleotide. In some embodiments, the target-specific adaptor pairs are designed to amplify an exon, gene, exome or region of the genome associated with a clinical or pathological condition, e.g., amplification of one or more sites comprising one or more mutations (e.g., driver mutation) associated with a cancer, e.g., lung, colon, breast cancer, etc., or amplification of mutations associated with an inherited disease, e.g., cystic fibrosis, muscular dystrophies, etc. In some embodiments, the target-specific adaptor pairs when hybridized to a target sequence and amplified as provided herein generates a library of adaptor-ligated amplified target sequences that are about 100 to about 600 base pairs in length. In some embodiments, no one adaptor-ligated amplified target sequence is overexpressed in the library by more than 30% as compared to the remainder of other adaptor-ligated amplified target sequences in the library. In some embodiments, an adaptor-ligated amplified target sequence library is substantially homogenous with respect to GC content, amplified target sequence length or melting temperature (Tm) of the respective target sequences.

In some embodiments, the target-specific primer sequences of adaptor pairs in the compositions of the invention are target-specific sequences that can amplify specific regions of a nucleic acid molecule. In some embodiments, the target-specific adaptors can amplify genomic DNA or cDNA. In some embodiments, target-specific adaptors can amplify mammalian nucleic acid, such as, but not limited to human DNA or RNA, murine DNA or RNA, bovine DNA or RNA, canine DNA or RNA, equine DNA or RNA, or any other mammal of interest. In other embodiments, target specific adaptors include sequences directed to amplify plant nucleic acids of interest. In other embodiments, target specific adaptors include sequences directed to amplify infectious agents, e.g., bacterial and/or viral nucleic acids. In some embodiments, the amount of nucleic acid required for selective amplification is from about 1 ng to 1 microgram. In some embodiments, the amount of nucleic acid required for selective amplification of one or more target sequences is about 1 ng, about 5 ng or about 10 ng. In some embodiments, the amount of nucleic acid required for selective amplification of target sequence is about 10 ng to about 200 ng.

As described herein, each of the plurality of adaptors comprises a 5′ universal handle sequence. In some embodiments a universal handle sequence comprises any one or any combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence. In some embodiments the comparable maximal minimum melting temperatures of each adaptor universal handle sequence is higher than the comparable maximal minimum melting temperatures of each target nucleic acid sequence and each tag sequence present in the same adaptor. Preferably, the universal handle sequences of provided adaptors do not exhibit significant complementarity and/or hybridization to any portion of a unique tag sequence and/or target nucleic acid sequence of interest. In some embodiments a first universal handle sequence comprises any one or any combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence. In some embodiments a second universal handle sequence comprises any one or any combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence. In certain embodiments first and second universal handle sequences correspond to forward and reverse universal handle sequences and in certain embodiments the same first and second universal handle sequences are included for each of the plurality of target specific adaptor pairs. Such forward and reverse universal handle sequences are targeted in conjunction with universal primers to carry out a second amplification of repaired amplicons in production of libraries according to methods of the invention. In certain embodiments a first 5′ universal handle sequence comprises two universal handle sequences (e.g., a combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence); and a second 5′ universal sequence comprises two universal handle sequences (e.g., a combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence), wherein the 5′ first and second universal handle sequences do not exhibit significant hybridization to any portion of a target nucleic acid sequence of interest.

The structure and properties of universal amplification primers or universal primers are well known to those skilled in the art and can be implemented for utilization in conjunction with provided methods and compositions to adapt to specific analysis platforms. Universal handle sequences of the adaptors provided herein are adapted accordingly to accommodate a preferred universal primer sequences. For example, e.g., as described herein universal P1 and A primers with optional barcode sequences have been described in the art and utilized for sequencing on Ion Torrent sequencing platforms (Ion Xpress™ Adapters, Thermo Fisher Scientific). Similarly, additional and other universal adaptor/primer sequences described and known in the art (e.g., Illumina universal adaptor/primer sequences can be found, e.g., at https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/experiment-design/illumina-adapter-sequences_1000000002694-01.pdf; PacBio universal adaptor/primer sequences, can be found, e.g., at https://s3.amazonaws.com/files.pacb.com/pdf/Guide_Pacific_Biosciences_Template_Preparation_and_Sequencing.pdf; etc.) can be used in conjunction with the methods and compositions provided herein. Suitable universal primers of appropriate nucleotide sequence for use with adaptors of the invention are readily prepared using standard automated nucleic acid synthesis equipment and reagents in routine use in the art. One single type of universal primer or separate types (or even a mixture) of two different universal primers, for example a pair of universal amplification primers suitable for amplification of repaired amplicons in a second amplification are included for use in the methods of the invention. Universal primers optionally include a different tag (barcode) sequence, where the tag (barcode) sequence does not hybridize to the adaptor. Barcode sequences incorporated into amplicons in a second universal amplification can be utilized e.g., for effective identification of sample source.

In some embodiments adaptors further comprise a unique tag sequence located between the 5′ first universal handle sequence and the 3′ target-specific sequence, and wherein the unique tag sequence does not exhibit significant complementarity and/or hybridization to any portion of a unique tag sequence and/or target nucleic acid sequence of interest. In some embodiments the plurality of primer adaptor pairs has 104-10⁹ different tag sequence combinations. Thus in certain embodiments each generated target specific adaptor pair comprises 104-10⁹ different tag sequences. In some embodiments the plurality of primer adaptors comprise each target specific adaptor comprising at least 1 different unique tag sequence and up to 10⁵ different unique tag sequences. In some embodiments the plurality of primer adaptors comprise each target specific adaptor comprising at least 1 different unique tag sequence and up to 10⁵ different unique tag sequences. In certain embodiments each generated target specific amplicon generated comprises at least two and up to 10⁹ different adaptor combinations comprising different tag sequences, each having two different unique tag sequences. In some embodiments the plurality of primer adaptors comprise each target specific adaptor comprising 4096 different tag sequences. In certain embodiments each generated target specific amplicon generated comprises up to 16,777,216 different adaptor combinations comprising different tag sequences, each having two different unique tag sequences.

In some embodiments individual primer adaptors in the plurality of adaptors include a unique tag sequence (e.g., contained in a tag adaptor) comprising different random tag sequences alternating with fixed tag sequences. In some embodiments, the at least one unique tag sequence comprises a at least one random sequence and at least one fixed sequence, or comprises a random sequence flanked on both sides by a fixed sequence, or comprises a fixed sequence flanked on both sides by a random sequence. In some embodiments a unique tag sequence includes a fixed sequence that is 2-2000 nucleotides or base-pairs in length. In some embodiments a unique tag sequence includes a random sequence that is 2-2000 nucleotides or base-pairs in length.

In some embodiments, unique tag sequences include a sequence having at least one random sequence interspersed with fixed sequences. In some embodiments, individual tag sequences in a plurality of unique tags have the structure (N)_(n)(X)_(x)(M)_(m)(Y)_(y), wherein “N” represents a random tag sequence that is generated from A, G, C, T, U or I, and wherein “n” is 2-10 which represents the nucleotide length of the “N” random tag sequence; wherein “X” represents a fixed tag sequence, and wherein “x” is 2-10 which represents the nucleotide length of the “X” random tag sequence; wherein “M” represents a random tag sequence that is generated from A, G, C, T, U or I, wherein the random tag sequence “M” differs or is the same as the random tag sequence “N”, and wherein “m” is 2-10 which represents the nucleotide length of the “M” random tag sequence; and wherein “Y” represents a fixed tag sequence, wherein the fixed tag sequence of “Y” is the same or differs from the fixed tag sequence of “X”, and wherein “y” is 2-10 which represents the nucleotide length of the “Y” random tag sequence. In some embodiments, the fixed tag sequence “X” is the same in a plurality of tags. In some embodiments, the fixed tag sequence “X” is different in a plurality of tags. In some embodiments, the fixed tag sequence “Y” is the same in a plurality of tags. In some embodiments, the fixed tag sequence “Y” is different in a plurality of tags. In some embodiments, the fixed tag sequences “(X),” and “(Y)” within the plurality of adaptors are sequence alignment anchors.

In some embodiments, the random sequence within a unique tag sequence is represented by “N”, and the fixed sequence is represented by “X”. Thus, a unique tag sequence is represented by N₁N₂N₃X₁X₂X₃ or by N₁N₂N₃X₁X₂X₃N₄N₅N₆X₄X₅X₆. Optionally, a unique tag sequence can have a random sequence in which some or all of the nucleotide positions are randomly selected from a group consisting of A, G, C, T, U and I. For example, a nucleotide for each position within a random sequence is independently selected from any one of A, G, C, T, U or I, or is selected from a subset of these six different types of nucleotides. Optionally, a nucleotide for each position within a random sequence is independently selected from any one of A, G, C or T. In some embodiments, the first fixed tag sequence “X₁X₂X₃” is the same or different sequence in a plurality of tags. In some embodiments, the second fixed tag sequence “X₄X₅X₆” is the same or different sequence in a plurality of tags. In some embodiments, the first fixed tag sequence “X₁X₂X₃” and the second fixed tag sequence “X₄X₅X₆” within the plurality of adaptors are sequence alignment anchors.

In some embodiments, a unique tag sequence comprises the sequence 5′-NNNACTNNNTGA-3′, where “N” represents a position within the random sequence that is generated randomly from A, G, C or T, the number of possible distinct random tags is calculated to be 4⁶ (or 4{circumflex over ( )}6) is about 4096, and the number of possible different combinations of two unique tags is 4¹² (or 4{circumflex over ( )}12) is about 16.78 million. In some embodiments, the underlined portions of 5′-NNNACTNNNTGA-3′ are a sequence alignment anchor.

In some embodiments, the fixed sequences within the unique tag sequence is a sequence alignment anchor that can be used to generate error-corrected sequencing data. In some embodiments fixed sequences within the unique tag sequence is a sequence alignment anchor that can be used to generate a family of error-corrected sequencing reads.

Adaptors provided herein comprise at least one cleavable moiety. In some embodiments a cleavable moiety is within the 3′ target-specific sequence. In some embodiments a cleavable moiety is at or near the junction between the 5′ first universal handle sequence and the 3′ target-specific sequence. In some embodiments a cleavable moiety is at or near the junction between the 5′ first universal handle sequence and the unique tag sequence, and at or near the junction between the unique tag sequence and the 3′ target-specific sequence. The cleavable moiety can be present in a modified nucleotide, nucleoside or nucleobase. In some embodiments, the cleavable moiety can include a nucleobase not naturally occurring in the target sequence of interest.

In some embodiments the at least one cleavable moiety in the plurality of adaptors is a uracil base, uridine or a deoxyuridine nucleotide. In some embodiments a cleavable moiety is within the 3′ target-specific sequence and the junctions between the 5′ universal handle sequence and the unique tag sequence and/or the 3′target specific sequence wherein the at least one cleavable moiety in the plurality of adaptors is cleavable with uracil DNA glycosylase (UDG). In some embodiments, a cleavable moiety is cleaved, resulting in a susceptible abasic site, wherein at least one enzyme capable of reacting on the abasic site generates a gap comprising an extendible 3′ end. In certain embodiments the resulting gap comprises a 5′-deoxyribose phosphate group. In certain embodiments the resulting gap comprises an extendible 3′ end and a 5′ ligatable phosphate group.

In another embodiment, inosine can be incorporated into a DNA-based nucleic acid as a cleavable group. In one exemplary embodiment, EndoV can be used to cleave near the inosine residue. In another exemplary embodiment, the enzyme hAAG can be used to cleave inosine residues from a nucleic acid creating abasic sites.

Where a cleavable moiety is present, the location of the at least one cleavable moiety in the adaptors does not significantly change the melting temperature (Tm) of any given double-stranded adaptor in the plurality of double-stranded adaptors. The melting temperatures (Tm) of any two given double-stranded adaptors from the plurality of double-stranded adaptors are substantially the same, wherein the melting temperatures (Tm) of any two given double-stranded adaptors does not differ by more than 10° C. of each other. However, within each of the plurality of adaptors, the melting temperatures of sequence regions differs, such that the comparable maximal minimum melting temperature of, for example, the universal handle sequence, is higher than the comparable maximal minimum melting temperatures of either the unique tag sequence and/or the target specific sequence of any adaptor. This localized differential in comparable maximal minimum melting temperatures can be adjusted to optimize digestion and repair of amplicons and ultimately improved effectiveness of the methods provided herein.

Further provided are compositions comprising a nucleic acid library generated by methods of the invention. Thus, provided are composition comprising a plurality of amplified target nucleic acid amplicons, wherein each of the plurality of amplicons comprises a 5′ universal handle sequence, optionally a first unique tag sequences, an intermediate target nucleic acid sequence, optionally a second unique tag sequences and a 3′ universal handle sequence. At least two and up to one hundred thousand target specific amplicons are included in provided compositions. Provided compositions include highly multiplexed targeted libraries. In some embodiments, provided compositions comprise a plurality of nucleic acid amplicons, wherein each of the plurality of amplicons comprise a 5′ universal handle sequence, a first unique tag sequences, an intermediate target nucleic acid sequence, a second unique tag sequences and a 3′ universal handle sequence. At least two and up to one hundred thousand target specific tagged amplicons are included in provided compositions. Provided compositions include highly multiplexed tagged targeted libraries.

In some embodiments, library compositions include a plurality of target specific amplicons comprising a multiplex of at least two different target nucleic acid sequences. In some embodiments, the composition comprises at least 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 2750, 3000, 3250, 3500, 3750, 4000, 4500, 5000, 5500, 6000, 7000, 8000, 9000, 10000, 11000, or 12000, or more target-specific amplicons. In some embodiments, the target-specific amplicons comprise one or more exon, gene, exome or region of the genome associated with a clinical or pathological condition, e.g., amplicons comprising one or more sites comprising one or more mutations (e.g., driver mutation) associated with a cancer, e.g., lung, colon, breast cancer, etc., or amplicons comprising mutations associated with an inherited disease, e.g., cystic fibrosis, muscular dystrophies, etc. In some embodiments, the target-specific amplicons comprise a library of adaptor-ligated amplicon target sequences that are about 100 to about 750 base pairs in length.

As described herein, each of the plurality of amplicons comprises a 5′ universal handle sequence. In some embodiments a universal handle sequence comprises any one or any combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence. Preferably, the universal handle sequences of provided adaptors do not exhibit significant complementarity and/or hybridization to any portion of a unique tag sequence and/or target nucleic acid sequence of interest. In some embodiments a first universal handle sequence comprises any one or any combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence. In some embodiments a second universal handle sequence comprises any one or any combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence. In certain embodiments first and second universal handle sequences correspond to forward and reverse universal handle sequences and in certain embodiments the same first and second universal handle sequences are included for each of the plurality of target specific amplicons. Such forward and reverse universal handle sequences are targeted in conjunction with universal primers to carry out a second amplification of a preliminary library composition in production of resulting amplified according to methods of the invention. In certain embodiments a first 5′ universal handle sequence comprises two universal handle sequences (e.g., a combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence); and a second 5′ universal sequence comprises two universal handle sequences (e.g., a combination of an amplification primer binding sequence, a sequencing primer binding sequence and/or a capture primer binding sequence), wherein the 5′ first and second universal handle sequences do not exhibit significant hybridization to any portion of a target nucleic acid sequence of interest.

The structure and properties of universal amplification primers or universal primers are well known to those skilled in the art and can be implemented for utilization in conjunction with provided methods and compositions to adapt to specific analysis platforms. Universal handle sequences of the adaptors and amplicons provided herein are adapted accordingly to accommodate a preferred universal primer sequences. For example, e.g., as described herein universal P1 and A primers with optional barcode sequences have been described in the art and utilized for sequencing on Ion Torrent sequencing platforms (Ion Xpress™ Adapters, Thermo Fisher Scientific). Similarly, additional and other universal adaptor/primer sequences described and known in the art (e.g., Illumina universal adaptor/primer sequences can be found, e.g., at https://support.illumina.com/content/dam/illumina-support/documents/documentation/chemistry_documentation/experiment-design/illumina-adapter-sequences_1000000002694-01.pdf; PacBio universal adaptor/primer sequences, can be found, e.g., at https://s3.amazonaws.com/files.pacb.com/pdf/Guide_Pacific_Biosciences_Template_Preparation_and_Sequencing.pdf; etc.) can be used in conjunction with the methods and compositions provided herein. Suitable universal primers of appropriate nucleotide sequence for use with libraries of the invention are readily prepared using standard automated nucleic acid synthesis equipment and reagents in routine use in the art. One single type or separate types (or even a mixture) of two different universal primers, for example a pair of universal amplification primers suitable for amplification of a preliminary library may be used in production of the libraries of the invention. Universal primers optionally include a tag (barcode) sequence, where the tag (barcode) sequence does not hybridize to adaptor sequence or to target nucleic acid sequences. Barcode sequences incorporated into amplicons in a second universal amplification can be utilized e.g., for effective identification of sample source to thereby generate a barcoded library. Thus provided compositions include highly multiplexed barcoded targeted libraries. Provided compositions also include highly multiplexed barcoded tagged targeted libraries.

In some embodiments amplicon libraries comprise a unique tag sequence located between the 5′ first universal handle sequence and the 3′ target-specific sequence, and wherein the unique tag sequence does not exhibit significant complementarity and/or hybridization to any portion of a unique tag sequence and/or target nucleic acid sequence. In some embodiments the plurality of amplicons has 104-10⁹ different tag sequence combinations. Thus in certain embodiments each of the plurality of amplicons in a library comprises 104-10⁹ different tag sequences. In some embodiments each of the plurality of amplicons in a library comprises at least 1 different unique tag sequence and up to 10⁵ different unique tag sequences. In certain embodiments each target specific amplicon in a library comprises at least two and up to 10⁹ different combinations comprising different tag sequences, each having two different unique tag sequences. In some embodiments each of the plurality of amplicons in a library comprise a tag sequence comprising 4096 different tag sequences. In certain embodiments each target specific amplicon of a library comprises up to 16,777,216 different combinations comprising different tag sequences, each having two different unique tag sequences.

In some embodiments individual amplicons in the plurality of amplicons of a library include a unique tag sequence (e.g., contained in a tag adaptor sequence) comprising different random tag sequences alternating with fixed tag sequences. In some embodiments, the at least one unique tag sequence comprises a at least one random sequence and at least one fixed sequence, or comprises a random sequence flanked on both sides by a fixed sequence, or comprises a fixed sequence flanked on both sides by a random sequence. In some embodiments a unique tag sequence includes a fixed sequence that is 2-2000 nucleotides or base-pairs in length. In some embodiments a unique tag sequence includes a random sequence that is 2-2000 nucleotides or base-pairs in length.

In some embodiments, unique tag sequences include a sequence having at least one random sequence interspersed with fixed sequences. In some embodiments, individual tag sequences in a plurality of unique tags have the structure (N)_(n)(X)_(x)(M)_(m)(Y)_(y), wherein “N” represents a random tag sequence that is generated from A, G, C, T, U or I, and wherein “n” is 2-10 which represents the nucleotide length of the “N” random tag sequence; wherein “X” represents a fixed tag sequence, and wherein “x” is 2-10 which represents the nucleotide length of the “X” random tag sequence; wherein “M” represents a random tag sequence that is generated from A, G, C, T, U or I, wherein the random tag sequence “M” differs or is the same as the random tag sequence “N”, and wherein “m” is 2-10 which represents the nucleotide length of the “M” random tag sequence; and wherein “Y” represents a fixed tag sequence, wherein the fixed tag sequence of “Y” is the same or differs from the fixed tag sequence of “X”, and wherein “y” is 2-10 which represents the nucleotide length of the “Y” random tag sequence. In some embodiments, the fixed tag sequence “X” is the same in a plurality of tags. In some embodiments, the fixed tag sequence “X” is different in a plurality of tags. In some embodiments, the fixed tag sequence “Y” is the same in a plurality of tags. In some embodiments, the fixed tag sequence “Y” is different in a plurality of tags. In some embodiments, the fixed tag sequences “(X),” and “(Y)” within the plurality of amplicons are sequence alignment anchors.

In some embodiments, the random sequence within a unique tag sequence is represented by “N”, and the fixed sequence is represented by “X”. Thus, a unique tag sequence is represented by N₁N₂N₃X₁X₂X₃ or by N₁N₂N₃X₁X₂X₃N₄N₅N₆X₄X₅X₆. Optionally, a unique tag sequence can have a random sequence in which some or all of the nucleotide positions are randomly selected from a group consisting of A, G, C, T, U and I. For example, a nucleotide for each position within a random sequence is independently selected from any one of A, G, C, T, U or I, or is selected from a subset of these six different types of nucleotides. Optionally, a nucleotide for each position within a random sequence is independently selected from any one of A, G, C or T. In some embodiments, the first fixed tag sequence “X₁X₂X₃” is the same or different sequence in a plurality of tags. In some embodiments, the second fixed tag sequence “X₄X₅X₆” is the same or different sequence in a plurality of tags. In some embodiments, the first fixed tag sequence “X₁X₂X₃” and the second fixed tag sequence “X₄X₅X₆” within the plurality of amplicons are sequence alignment anchors.

In some embodiments, a unique tag sequence comprises the sequence 5′-NNNACTNNNTGA-3′, where “N” represents a position within the random sequence that is generated randomly from A, G, C or T, the number of possible distinct random tags is calculated to be 4⁶ (or 4{circumflex over ( )}6) is about 4096, and the number of possible different combinations of two unique tags is 4¹² (or 4{circumflex over ( )}12) is about 16.78 million. In some embodiments, the underlined portions of 5′-NNNACTNNNTGA-3′ are a sequence alignment anchor.

In some embodiments, the fixed sequences within the unique tag sequence is a sequence alignment anchor that can be used to generate error-corrected sequencing data. In some embodiments fixed sequences within the unique tag sequence is a sequence alignment anchor that can be used to generate a family of error-corrected sequencing reads.

Kits, Systems

Further provided herein are kits for use in preparing libraries of target nucleic acids using methods of the first or second aspects of the invention. Embodiments of a kit comprise a supply of at least a pair of target specific adaptors as defined herein which are capable of producing a first amplification product; as well as optionally a supply of at least one universal pair of amplification primers capable of annealing to the universal handle(s) of the adaptor and priming synthesis of an amplification product, which amplification product would include a target sequence of interest ligated to a universal sequence. Adaptors and/or primers may be supplied in kits ready for use, or more preferably as concentrates requiring dilution before use, or even in a lyophilized or dried form requiring reconstitution prior to use. In certain embodiments kits further include a supply of a suitable diluent for dilution or reconstitution of the components. Optionally, kits further comprise supplies of reagents, buffers, enzymes, dNTPs, etc., for use in carrying out amplification, digestion, repair, and/or purification in the generation of library as provided herein. Non-limiting examples of such reagents are as described in the Materials and Methods sections of the accompanying Exemplification. Further components which optionally are supplied in the kit include components suitable for purification of libraries prepared using the provided methods._In some embodiments, provided is a kit for generating a target-specific library comprising a plurality of target-specific adaptors having a 5′ universal handle sequence, a 3′ target specific sequence and a cleavable group, a DNA polymerase, an adaptor, dATP, dCTP, dGTP, dTTP, and a digestion reagent. In some embodiments, the kit further comprises one or more antibodies, a repair reagent, universal primers optionally comprising nucleic acid barcodes, purification solutions or columns.

Particular features of adaptors for inclusion in kits are as described elsewhere herein in relation to other aspects of the invention. The structure and properties of universal amplification primers are well known to those skilled in the art and can be implemented for utilization in conjunction with provided methods and compositions to adapt to specific analysis platforms (e.g., as described herein universal P1 and A primers have been described in the art and utilized for sequencing on Ion Torrent sequencing platforms). Similarly, additional and other universal adaptor/primer sequences described and known in the art (e.g., Illumina universal adaptor/primer sequences, PacBio universal adaptor/primer sequences, etc.) can be used in conjunction with the methods and compositions provided herein. Suitable primers of appropriate nucleotide sequence for use with adaptors included in the kit is readily prepared using standard automated nucleic acid synthesis equipment and reagents in routine use in the art. A kit may include a supply of one single type of universal primer or separate types (or even a mixture) of two different universal primers, for example a pair of amplification primers suitable for amplification of templates modified with adaptors in a first amplification. A kit may comprise at least a pair of adaptors for first amplification of a sample of interest according to the methods of the invention, plus at least two different amplification primers that optionally carry a different tag (barcode) sequence, where the tag (barcode) sequence does not hybridize to the adaptor. A kit can be used to amplify at least two different samples where each sample is amplified according to methods of the invention separately and a second amplification comprises using a single universal primer having a barcode, and then pooling prepared sample libraries after library preparations. In some embodiments a kit includes different universal primer-pairs for use in second amplification step described herein. In this context the ‘universal’ primer-pairs may be of substantially identical nucleotide sequence but differ with respect to some other feature or modification.

Further provided are systems, e.g., systems used to practice methods provided herein, and/or comprising compositions provided herein. In some embodiments, systems facilitate methods carried out in automated mode. In certain embodiments, systems facilitate high throughput mode. In certain embodiments, systems include, e.g., a fluid handling element, a fluid containing element, a heat source and/or heat sink for achieving and maintaining a desired reaction temperature, and/or a robotic element capable of moving components of the system from place to place as needed (e.g., a multiwell plate handling element).

Samples

As defined herein, “sample” and its derivatives, is used in its broadest sense and includes any specimen, culture and/or the like that is suspected of including a target nucleic acid. In some embodiments, a sample comprises DNA, RNA, TNA, chimeric nucleic acid, hybrid nucleic acid, multiplex-forms of nucleic acids or any combination of two or more of the foregoing. In some embodiments a sample useful in conjunction with methods of the invention includes any biological, clinical, surgical, agricultural, atmospheric or aquatic-based specimen containing one or more target nucleic acid of interest. In some embodiments, a sample includes nucleic acid molecules obtained from an animal such as a human or mammalian source. In another embodiment, a sample includes nucleic acid molecules obtained from a non-mammalian source such as a plant, bacteria, virus or fungus. In some embodiments, the source of the nucleic acid molecules may be an archived or extinct sample or species. In some embodiments a sample includes isolated nucleic acid sample prepared, for example, from a source such as genomic DNA, RNA TNA or a prepared sample such as, e.g., fresh-frozen or formalin-fixed paraffin-embedded (FFPE) nucleic acid specimen. It is also envisioned that a sample is from a single individual, a collection of nucleic acid samples from genetically related members, multiple nucleic acid samples from genetically unrelated members, multiple nucleic acid samples (matched) from a single individual such as a tumor sample and normal tissue sample, or genetic material from a single source that contains two distinct forms of genetic material such as maternal and fetal DNA obtained from a maternal subject, or the presence of contaminating bacteria DNA in a sample that contains plant or animal DNA. In some embodiments, a source of nucleic acid material includes nucleic acids obtained from a newborn (e.g., a blood sample for newborn screening). In some embodiments, provided methods comprise amplification of multiple target-specific sequences from a single nucleic acid sample. In some embodiments, provided methods comprise target-specific amplification of two or more target sequences from two or more nucleic acid samples or species. In certain embodiments, provided methods comprise amplification of highly multiplexed target nucleic acid sequences from a single sample. In particular embodiments, provided methods comprise amplification of highly multiplexed target nucleic acid sequences from more than one sample, each from the same source organism.

In some embodiments a sample comprises a mixture of target nucleic acids and non-target nucleic acids. In certain embodiments a sample comprises a plurality of initial polynucleotides which comprises a mixture of one or more target nucleic acids and may include one or more non-target nucleic acids. In some embodiments a sample comprising a plurality of polynucleotides comprises a portion or aliquot of an originating sample; in some embodiments, a sample comprises a plurality of polynucleotides which is the entire originating sample. In some embodiments a sample comprises a plurality of initial polynucleotides is isolated from the same source or from the same subject at different time points.

In some embodiments, a nucleic acid sample includes cell-free nucleic acids from a biological fluid, nucleic acids from a tissue, nucleic acids from a biopsied tissue, nucleic acids from a needle biopsy, nucleic acids from a single cell or nucleic acids from two or more cells. In certain embodiments, a single reaction mixture contains 1-100 ng of the plurality of initial polynucleotides. In some embodiments a plurality of initial polynucleotides comprises a formalin fixed paraffin-embedded (FFPE) sample; genomic DNA; RNA; TNA; cell free DNA or RNA or TNA; circulating tumor DNA or RNA or TNA; fresh frozen sample, or a mixture of two or more of the foregoing; and in some embodiments a the plurality of initial polynucleotides comprises a nucleic acid reference standard. In some embodiments, a sample includes nucleic acid molecules obtained from biopsies, tumors, scrapings, swabs, blood, mucus, urine, plasma, semen, hair, laser capture micro-dissections, surgical resections, and other clinical or laboratory obtained sample. In some embodiments, a sample is an epidemiological, agricultural, forensic or pathogenic sample. In certain embodiments, a sample includes a reference. In some embodiments a sample is a normal tissue or well documented tumor sample. In certain embodiments a reference is a standard nucleic acid sequence (e.g., Hg19).

Target Nucleic Acid Sequence Analysis

Provided methods and compositions of the invention are particularly suitable for amplifying, optionally tagging, and preparing target sequences for subsequent analysis. Thus, in some embodiments, methods provided herein include analyzing resulting library preparations. For example, methods comprise analysis of a polynucleotide sequence of a target nucleic acid, and, where applicable, analysis of any tag sequence(s) added to a target nucleic acid. In some embodiments wherein multiple target nucleic acid regions are amplified, provided methods include determining polynucleotide sequences of multiple target nucleic acids. Provided methods further optionally include using a second tag sequence(s), e.g., barcode sequence, to identify the source of the target sequence (or to provide other information about the sample source). In certain embodiments, use of prepared library composition is provided for analysis of the sequences of the nucleic acid library.

In particular embodiments, use of prepared tagged library compositions is provided for further analyzing the sequences of the target nucleic acid library. In some embodiments determination of sequences comprises determining the abundance of at least one of the target sequences in the sample. In some embodiments determination of a low frequency allele in a sample is comprised in determination of sequences of a nucleic acid library. In certain embodiments, determination of the presence of a mutant target nucleic acid in the plurality of polynucleotides is comprised in determination of sequences of a nucleic acid library. In some embodiments, determination of the presence of a mutant target nucleic acid comprises detecting the abundance level of at least one mutant target nucleic acid in the plurality of polynucleotides. For example, such determination comprises detecting at least one mutant target nucleic acid is present at 0.05% to 1% of the original plurality of polynucleotides in the sample, detecting at least one mutant target nucleic acid is present at about 1% to about 5% of the polynucleotides in the sample, and/or detecting at least 85%-100% of target nucleic acids in sample. In some embodiments, determination of the presence of a mutant target nucleic acid comprises detecting and identification of copy number variation and/or genetic fusion sequences in a sample.

In some embodiments, nucleic acid sequencing of the amplified target sequences produced by the teachings of this disclosure include de novo sequencing or targeted re-sequencing. In some embodiments, nucleic acid sequencing further includes comparing the nucleic acid sequencing results of the amplified target sequences against a reference nucleic acid sequence. In some embodiments, nucleic acid sequencing of the target library sequences further includes determining the presence or absence of a mutation within a nucleic acid sequence. In some embodiments, nucleic acid sequencing includes the identification of genetic markers associated with disease (e.g., cancer and/or inherited disease).

In some embodiments, prepared library of target sequences of the disclosed methods is used in various downstream analysis or assays with, or without, further purification or manipulation. In some embodiments analysis comprises sequencing by traditional sequencing reactions, high throughput next generation sequencing, targeted multiplex array sequence detection, or any combination of two or more of the foregoing. In certain embodiments analysis is carried out by high throughput next generation sequencing. In particular embodiments sequencing is carried out in a bidirectional manner, thereby generating sequence reads in both forward and reverse strands for any given amplicon.

In some embodiments, library prepared according to the methods provided herein is then further manipulated for additional analysis. For example, prepared library sequences is used in downstream enrichment techniques known in the art, such a bridge amplification or emPCR to generate a template library that is then used in next generation sequencing. In some embodiments, the target nucleic acid library is used in an enrichment application and a sequencing application. For example, sequence determination of a provided target nucleic acid library is accomplished using any suitable DNA sequencing platform. In some embodiments, the library sequences of the disclosed methods or subsequently prepared template libraries is used for single nucleotide polymorphism (SNP) analysis, genotyping or epigenetic analysis, copy number variation analysis, gene expression analysis, analysis of gene mutations including but not limited to detection, prognosis and/or diagnosis, detection and analysis of rare or low frequency allele mutations, nucleic acid sequencing including but not limited to de novo sequencing, targeted resequencing and synthetic assembly analysis. In one embodiment, prepared library sequences are used to detect mutations at less than 5% allele frequency. In some embodiments, the methods disclosed herein is used to detect mutations in a population of nucleic acids at less than 4%, 3%, 2% or at about 1% allele frequency. In another embodiment, libraries prepared as described herein are sequenced to detect and/or identify germline or somatic mutations from a population of nucleic acid molecules. In certain embodiments, sequencing adaptors are ligated to the ends of the prepared libraries generate a plurality of libraries suitable for nucleic acid sequencing.

In some embodiments, methods for preparing a target-specific amplicon library are provided for use in a variety of downstream processes or assays such as nucleic acid sequencing or clonal amplification. In some embodiments, the library is amplified using bridge amplification or emPCR to generate a plurality of clonal templates suitable for nucleic acid sequencing. For example, optionally following target-specific amplification a secondary and/or tertiary amplification process including, but not limited to, a library amplification step and/or a clonal amplification step is performed. “Clonal amplification” refers to the generation of many copies of an individual molecule. Various methods known in the art is used for clonal amplification. For example, emulsion PCR is one method, and involves isolating individual DNA molecules along with primer-coated beads in aqueous bubbles within an oil phase. A polymerase chain reaction (PCR) then coats each bead with clonal copies of the isolated library molecule and these beads are subsequently immobilized for later sequencing. Emulsion PCR is used in the methods published by Marguilis et al. and Shendure and Porreca et al. (also known as “polony sequencing”, commercialized by Agencourt and recently acquired by Applied Biosystems). Margulies, et al. (2005) Nature 437: 376-380; Shendure et al., Science 309 (5741): 1728-1732. Another method for clonal amplification is “bridge PCR,” where fragments are amplified upon primers attached to a solid surface. These methods, as well as other methods of clonal amplification, both produce many physically isolated locations that each contain many copies derived from a single molecule polynucleotide fragment. Thus, in some embodiments, the one or more target specific amplicons are amplified using for example, bridge amplification or emPCR to generate a plurality of clonal templates suitable for nucleic acid sequencing.

In some embodiments, at least one of the library sequences to be clonally amplified are attached to a support or particle. A support can be comprised of any suitable material and have any suitable shape, including, for example, planar, spheroid or particulate. In some embodiments, the support is a scaffolded polymer particle as described in U.S. Published App. No. 20100304982, hereby incorporated by reference in its entirety. In certain embodiments methods comprise depositing at least a portion of an enriched population of library sequences onto a support (e.g., a sequencing support), wherein the support comprises an array of sequencing reaction sites. In some embodiments, an enriched population of library sequences are attached to the sequencing reaction sites on the support wherein the support comprises an array of 10²-10¹⁰ sequencing reaction sites.

Sequence determination means determination of information relating to the sequence of a nucleic acid and may include identification or determination of partial as well as full sequence information of the nucleic acid. Sequence information may be determined with varying degrees of statistical reliability or confidence. In some embodiments sequence analysis includes high throughput, low depth detection such as by qPCR, rtPCR, and/or array hybridization detection methodologies known in the art. In some embodiments, sequencing analysis includes the determination of the in depth sequence assessment, such as by Sanger sequencing or other high throughput next generation sequencing methods. Next-generation sequencing means sequence determination using methods that determine many (typically thousands to billions) nucleic acid sequences in an intrinsically massively parallel manner, e.g. where many sequences are read out, e.g., in parallel, or alternatively using an ultra-high throughput serial process that itself may be parallelized. Thus, in certain embodiments, methods of the invention include sequencing analysis comprising massively parallel sequencing. Such methods include but are not limited to pyrosequencing (for example, as commercialized by 454 Life Sciences, Inc., Branford, Conn.); sequencing by ligation (for example, as commercialized in the SOLiD™. technology, Life Technologies, Inc., Carlsbad, Calif.); sequencing by synthesis using modified nucleotides (such as commercialized in TruSeq™ and HiSeg™ and MiSeq™ and/or NovaSeq™ technology by Illumina, Inc., San Diego, Calif.; HeliScope™ by Helicos Biosciences Corporation, Cambridge, Mass.; and PacBio Sequel® or RS systems by Pacific Biosciences of California, Inc., Menlo Park, Calif.), sequencing by ion detection technologies (e.g., Ion Torrent™ technology, Life Technologies, Carlsbad, Calif.); sequencing of DNA nanoballs (Complete Genomics, Inc., Mountain View, Calif.); nanopore-based sequencing technologies (for example, as developed by Oxford Nanopore Technologies, LTD, Oxford, UK), and like highly parallelized sequencing methods.

For example, in certain embodiments, libraries produced by the teachings of the present disclosure are sufficient in yield to be used in a variety of downstream applications including the Ion Xpress™ Template Kit using an Ion Torrent™ PGM system (e.g., PCR-mediated addition of the nucleic acid fragment library onto Ion Sphere™ Particles)(Life Technologies, Part No. 4467389) or Ion Torrent Proton™ system). For example, instructions to prepare a template library from the amplicon library can be found in the Ion Xpress Template Kit User Guide (Life Technologies, Part No. 4465884), hereby incorporated by reference in its entirety. Instructions for loading the subsequent template library onto the Ion Torrent™ Chip for nucleic acid sequencing are described in the Ion Sequencing User Guide (Part No. 4467391), hereby incorporated by reference in its entirety.

The initiation point for the sequencing reaction may be provided by annealing a sequencing primer to a product of a solid-phase amplification reaction. In this regard, one or both of the adaptors added during formation of template library may include a nucleotide sequence which permits annealing of a sequencing primer to amplified products derived by whole genome or solid-phase amplification of the template library. Depending on implementation of an embodiment of the invention, a tag sequence and/or target nucleic acid sequence may be determined in a single read from a single sequencing primer, or in multiple reads from two different sequencing primers. In the case of two reads from two sequencing primers, a ‘tag read’ and a ‘target sequence read’ are performed in either order, with a suitable denaturing step to remove an annealed primer after the first sequencing read is completed.

In some embodiments, a sequencer is coupled to server that applies parameters or software to determine the sequence of the amplified target nucleic acid molecules. In certain embodiments, the sequencer is coupled to a server that applies parameters or software to determine the presence of a low frequency mutation allele present in a sample.

EXEMPLIFICATION Example 1 Materials and Methods

Reverse Transcription (RT) Reaction method (21 uL reaction)_may be carried out in samples where RNA and DNA are analyzed, e.g., FFPE RNA and cfTNA:

-   -   1. Thaw the 5×URT buffer at room temperature for at least 5         minutes. (NOTE: Check for white precipitate in the tube. Vortex         to mix as needed)

URT Buffer 5× concentration TrisHCl ph 8.4 125 mM Ammonium sulfate  50 mM MgCl2  20 mM dNTP pH 7.6   5 mM

-   -   2. In a MicroAmp EnduraPlate 96-well plate, set up the RT         reaction by adding the following components.

(5-15ng RNA or DNA//5-40ng cfTNA)

Component Volume 20 ng input cfTNA/10 ng FFPE RNA 15 μL 5 × URT buffer  4 μL 10 × RT (SSIV) Enzyme Mix  2 μL Total volume  21 L  

-   -   3. Mix entire contents by vortexing or pipetting. Spin down         briefly.     -   4. Add 20 μl Parol 40 C oil to the top of each reaction mix.     -   5. Load the plate into thermocycler (e.g., SimpliAmp         Thermocycler), and run the following program:

Stage Temperature Time Stage 1 25° C. 10 min Stage 2 50° C. 10 min Stage 3 85° C.  5 min Hold  4° C. ∞

Low-Cycle Tagging PCR (38 uL Reaction Volume+20 uL Oil):

Assemble tagging PCR reaction in 96-well PCR plate wells:

FFPE DNA Samples Only

1. Assemble the reaction by adding the following components to a MicroAmp EnduraPlate 96-well plate:

a. Prepare UDG mix: 1 ul+5 ul 5×URT buffer

b. Add the 6 ul diluted UDG to 15 μl FFPE DNA samples.

c. Mix by vortexing. Briefly spin down to collect reaction at the bottom of the wells.

d. Add 20 μL Parol 40 C Oil to the top of each sample.

e. Perform the reaction as following:

Stage Temperature Time Stage 1 37° C.      2 min Stage 2 50° C.     10 min Hold  4° C.  >=1 min

2. Prepare Amplification Master Mix:

Component Volume Hawkeye panel FWD pool (125 nM) 3.75 μL Hawkeye panel REV pool (125 nM) 3.75 μL 4 × SuperFiU MM v2.0  9.5 μL Total volume   17 μL 3. Add 17 μL PCR Master Mix to 21 μL UDG treated FFPE DNA samples. Set a pipette at 20 μL volume. Mix the reaction below oil by pipetting up and down 20 times to ensure thorough mix of the reaction without disturbing the oil phase. Spin down the plate briefly.

FFPE RNA and cfTNA Samples Only

1. Add components directly to the RT reactions from RT steps above:

Component Volume RT reaction  21 μL Hawkeye panel FWD pool (10×, 125 nM) 3.8 μL Hawkeye panel REV pool (10×, 125 nM) 3.8 μL 4 × SuperFiU MM v2.0 9.5 μL Total volume  38 L  2. Set a pipette at 20 μL volume. Mix the reaction below oil by pipetting up and down 20 times to ensure thorough mix of the reaction without disturbing the oil phase. Spin down the plate briefly. 3. Perform 3-cycles tagging PCR using the following cycling condition on SimpliAmp:

For FFPE DNA and RNA Libraries:

Stage Temperature Time Hold 99° C. 1 min Cycle: 99° C. 30 sec 3 64° C. 2 min 60° C. 12 min 66° C. 2 min 72° C. 2 min Hold 72° C. 2 min Hold  4° C. ∞

For cfTNA Libraries

Stage Temperature Time Cycle: 99° C. 30 sec 3 64° C. 2 min 60° C. 12 min 66° C. 2 min 72° C. 2 min Hold 72° C. 2 min Hold  4° C. ∞

Digestion-Filling-Ligation (45.6 μL Reaction Volume+20 μL Oil):

-   1. Add 7.6 μL of SUPA into each of the above PCR reaction well. Add     SUPA directly to the sample below the oil layer. -   2. Set a pipette at 25 μL. Mix the reaction below oil layer by     pipetting up and down for 20 times. Spin down the plate briefly. -   3. Load the plate into thermocycler and run the following program:

Stage Temperature Time Stage 1 30° C. 15 min Stage 2 50° C. 15 min Stage 3 55° C. 15 min Stage 4 25° C. 10 min Stage 5 98° C. 2 min Hold  4° C. ∞

Library Amplification (˜51 μL Reaction Volume+20 μL Oil)

1. Carefully transfer 30 μL the above post digestion-filling-ligation reaction to AmpliSeq HD Dual Barcodes. Mix well by pipetting up and down 20 times. Transfer all the reactions back to the original well under the oil layer. 2. Set a pipette at 30 μL. Mix entire reaction below oil by pipetting up and down 20 times. Spin down the plate briefly. 3. Load the plate into thermocycler and run the following program:

Stage Temperature Time Hold 99° C. 15 sec Cycle: 5 99° C. 15 sec 62° C. 20 sec 72° C. 20 sec Cycle: 15 (FFPE DNA 99° C. 15 sec and cfFNA) Cycle: 18 (FFPE RNA) 70° C. 40 sec Hold 72° C. 5 min Hold  4° C. ∞

2—Round AmpurcXP library purification

Resulting repaired sample is purified using 36.8 ul Ampure® beads (Beckman Coulter, Inc.) according to the manufacturer instructions for two rounds. Briefly:

-   -   Transfer 46 μL of library reaction below oil layer to new, clean         wells on the PCR plate.     -   Add 36.8 μl of Agencourt™ AMPure™ XP Reagent to each sample and         mix by pipetting then incubate at room temperature for 5         minutes.     -   Place the plate on magnet until the solutions in wells become         clear.     -   Carefully remove the supernatant; then remove residual         supernatant.     -   Add 150 uL of 80% ethanol in 10 mM pH 8 Tris-HCl. Do not disturb         the bead pellet.     -   Toggle plate on magnet 3 times with 5 seconds interval; Remove         the supernatant; Repeat wash steps one more time. Use a pipette         to remove residual buffer in the wells.     -   Dry wells at room temperature for 5 min.     -   Add 30 uL of low TE buffer to the wells and pipette to resuspend         beads.     -   Incubate the solution at room temperature for 5 min, Place plate         on magnet to clear solution.     -   Transfer 30 uL of the eluent into clean well on a plate.     -   Add into the above well 30 μL (1× Volume) of AmpureXP beads;         Pipette in well to mix.     -   Repeat steps as above, using 40 uL of low TE buffer to elute         after second purification.     -   Transfer 40 uL of the library into a new clean well.

Library Normalization with Individual Equalizer

First, warm all reagents in the Ion Library Equalizer™ Kit to room temperature. Vortex and centrifuge all reagents. Wash the Equalizer™ Beads (f previously performed skip to Add Equalizer™ Beads and Wash).

-   -   1. For each 4 reaction, add 12 μL of beads into a clean 1.5-mL         tube and 24 μL/reaction Equalizer™ Wash Buffer.     -   2. Place tube in a magnetic rack for 3 minutes or until the         solution is completely clear.     -   3. Carefully remove and discard the supernatant without         disturbing the pellet.     -   4. Remove from magnet, add 24 μL per reaction Equalizer™ Wash         Buffer, and resuspend.

Amplify the Library

-   -   5. Remove plate with purified libraries from the magnet, then         add 10 μL of 5× DV-Amp Mix and     -   2 μL of Equalizer™ Primers (pink cap in Equalizer kit). Total         volume=52 μL     -   6. Mix.     -   7. Add 20 μL Parol 40 C Oil gently on top of samples.     -   8. run the following program on thermocycler:         -   98 C for 2 min         -   9-cycles amplification for FFPE DNA/RNA OR 6-cycles             amplification for cfTNA:         -   98 C for 15 sec         -   64 C for 1 min         -   Then         -   Hold at 4 C for infinite     -   9. (Optional) after thermal cycling, centrifuge plate to collect         any droplets.

Add Equalizer™ Capture to the amplified library

-   -   10. Add 10 μL of Equalizer Capture to each library amplification         reaction beneath the oil layer.     -   11. mix up and down 10×.     -   12. Incubate at room temperature for 5 minutes.

Add Equalizer™ Beads and wash

-   -   13. Transfer 60 μL amplified library samples beneath the oil         layer into well with washed beads.     -   14. mix thoroughly.     -   15. Incubate at room temperature for 5 minutes.     -   16. Place plate in magnet, then incubate for 2 minutes or until         the solution is clear.     -   17. remove the supernatant.     -   18. Add 150 μL of Equalizer™ Wash Buffer to each reaction.     -   19. With the plate still in the magnet, remove, and discard         supernatant.     -   20. Repeat the bead wash Elute the Equalized Library.

Elute the Equalized library

-   -   21. Remove plate from magnet, add 100 μL of Equalizer™ Elution         Buffer to each pellet.     -   22. Pipette mix with 50 ul volume 5×.     -   23. Elute library by incubating on thermo cycler at 32° C. for 5         minutes.     -   24. Remove immediately, place plate in magnet, as soon as         solution is clear, move to new wells.     -   25. Perform qPCR and adjust pool @100 pM for templating and         sequencing.

Example 2 Compositions and Methods

The first step of provided methods comprises a few rounds of amplification, for example, three to six cycles of amplification, and in certain instances, three cycles of amplification using forward and reverse adaptors to each gene specific target sequence. Each adaptor contains a 5′universal sequence, and a 3′ gene specific target sequence. In some embodiments adaptors optionally comprise a unique tag sequence located between the 5′ universal and the 3′ gene specific target sequences.

In specific embodiments wherein unique tag sequences are utilized, each gene specific target adaptor pair includes a multitude of different unique tag sequences in each adaptor. For example, each gene specific target adaptor comprises up to 4096 TAGs. Thus, each target specific adaptor pair comprises at least four and up to 16,777,216 possible combinations.

Each of the provided adaptors comprises a cleavable uracil in place of thymine at specific locations in the forward and reverse adaptor sequences. Positions of uracils (Us) are consistent for all forward and reverse adaptors having unique tag sequences, wherein uracils (Us) are present flanking the 5′ and 3′ ends of the unique tag sequence when present; and Us are present in each of the gene specific target sequence regions, though locations for each gene specific target sequence will inevitably vary. Uracils flanking each unique tag sequence (UT) and in gene-specific sequence regions are designed in conjunction with sequences and calculated Tm of such sequences, to promote fragment dissociation at a temperature lower than melting temperature of the universal handle sequences, which are designed to remain hybridized at a selected temperature. Variations in Us in the flanking sequences of the UT region are possible, however designs keep the melting temperature below that of the universal handle sequences on each of the forward and reverse adaptors. Exemplary adaptor sequence structures comprise:

Forward Adaptor: SEQ ID NO: 1564 ------A Handle------------*UT*------ -Gene Specific-- TCTGTACGGTGACAAGGCG-U-NNNACTNNNTGA-U-XXXXXXXXXXXXXXXX  Reverse Adaptor SEQ ID NO: 1565 TGACAAGGCGTAGTCACGG-U-NNNACTNNNTGA-U-XXXXXXXXXXXXXXXX  -----B Handle------- ------UT------- -------Gene Specific------- Wherein each N is a base selected from A, C, G, or T and the constant sections of the UT region are used as anchor sequences to ensure correct identification of variable (N) portion. The constant and variable regions of the UT can be significantly modified (e.g., alternative constant sequence, >3Ns per section) as long as the Tm of the UT region remains below that of the universal handle regions. Importantly, cleavable uracils are absent from each forward (e.g., TCTGTACGGTGACAAGGCG (SEQ ID NO:1566 and reverse (e.g., TGACAAGGCGTAGTCACGG (SEQ ID NO:1567) universal handle sequence. In the present example, universal sequences have been designed to accommodate follow on amplification and addition of sequencing sequences on the ION Torrent platform, however, one skilled in the art would understand that such universal sequences could be adaptable to use other universal sequences which may be more amenable to alternative sequencing platforms (e.g., ILLUMINA sequencing systems, QIAGEN sequencing systems, PACBIO sequencing systems, BGI sequencing systems, or others).

Methods of use of provided compositions comprise library preparation via AmpliSeq HD technology with slight variations thereof and using reagents and kits available from Thermo Fisher Scientific. SuperFiU DNA comprises a modification in the uracil-binding pocket (e.g., AA 36) and a family B polymerase catalytic domain (e.g., AA 762). SuperFiU is described in U.S. Provisional patent application No. 62/524,730 filed Jun. 26, 2017, which is hereby incorporated by reference. Polymerase enzymes may be limited in their ability to utilize uracil and/or any alternative cleavable residues (e.g., inosine, etc.) included into adaptor sequences. In certain embodiments, it may also be advantageous to use a mixture of polymerases to reduce enzyme specific PCR errors.

The second step of methods involves partial digestion of resulting amplicons, as well as any unused uracil-containing adaptors. For example, where uracil is incorporated as a cleavable site, digestion and repair includes enzymatic cleavage of the uridine monophosphate from resulting primers, primer dimers and amplicons, and melting DNA fragments, then repairing gapped amplicons by polymerase fill-in and ligation. This step reduces and potentially eliminates primer-dimer products that occur in multiplex PCR. In some instances, digestion and repair are carried out in a single step. In certain instances, it may be desirable to separate digestion and repair-steps temporally. For example, thermolabile polymerase inhibitors may be utilized in conjunction with methods, such that digestion occurs at lower temperatures (25-40° C.), then repair is activated by increasing temperature enough to disrupt a polymerase-inhibitor interaction (e.g., polymerase-Ab), though not high enough to melt the universal handle sequences.

Uracil-DNA Glycosylase (UDG) enzyme can be used to remove uracils, leaving abasic sites which can be acted upon by several enzymes or enzyme combinations including (but not limited to): APE 1-Apurinic/apyrimidinic endonuclease; FPG-Formamidopyrimidine [fapy]-DNA glycosylase; Nth-Endonuclease II; Endo VIII-Endonuclease VIII; PNK-Polynucleotide Kinase; Taq-Thermus aquaticus DNA polymerase; DNA pol I-DNA polymerase I; Pol beta-Human DNA polymerase beta. In a particular implementation, the method uses Human apurinic/apyrimidinic endonuclease, APE1. APE1 activity leaves a 3′-OH and a 5′deoxyribose-phosphate (5′-dRP). Removal of the 5′-dRP can be accomplished by a number of enzymes including recJ, Polymerase beta, Taq, DNA pol I, or any DNA polymerase with 5′-3′ exonuclease activity. Removal of the 5′-dRP by any of these enzymes creates a ligatable 5′-phosphate end. In another implementations, UDG activity removes the Uracil and leaves and abasic site which is removed by FPG, leaving a 3′ and 5′-phosphate. The 3′-phosphate is then removed by T4 PNK, leaving a polymerase extendable 3′-OH. The 5′-deoxyribose phosphate can then be removed by Polymerase beta, fpg, Nth, Endo VIII, Taq, DNA pol I, or any other DNA polymerase with 5′-3′ exonuclease activity. In a particular implementation Taq DNA polymerase is utilized.

Repair fill-in process can be accomplished by almost any polymerase, possibly the amplification polymerase used for amplification in step 1 or by any polymerase added in step 2 including (but not limited to): Phusion DNA polymerase; Phusion U DNA polymerase; SuperFi DNA polymerase; SuperFi U DNA polymerase; TAQ; Pol beta; T4 DNA polymerase; and T7 DNA polymerase. Ligation repair of amplicons can be performed by many ligases including (but not limited to): T4 DNA ligase; T7 DNA ligase; Taq DNA ligase. In a particular implementation of the methods, Taq DNA polymerase is utilized and ligation repaired in accomplished by T7 DNA ligase.

A last step of library preparation involves amplification of the repaired amplicons by standard PCR protocols using universal primers that contain sequences complementary to the universal handle sequences on the 5′ and 3′ ends of prepared amplicons. For example, an A-universal primer, and a P1 universal primer, each part of the Ion Express Adaptor Kit (Thermo Fisher Scientific, Inc.) may optionally contain a sample specific barcode. The last library amplification step may be performed by many polymerases including, but not limited to: Phusion DNA polymerase; Phusion U DNA polymerase; SuperFi DNA polymerase; SuperFi U DNA polymerase; Taq DNA polymerase; Veraseq Ultra DNA polymerase.

Example 3 Assay Content and Methods

With primers directed to target sequences specific to targets in Table 1, adaptors each comprise 4096 unique tag sequences for each gene specific target sequence, resulting in an estimate of 16,777,216 different unique tag combinations for each gene specific target sequence pair.

Preparation of library was carried out according to the method described above. Prepared libraries are prepared for templating and sequenced, and analyzed. Sequencing can be carried out by a variety of known methods, including, but not limited to sequencing by synthesis, sequencing by ligation, and/or sequencing by hybridization. Sequencing has been carried out in the examples herein using the Ion Torrent platform (Thermo Fisher Scientific, Inc.), however, libraries can be prepared and adapted for analysis, e.g., sequencing, using any other platforms, e.g., Illumina, Qiagen, PacBio, etc. Results may be analyzed using a number of metrics to assess performance, for example:

-   -   # of families (with ng input DNA captured) The median # of         families is a measure of the number of families that maps to an         individual target. In this case, each unique molecular tag is a         family.     -   Uniformity is a measure of the percentage of target bases         covered by at least 0.2× the average read depth. This metric is         used to ensure that the technology does not selectively         under-amplify certain targets.     -   Positives/Negatives: When a control sample with known mutations         is utilized is analyzed (e.g., Acrometrix Oncology Hotspot         Control DNA, Thermo Fisher Scientific, Inc.), the number of True         Positives can be tracked.         -   True Positives: The number of True Positives informs on the             number of mutations that were present and correctly             identified.         -   False positives (FP): (Hot spot and Whole Target) The number             of False Positives informs on the number of mutations that             are determined to be present, but known not to be in the             sample.         -   False negatives (FN) (if acrometrix spike-in is used) The             number of False Negatives informs on the number of mutations             that were present but not identified.     -   On/Off Target is the percentage of mapped reads that were         aligned/not aligned over a target region. This metric is used to         ensure the technology amplifies predominantly the targets to         which the panel was designed.     -   Low quality is tracked to ensure the data is worth analyzing.         This metric is a general system metric and isn't directly         related to this technology.

TABLE 1 Precision Assay Gene Content by Variant Class DNA Inter-Genetic Intra-Genetic Hotspots CNV Fusions Fusions AKT1 GNAS ALK ALK AR AKT2 HRAS AR BRAF EGFR AKT3 IDH1 CD274 ESR1 MET ALK IDH2 CDKN2A FGFR1 AR KIT EGFR FGFR2 ARAF KRAS ERBB2 FGFR3 BRAF MAP2K1 ERBB3 MET CDK4 MAP2K2 FGFR1 NRG1 CDKN2A MET FGFR2 NTRK1 CHEK2 MTOR FGFR3 NTRK2 CTNNB1 NRAS KRAS NTRK3 EGFR NTRK1 MET NUTM1 ERBB2 NTRK2 PIK3CA RET ERBB3 NTRK3 PTEN ROS1 ERBB4 PDGFRA RSPO2 ESR1 PIK3CA RSPO3 FGFR1 PTEN 50 Total Genes FGFR2 RAF1 45 DNA Hotspot Genes FGFR3 RET 14 CNV Genes FGFR4 ROS1 16 Inter-Genetic Fusions FLT3 SMO  3 Intra-Genetic Fusions GNA11 TP53 GNAQ Bold includes non-targeted fusion

Clinical evidence is defined as number of instances that a gene/variant combination appears in drug labels, guidelines, and/or clinical trials. Tables 2 and 3 depict top genes/variants and indications relevant to provided assay, as supported by clinical evidence.

TABLE 2 Top 5 assay genes/variant types with the most clinical evidence ERBB2 (HER2) amplification EGFR hotspot mutations BRAF hotspot mutations KRAS hotspot mutations ALK fusions

TABLE 3 Top 5 indications with the most clinical evidence NSCLC Breast Colorectal Melanoma Kidney

Up to 29 gene and variant combinations covered under the provided assay are on drug labels and/or guidelines (NCCN and ESMO)

TABLE 4 Cancer Indications Ranked by Clinical Evidence Non-Small Cell Lung Cancer Ovarian Cancer Thyroid Cancer Unspecified Solid Tumor Bladder Cancer Glioblastoma Breast Cancer Esophageal Cancer Soft Tissue Sarcoma Colorectal Cancer Head and Neck Cancer Gastrointestinal Stromal Tumor Melanoma Endometrial Cancer Small Cell Lung Cancer Kidney Cancer Pancreatic Cancer Cervical Cancer Gastric Cancer Liver Cancer

Example 4 Results

Primers were designed using the composition design approach provided herein and targeted to oncology genes using those of the panel target genes as described above in Table 1, where the library amplification step utilized two primer pairs (to put the two universal sequences on each end of amplicons, e.g., an A-universal handle and a P1-universal handle on each end) to enable bi-directional sequencing as described herein. Prepared library was sequenced using Ion Gene Studio Templating/and Sequencing kits and instrumentation (Thermo Fisher Scientific, Inc.) and/or a new fully integrated library preparation, templating and sequencing system. Performance with the instant panel indicates the technology is able to appropriately detect targeted mutations, copy number variations and fusions as intended.

A. Fusion Detection Capability in Various ALK and ROS Isoforms from NSCLC FFPE Samples

Libraries were prepared and sequenced as described above. Various fusion isoform detection was demonstrated as expected:

HIP1-ALK.H21A20 KIF5B-ALK.K17A20 EML4-ALK.E20A20 Read Count: 373 Read Count: 602 Read Count: 671 Molecular Count: 3 Molecular Count: 10 Molecular Count: 12 CD74-ROS1. C6R34 SLC34A2-ROS1.S13R32 Read Count: 1947 Read Count: 2518 Molecular Count: 82 Molecular Count: 82

4B: Mutation Detection in Matched Samples with GeneStudio S5 and New Sequencer

Sample GeneStudio S5 NEW System Type FFPE Plasma FFPE Plasma Breast ✓ PIK3CA G1049R ✓ PIK3CA G1049R ✓ PIK3CA G1049R ✓ PIK3CA G1049R Colon ✓ None ✓ None ✓ None ✓ None Colon ✓ KRAS G12V ✓ KRAS G12V ✓ KRAS G12V ✓ KRAS G12V Colon ✓ KRAS G12D ✓ KRAS G12D ✓ KRAS G12D ✓ KRAS G12D NSCLC ✓ KRAS Q61H ✓ KRAS Q61H ✓ KRAS Q61H ✓ KRAS Q61H

Library preparation, sequencing and analysis was carried out for mutation detection in matched samples as described above using both manual preparation and sequencing on ION GeneStudio S5 as well as an automated and integrated library preparation, templating and sequencing system. The precision assay demonstrated concordant PIK3CA and KRAS mutation detection across matched tissue and plasma samples with both the GeneStudio S5 with manual workflow as compared to the automated system.

4C: DNA Variant Detection Across Various Cancer Indications

Library preparation, sequencing and analysis was carried out for mutation detection in a variety of different sample types as described above using both manual preparation and sequencing on ION GeneStudio S5 as well as an automated and integrated library preparation, templating and sequencing system. The precision assay demonstrated detected various driver mutations across different cancer indication sample types.

Squamous Cell Carcinoma Solid Melanoma Breast Colon (SCC) Pancreas Glioblastoma Tumor NSCLC NRAS NRAS EGFR KRAS KRAS EGFR NTRK EGFR BRAF BRAF BRAF TP53 Amplification fusions BRAF KIT PIK3CA KRAS KRAS ERBB2 NRAS ERBB2 amplification MET ALK fusions ROS fusions RET fusions

4D: Detection Using Cohort of Matched FFPE and Plasma Samples

Library preparation, sequencing and analysis was carried out for evaluation of performance of the assay in detecting variants across cohort of matched FFPE and plasma samples. The assay demonstrated detection of various driver mutations across different cancer indication sample types. Using the assay on a set of matched FFPE and plasma samples, 4 out of 8 had concordant PIK3CA(1) and KRAS(3) mutations; while 1 out of 8 had concordant NO variants detected

Sample Cancer Tumor FFPE Variant Plasma Variant # Type Grade Stage Results Results 1 Breast G2 IIIA PIK3CA PIK3CA G1049R G1049R (32.26%) (12.88%) 2 Breast G3 IIIA FGFR1 CNV TBD* (7.2) 3 Breast G3 IIIC TP53 H179R None (68.42%) ERBB2 CNV TBD* (16.2) 4 Colon G2 IIIA None None 5 Colon G3 IIIA KRAS G12V KRAS G12V (41.35%) (12.81%) PTEN 1.14 TBD* 6 Colon G2 IIIA KRAS G12D KRAS G12D (11.29%) (15.42%) 7 NSCLC Unknown IIIB KRAS G12D None (12.24%) 8 NSCLC Unknown IIIA KRAS Q61H KRAS Q61H (26.41%) (1.67%)

4E: Detection of Variants in FFPE Cancer Samples with Known Variants

Library preparation, sequencing and analysis was carried out for evaluation of performance of the assay in detecting variants in 16 FFPE samples (NSCLC, Breast, and CRC) with known mutations previously confirmed using ONCOMINE cfDNA assays. Samples were tested within a single run (chip) using the assay on an integrated system. 8 samples had previously been characterized using Oncomine cfDNA assays In this cohort, 17 mutations were detected by the present assay, within EGFR, ERBB4, IDH1, KRAS, MET, PIK3CA, and TP53 Additionally, 3 amplifications in EGFR, ERBB2, and FGFR1 were detected Lastly, 3 fusions with FGFR2 and RSPO3 driver genes were also detected. The assay was able to detect a number of variants, including SNV mutations, CNV amplifications, and fusions in a cohort of FFPE samples.

4F. SNV and CNV Detection with Multiple Cancer Tvpe from FFPE

The assay was used to detect various driver mutations across different cancer indications. All results were concordant with previous characterization using different assay and system:

Allele Allele freq. Allele freq. Expected Sample Previous FFPE freq. FFPE CNV Pathological ID SNV family- FFPE read- based on Detected diagnosis FFPE Previous SNV AF based hybrid based S5 CNV Adenocarcinoma AB 2  KRAS 4.03% 9.4% 9.4% 10.8% ductal COSM521_p.G12D Invasive AB 3  IDH1 45.54% 48.7% 51.2% 49.9% adenocarcinoma COSM97131_p.V178I EGFR 13.81% 9.5% 13.9% 15.1% COSM6224_p.L858R Colon AB 4  BRAE 18.75% 34.2% 17.2% 17.3% adenocarcinoma COSM476_p.V600E Invasive AB 5  none none none none none carcinoma of no special type (NCT) Glioblastoma AB 8  none none none none none EGFR, EGFR multiforme 40 gain (22x) Melanoma AB 10 NRAS 18.57% 28.6% 25.3% 26.5% COSM584_p.Q61R Squamous cell AB 11 HRAS 11.83% 25.0% 21.6% 21.6% carcinoma COSM487_p.G13S Infiltrative AB 14 none none none none none FGFR1, FGFR1 urothelial 6 gain (3x) carcinoma (high grade) Melanoma AB 1  BRAE 63.16% 88.9% 65.2% 65.2% COSM476_p.V600E Invasive AB 6  PIK3CA 27.59% 14.6% 13.2% 13.2% carcinoma of no COSM763_p.E545K special type (NCT) Squamous cell AB 12 TP53 23.88% 23.7% 22.2% 23.4% CDKN2 carcinoma COSM10660_p.R273H A loss (0.6x)  Glioblastoma AB 20 none none none none none EGFR, EGFR multiforme 42 gain (24x)

4G. Detection of Fusions Across ALK, ROS1, RET, NTRK1, NTRK2, and NTRK3 Driver Genes

Library preparation, sequencing and analysis was carried out for evaluation of performance of the assay in detecting fusion variants The assay was able to reproducibly detect 11 fusion isoforms representing 6 driver genes (ALK, BRAF FGFR3, NTRK1, NTRK3, RET, and ROS1), as well as 15 NTRK fusion isoforms representing 3 driver genes (NTRK1, NTRK2, and NTRK3) using targeted isoform detection.

Replicate 1 Replicate 2 (read/ (read/ molecular molecular Material Fusion Isoform counts) counts) SeraCare Seraseq CD74-ROS1.C6R34 78/6 141/12 FFPE Tumor EML4-ALK.E13A20 583/18 530/21 Fusion RNA ETV6-NTRK3.E5N15 639/34 307/17 Reference FGFR3-BAIAP2L1.F17B2 343/14 443/24 Material FGFR3-TACC3.F17T11 504/26 360/22 KIF5B-RET.K24R11 333/20 153/3  LMNA-NTRK1.L2N11 819/22 815/26 NCOA4-RET.N7R12 664/22 805/25 SLC34A2-ROS1.S4R34 74/4 121/9  SLC45A3-BRAF.S1B8 519/35 566/34 TPM3-NTRK1.T7N10 553/28 464/30 SeraCare Seraseq AFAP1-NTRK2.A14N10 2542/157 1823/137 FFPE NTRK BTBD1-NTRK3.B4N14 1676/153 1753/169 Fusion RNA ETV6-NTRK3.E4N14 1892/144 1815/161 Reference ETV6-NTRK3.E4N15 2224/132 2348/164 Material ETV6-NTRK3.E5N14 1605/132 1775/145 ETV6-NTRK3.E5N15 2811/160 2208/165 IRF2BP2-NTRK1.I1N9 1584/122 1877/156 LMNA-NTRK1.L11N11 3618/184 3000/185 NACC2-NTRK2.N4N12 1839/94  1626/106 PAN3-NTRK2.P1N15 772/48 783/68 QKI-NTRK2.Q6N14 2376/196 1891/181 SQSTM1-NTRK1.S5N9 4679/186 3260/159 TFG-NTRK1.T5N9 1842/141 1529/134 TPM3-NTRK1.T7N9 2645/185 2891/207 TRIM24-NTRK2.T12N13 2940/112 1969/92 

4H: Detection of EGFR and KRAS Variants in Control Materials

Expected Replicate 1 Replicate 2 Material Variant Variant Type AF % Observed AF % Horizon EGFR p.G719S SNV 5% 6.02% 8.45% 5% FFPE EGFR INDEL 5% 3.26% 5.26% p.E746_A750delELREA EGFR p.T790M SNV 5% 6.76% 4.40% EGFR p.L858R SNV 5% 5.00% 5.29% Horizon EGFR p.G719S SNV 1% ND 1.46% 1% FFPE EGFR INDEL 1% 1.35% 1.08% p.E746_A750delELREA EGFR p.T790M SNV 1% 2.21% 0.77% EGFR p.L858R SNV 1% 1.53% 1.00% KRAS NRAS p.Q61K SNV 5% 2.46% 3.67% Gene- NRAS p.G12V SNV 5% 5.51% 4.26% Specific KRAS p.A146T SNV 5% 2.94% 4.00% Multiplex KRAS p.Q61H SNV 5% 6.45% 5.66% Reference KRAS p.G13D SNV 5% 2.48% 6.14% Standard KRAS p.G12D SNV 5% 2.97% 3.07% 5% FFPE

Library preparation, sequencing and analysis was carried out for evaluation of performance of the assay in detecting variants of EGFR Using Horizon EGFR Gene-Specific Multiplex Reference Standard 5% and 1% FFPE Controls; and in detecting fusion variants of RAS Using Horizon KRAS Gene-Specific Multiplex Reference Standard 5% FFPE. The assay was able to detect all EGFR variants at 5% allele frequency using a Horizon FFPE control. At 1% allele frequency—which is below typical LOD—the assay picked up 7 out of 8 instances across 2 replicates: The assay was able to reproducibly detect 6 RAS mutations using Horizon control.

4I: Detection of KRAS, BRAF, KIT, EGFR Mutations Using cfDNA Controls

Library preparation, sequencing and analysis was carried out for evaluation of performance of the assay in detecting KRAS, BRAF, KIT, EGFR mutations using cfDNA controls SeraCare Seraseq ctDNA Reference Material v2 AF 0.125% or Horizon Multiplex I cfDNA Reference Standard Set (1% and 0.1%). The assay was able to detect mutations down to an allele frequency of 0.1% using cfDNA controls.

Replicate Replicate Expected 1 2 Material Variant Type AF Observed AF Seraseq KRAS G12D SNV  0.11% 0.089% ND ctDNA BRAF V600E SNV  0.14% 0.111% 0.206% KIT D816V SNV 0.125% 0.193% ND EGFRp.E746_A750 INDEL  0.12% 0.155% 0.143% delELREA EGFR INDEL  0.18% 0.101% 0.086% p.D770_N771insG EGFR T790M SNV  0.18% 0.177% 0.184% EGFRL858R SNV  0.17% 0.225% ND Horizon KRAS G12D SNV    1% 1.272% 1.269% 1% Horizon KRAS G12D SNV  0.1% 0.094% 0.232% 0.1%

4J: Detection of MET and PTEN Copy Number Variation

Library preparation, sequencing and analysis was carried out for evaluation of performance of the assay in detection of MET copy gain and PTEN copy loss using control and cell line. Structural Multiplex FFPE Reference Standard (Horizon) was utilized to detect MET, and a PTEN cell line (ATCC) was used for detection of PTEN copy number variation. The assay was able to detect the MET copy number gain and PTEN copy number loss using control and cell line, respectively.

Expected Expected Observed Observed CNV Copy Copy Copy Sample Gene Status Number Number R1 Number R2 Wild- MET 2 2.3 2.3 type Horizon MET 4.5 4.6 4.6 Wild- PTEN 2 2.5 2.6 type Cell Line PTEN 0 0 0

4K: Detection of NTRK1, FGFR3, RET Fusions in Cell Lines.

Library preparation, sequencing and analysis was carried out for evaluation of performance of the assay in detection in NTRK1, FGFR3, RET fusion cell lines. KM12 cell line (ATCC); SW780 cell line (ATCC); LC-2/ad cell line (Sigma Aldrich) were used for nucleic acid preparation and evaluation. The assay was able to detect the TPM3-NTRK1 fusion isoform using both the targeted isoform and imbalance assay methods of the assay. The assay was able to detect the FGFR3-BAIAP2L1 fusion isoform using both the targeted isoform and imbalance assay methods of the assay. Interestingly, an ALK imbalance was also defected in this cell line; research is ongoing to understand these results further The assay was able to detect the CCDC6-RET fusion isoform using both the targeted isoform and imbalance assay methods

Targeted Targeted Read Molecular Imbalance Imbalance Imbalance Isoform Rep Isoform Count Counts Assay Score p-value TPM3- 1 DETECTED 4430 360 DETECTED 2.781 0.0017 NTRK1.T7N10 2 DETECTED 6665 531 FGFR3- 1 DETECTED 9096 763 DETECTED 1.716 0.0066 BAIAP2L1.F17B2 2 DETECTED 10913 952 CCDC6- 1 DETECTED 3342 318 DETECTED 1.763 0.0055 RET.C1R12 2 DETECTED 3233 301

4L: Detection of ALK and ROS1 Fusions in FFPE Samples

Library preparation, sequencing and analysis was carried out for evaluation of performance of the assay in detection of ALK and ROS1 fusions in FFPE samples. The assay was able to detect the ALK fusions using both the targeted isoform and imbalance assay methods, and ROS1 fusions using the targeted isoform method for FFPE samples

Targeted Read Molecular Imbalance Imbalance Imbalance Sample Isoform Isoform Count Counts Assay Score p-value 1 DETECTED EML4- 1535 50 DETECTED 4.767 0.0007 ALK.E13A20 DETECTED EML4- 6665 531 ALK.E6A20 2 DETECTED CD74- 85 5 No imbalance assays for ROS1 ROS1.C6R33 DETECTED CD74- 1566 110 ROS1.C6R34

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

TABLE A primer sequences of the oncology precision assay, FWD pool and REV pool SEQ SEQ ID ID NO PrimerSeqFWD(A) NO PrimerSeqREV(B) 1 TCTGTACGGTGACAAGGCGUNNNACTNN  997 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGAGUCGGGCTCUGGA CCGCUGUGGCCCUCGUG 2 TCTGTACGGTGACAAGGCGUNNNACTNN  998 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCACGGGUCGGGUGAGA GACAGCGGCUGCGAUCA 3 TCTGTACGGTGACAAGGCGUNNNACTNN  999 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGGUGCCGAGCCUCUG GGUCGCCCUCCACGCAG 4 TCTGTACGGTGACAAGGCGUNNNACTNN 1000 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGCCGUUAGGGUGCAG AAGUGCCCAGCGAGCUA 5 TCTGTACGGTGACAAGGCGUNNNACTNN 1001 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGCCUCACCUCCACCGT CAAUGCCGAUGGCCUCC 6 TCTGTACGGTGACAAGGCGUNNNACTNN 1002 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUUCUGCGCAGCUUCCC AGACGACAGGGCUGGUT 7 TCTGTACGGTGACAAGGCGUNNNACTNN 1003 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAUGGCCAUGGCGCGGA ACUGGCAUGACCCCCAC 8 TCTGTACGGTGACAAGGCGUNNNACTNN 1004 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUCGUCUCUCCAGCCC GGCUCUCGCGGAGGAAG 9 TCTGTACGGTGACAAGGCGUNNNACTNN 1005 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCCCCUGAGCGUCAUC UUUGUUGGCGGGCAACC 10 TCTGTACGGTGACAAGGCGUNNNACTNN 1006 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGUCUGAGGAGCCCGUG GCAGUCCGGCUUGGAGG 11 TCTGTACGGTGACAAGGCGUNNNACTNN 1007 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCGUCCUCCCAGCGUA AAGUCCUGCCGAGCACT 12 TCTGTACGGTGACAAGGCGUNNNACTNN 1008 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCGACCCCCUCAUCAT ACUGGUUGGUGGCUGGA 13 TCTGTACGGTGACAAGGCGUNNNACTNN 1009 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACUUGGAGGACCGUCGC AGCUGCAUGGUGCGGUT 14 TCTGTACGGTGACAAGGCGUNNNACTNN 1010 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGGACAGUGGGCCAA AGGCUCCAGUGCUGGUT 15 TCTGTACGGTGACAAGGCGUNNNACTNN 1011 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCUGGGCCAGAGUGT AGGCUCCUCCAGGCUCA 16 TCTGTACGGTGACAAGGCGUNNNACTNN 1012 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAACAUGGCCUCCUCCGC AUCCUCUGCCCCACCCT 17 TCTGTACGGTGACAAGGCGUNNNACTNN 1013 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGGUCCCCAUGGUGGC CAACAUGGCCUGGCAGC 18 TCTGTACGGTGACAAGGCGUNNNACTNN 1014 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGCGCCUUCCAUGGAG CAAAAAGGGAUUCAAUUGCCAUCCA 19 TCTGTACGGTGACAAGGCGUNNNACTNN 1015 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGCAGCAGUGGAGCCA CAUCUCCACCGCCGUGT 20 TCTGTACGGTGACAAGGCGUNNNACTNN 1016 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCAGGACGUGCUGCUC CCCAUCCUCUGGAGCCA 21 TCTGTACGGTGACAAGGCGUNNNACTNN 1017 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGGCAACGUGGUUGG CCCCCACCUGAGACUCC 22 TCTGTACGGTGACAAGGCGUNNNACTNN 1018 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCAUCGAGCCUCCGAC CUGCUUGGCCUGGAGGG 23 TCTGTACGGTGACAAGGCGUNNNACTNN 1019 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGCAACCUGCAGCAC GAGCUGAGCGCCUGGCA 24 TCTGTACGGTGACAAGGCGUNNNACTNN 1020 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUUUGGUGGCACGCAGC GAUGUCCCGGCGCUUGA 25 TCTGTACGGTGACAAGGCGUNNNACTNN 1021 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUCUUCCCCAACGGCA GCACACGCGGAUGUGCA 26 TCTGTACGGTGACAAGGCGUNNNACTNN 1022 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCGUGGAGCUAUGGGT GCGUGACCGGGACUUCC 27 TCTGTACGGTGACAAGGCGUNNNACTNN 1023 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUGCCCCCACUCCCAG GGCAGCAGGGUGGUGAG 28 TCTGTACGGTGACAAGGCGUNNNACTNN 1024 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGGCCUCCUGCACUCC GGCCACCUGGACCUUCC 29 TCTGTACGGTGACAAGGCGUNNNACTNN 1025 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGACGGUCGGACUCCC GGCCAGACUGACCCUCC 30 TCTGTACGGTGACAAGGCGUNNNACTNN 1026 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGGCGAUGUCGCCGAA GGCCCGUGUCUUGGAGG 31 TCTGTACGGTGACAAGGCGUNNNACTNN 1027 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCUUCGAGGCCGUUGA GGGUAGGCCGUGUCUGG 32 TCTGTACGGTGACAAGGCGUNNNACTNN 1028 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCGAAGGCGUCUCCCUG GUCAGCCAGGGCACCUG 33 TCTGTACGGTGACAAGGCGUNNNACTNN 1029 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCGGCUUGGGAGAAUG GUCAGCCCCAGGGAUGG 34 TCTGTACGGTGACAAGGCGUNNNACTNN 1030 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUACACGGUGCGCGAGG GUGUCCUCCGCUGAGGC 35 TCTGTACGGTGACAAGGCGUNNNACTNN 1031 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUGUCCAGAGGACCCC UCAGGGCUCUGCAGCUC 36 TCTGTACGGTGACAAGGCGUNNNACTNN 1032 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGAGCCAUGGGCUGCAT UCCACGCUGCUCGGCAT 37 TCTGTACGGTGACAAGGCGUNNNACTNN 1033 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGGCUCAGUGAGGCUCG UCCGGCAUUCGUGUUGC 38 TCTGTACGGTGACAAGGCGUNNNACTNN 1034 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGUGCCACCCGCCUAUG UCUCUGGGAGGGCACUG 39 TCTGTACGGTGACAAGGCGUNNNACTNN 1035 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGAGUGCUGGCAUGCCG UGAUGGUCGAGGUGCGG 40 TCTGTACGGTGACAAGGCGUNNNACTNN 1036 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGGUGGAGGACCUGG UGCACGUCGGUUUUGGG 41 TCTGTACGGTGACAAGGCGUNNNACTNN 1037 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUGGCACUGAGGGUCGC UGGCCGCUCCAACUCAC 42 TCTGTACGGTGACAAGGCGUNNNACTNN 1038 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAACCCGCGCUCUCUGA UGUUGCACUGUGCCUGG 43 TCTGTACGGTGACAAGGCGUNNNACTNN 1039 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAGCUCGGCUGUUCCA UUUUUCCGCGGCACCUC 44 TCTGTACGGTGACAAGGCGUNNNACTNN 1040 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUCAGAGCCCCACCUG CUCCUUCCUUGCCAACGC 45 TCTGTACGGTGACAAGGCGUNNNACTNN 1041 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGUGCUGGAGAGACCCC UGAGCCCACCUGACUUGG 46 TCTGTACGGTGACAAGGCGUNNNACTNN 1042 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGAGCCGUCAACGAUG GCUGCCGAAGACCAACUG 47 TCTGTACGGTGACAAGGCGUNNNACTNN 1043 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGUGCCCUCCGUGUUCA GAGCCCAGGCCUUUCUUG 48 TCTGTACGGTGACAAGGCGUNNNACTNN 1044 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCGGCGUCCACAACUCA AGGAACUCCCGCAGGUUT 49 TCTGTACGGTGACAAGGCGUNNNACTNN 1045 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGAGAUGCCGUCGGUG CUCCACCCCUGAAGCCUG 50 TCTGTACGGTGACAAGGCGUNNNACTNN 1046 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGGCCUUCGUACGGG CCGUCUCCUCCACGGAUG 51 TCTGTACGGTGACAAGGCGUNNNACTNN 1047 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCUGCCAGCGGCUCAG GUGAGGCAGAUGCCCAGC 52 TCTGTACGGTGACAAGGCGUNNNACTNN 1048 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCUGCAUGAUCUGCGG GGAGGUGGUGGUGGUCCC 53 TCTGTACGGTGACAAGGCGUNNNACTNN 1049 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCGUCAUGAGACCCGA CUAGUUGCAUGGGUGGCG 54 TCTGTACGGTGACAAGGCGUNNNACTNN 1050 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCCUCUCUGCCCAGC CCAGAUCAUCCGCGAGCT 55 TCTGTACGGTGACAAGGCGUNNNACTNN 1051 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGUUCUGCCUCCCGUGG GUGAGCCUGCAAUCCCUG 56 TCTGTACGGTGACAAGGCGUNNNACTNN 1052 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCCGACCUUGAGGCUG UUACCCUUGGCCGCGUAC 57 TCTGTACGGTGACAAGGCGUNNNACTNN 1053 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCUCUCAUGCCCGCAG CUCACAGGUCGUGUGUGC 58 TCTGTACGGTGACAAGGCGUNNNACTNN 1054 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCCCAGUGGCCCUCGG GUACCGGAGGAAGCGGUT 59 TCTGTACGGTGACAAGGCGUNNNACTNN 1055 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGGCCACUGGGUCACC AACCUGCAGCAUGAGCAC 60 TCTGTACGGTGACAAGGCGUNNNACTNN 1056 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGAGAUGGCCCGACA ACAUGUCUCCGCUGGUCG 61 TCTGTACGGTGACAAGGCGUNNNACTNN 1057 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACCGUCUCCUCGGAGC AUCAGCGAGAGUGGCAGG 62 TCTGTACGGTGACAAGGCGUNNNACTNN 1058 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGCUCCCAGCAAGCGA AUGCCAGGUGCAAGCACA 63 TCTGTACGGTGACAAGGCGUNNNACTNN 1059 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCACCGCAUCGUGCAG CACGACUGUUGGACCGUG 64 TCTGTACGGTGACAAGGCGUNNNACTNN 1060 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCCGCUCGUCCACCAG CAGCGAAUGGGCAGCAUG 65 TCTGTACGGTGACAAGGCGUNNNACTNN 1061 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUCGCCCACGAGUAGC CAGGAGUCCGAGGUGGUG 66 TCTGTACGGTGACAAGGCGUNNNACTNN 1062 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCGCCACCUGCUGAC CCAGUAGCGCUGCUUCCT 67 TCTGTACGGTGACAAGGCGUNNNACTNN 1063 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCGCCUCUCACCAUCGA CCGUGGAGCUCCUCACAC 68 TCTGTACGGTGACAAGGCGUNNNACTNN 1064 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCGAGCCCGGGAAGUG CGGGAAGCGGGAGAUCUT 69 TCTGTACGGTGACAAGGCGUNNNACTNN 1065 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGACUCGAUGGACCGC CUCUUGCGGGUACCCACG 70 TCTGTACGGTGACAAGGCGUNNNACTNN 1066 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUACUGCCUGGCUGGCUG CUGCUUCCUCAAGGCCGA 71 TCTGTACGGTGACAAGGCGUNNNACTNN 1067 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUGUGCCCACCAGGCAA CUGUAGGGACACAGGGCA 72 TCTGTACGGTGACAAGGCGUNNNACTNN 1068 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAAUCUCCUGCGCCCUGG GCCAUGCGGGUCUCUCUG 73 TCTGTACGGTGACAAGGCGUNNNACTNN 1069 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGAUUGCUCCGGCCGT GCCUCCGGAAGGUCAUCT 74 TCTGTACGGTGACAAGGCGUNNNACTNN 1070 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGAGGCACUGAGGCG GCCUUUUGUCCGGCUCCT 75 TCTGTACGGTGACAAGGCGUNNNACTNN 1071 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCGCCAUGCAAGGCT GCUCGUGUCCCCCAACAA 76 TCTGTACGGTGACAAGGCGUNNNACTNN 1072 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGUCCAGGGAGAGCCUG GGCGAUCUCCUCGUUUGC 77 TCTGTACGGTGACAAGGCGUNNNACTNN 1073 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCCGACUCCGAGGACG GGGCUUGUCUUGAGGCUG 78 TCTGTACGGTGACAAGGCGUNNNACTNN 1074 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCUGCAGAACGGGAG GUGAGGGCUGACGCAGAG 79 TCTGTACGGTGACAAGGCGUNNNACTNN 1075 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUCGUUCCGCUUCGGG GUGGGCUCAGGAACCGAG 80 TCTGTACGGTGACAAGGCGUNNNACTNN 1076 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCAGCAAGGCCUGGUG UACCCGAGGUCCCUGGAG 81 TCTGTACGGTGACAAGGCGUNNNACTNN 1077 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUAGCUUUGGCGAGGG UCAGCGCGAUCAGCAUCT 82 TCTGTACGGTGACAAGGCGUNNNACTNN 1078 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAGCUUGCCCUGACCC UCCGCAGGCUUCCUUAGG 83 TCTGTACGGTGACAAGGCGUNNNACTNN 1079 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGAGGGCGAUGGGCUG UCUGCAGAGGACUCCAGC 84 TCTGTACGGTGACAAGGCGUNNNACTNN 1080 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGUGAGCUGCCUGCGT UGGGUCUCUGUGAGGGCA 85 TCTGTACGGTGACAAGGCGUNNNACTNN 1081 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCGGCGAGUCCUGAG UUCUUCCCGCCUUUCCCG 86 TCTGTACGGTGACAAGGCGUNNNACTNN 1082 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGCUCCGGGUGACAGC GAUCUCCCAGAGCAGGACC 87 TCTGTACGGTGACAAGGCGUNNNACTNN 1083 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAGCGGACUCCCCUCG CUGCACACACCAGUUGAGC 88 TCTGTACGGTGACAAGGCGUNNNACTNN 1084 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCCAGCAUCCGACCAC ACAUAGUCCCGGAAGCUGC 89 TCTGTACGGTGACAAGGCGUNNNACTNN 1085 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCCCUGCUGUCUGCCG GGUACGCCUCCAGAUGAGC 90 TCTGTACGGTGACAAGGCGUNNNACTNN 1086 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAUGCAGCCGUGCCAG UGUACACGUCCCGGGACAT 91 TCTGTACGGTGACAAGGCGUNNNACTNN 1087 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUCGGCAGCCGCAGAA UGAGGUUGGAGUCCAUGGG 92 TCTGTACGGTGACAAGGCGUNNNACTNN 1088 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCAGGAGGUGGAGGG GCACCUGGCUCCUCUUCAC 93 TCTGTACGGTGACAAGGCGUNNNACTNN 1089 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCCUGAGCCAGCAGGG AUUCCUACCGGAAGCAGGT 94 TCTGTACGGTGACAAGGCGUNNNACTNN 1090 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCAUUCCCGGGAGGG CGUGUGAUGCAGCUCUUCG 95 TCTGTACGGTGACAAGGCGUNNNACTNN 1091 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGCUCCACCUCAGCAG CUUGUGCCCACGAAGGAGT 96 TCTGTACGGTGACAAGGCGUNNNACTNN 1092 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGAAGUCAGCCGGCUC CUAGUCCCUGGCUGGACCA 97 TCTGTACGGTGACAAGGCGUNNNACTNN 1093 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAGGACGCCUUCUGCA CUCUUGACCAGCACGUUCC 98 TCTGTACGGTGACAAGGCGUNNNACTNN 1094 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGCCCAGGCUGGGAAG CGGUUUUCCCGGACAUGGT 99 TCTGTACGGTGACAAGGCGUNNNACTNN 1095 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUCACCACGAGCUGCC CUGCUGUGUGCUGGCAGAT 100 TCTGTACGGTGACAAGGCGUNNNACTNN 1096 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGGACCAGACCCUGC GAUGCACCACGGCCACAUA 101 TCTGTACGGTGACAAGGCGUNNNACTNN 1097 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAUGAGUCGGCCUGUGG AUCAGAACUGCCGACCACA 102 TCTGTACGGTGACAAGGCGUNNNACTNN 1098 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCACCCUUCCGACCUC CCUCUUGACCUGUCCAGGC 103 TCTGTACGGTGACAAGGCGUNNNACTNN 1099 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUUCCCGGGUCCCGAG CCAUGCUGGACCUUCUGCA 104 TCTGTACGGTGACAAGGCGUNNNACTNN 1100 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGGUGGGCAGCCAGGAG GGACGACCCAGAGCUGAUG 105 TCTGTACGGTGACAAGGCGUNNNACTNN 1101 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAAGGCUUUGGUCCAGCCA CUUGCAGUGGAACUCCACG 106 TCTGTACGGTGACAAGGCGUNNNACTNN 1102 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGAGUGGGCAGGAGGC CCCAUGGCAAACACCAUGA 107 TCTGTACGGTGACAAGGCGUNNNACTNN 1103 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAGUGGAGGCCGGAUG ACUCCUGAACCCUGAAGGC 108 TCTGTACGGTGACAAGGCGUNNNACTNN 1104 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCUCGGGCAGUGACAC CUCCCCUUCUCUGCCCAGA 109 TCTGTACGGTGACAAGGCGUNNNACTNN 1105 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGCCGUGCAGCGAUUG GUUGCCCUUGGAGGCAUAC 110 TCTGTACGGTGACAAGGCGUNNNACTNN 1106 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCCACUGUGCUUCCUC AUUGCAGGCUCACCCCAAT 111 TCTGTACGGTGACAAGGCGUNNNACTNN 1107 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGUUCGCGCACACCCUA AAUGCACCAGUGGUGGUCT 112 TCTGTACGGTGACAAGGCGUNNNACTNN 1108 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCGUCUGCUGUUGCT GAAUCUGUCUGCUGCUCCUGT 113 TCTGTACGGTGACAAGGCGUNNNACTNN 1109 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAACGGCAGCUUCGUG AGAUGCUGCAGAUGCUGCT 114 TCTGTACGGTGACAAGGCGUNNNACTNN 1110 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUGGCCCUGUAGGACCT AGCAACCACUCGAUCCUGT 115 TCTGTACGGTGACAAGGCGUNNNACTNN 1111 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGAAUGCGCCCCGGACUT AGCUCCAUCUGCAUGGCUT 116 TCTGTACGGTGACAAGGCGUNNNACTNN 1112 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGCUGGUGGAGGCUGAC AGCUGAGGCCUUGCAGAAC 117 TCTGTACGGTGACAAGGCGUNNNACTNN 1113 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGCCCGUGAAGUGGAT CAAAGCAGCCCUCUCCCAG 118 TCTGTACGGTGACAAGGCGUNNNACTNN 1114 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUGUCCUCCACAGGCAT CACCAGACACAGCAUCUGC 119 TCTGTACGGTGACAAGGCGUNNNACTNN 1115 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGACCCGGAGCACUUCC CACUCCAGCCGUCUCUUGC 120 TCTGTACGGTGACAAGGCGUNNNACTNN 1116 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCUGCAACUGCUUCCCT CAGUGGGCAGGUCCUUCAA 121 TCTGTACGGTGACAAGGCGUNNNACTNN 1117 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGAGUGGGCGAGUUUGC CAUCGGAACCUGCACACAG 122 TCTGTACGGTGACAAGGCGUNNNACTNN 1118 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGCUCCUGACCUGGAGT CCUUGUGGCUUUCAGGGUC 123 TCTGTACGGTGACAAGGCGUNNNACTNN 1119 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGCCCUCCCAGAAGGUC CGAUGUCAUUCGCUGCAGT 124 TCTGTACGGTGACAAGGCGUNNNACTNN 1120 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCCUGACAUCCACGGT CGCUCCAAAACACGACCUT 125 TCTGTACGGTGACAAGGCGUNNNACTNN 1121 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGCAUGGUCCACCACAG CUGCAGGGCCAUCUUGGAG 126 TCTGTACGGTGACAAGGCGUNNNACTNN 1122 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAUGGCACAGCCUCCCUT CUGCCUUGUCCCACAUCAG 127 TCTGTACGGTGACAAGGCGUNNNACTNN 1123 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACACAGCUGGGCGCUUUG CUUCCCCAUCCAUUUCGGG 128 TCTGTACGGTGACAAGGCGUNNNACTNN 1124 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCAGGCGCCAAGUAGGT GAGUUGAACUGGCGGCCAT 129 TCTGTACGGTGACAAGGCGUNNNACTNN 1125 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCACCAUGCUGCAGCAC GCAGGAGCCAAGGUCAGUG 130 TCTGTACGGTGACAAGGCGUNNNACTNN 1126 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUAGAUGGACGCACUGGGC GCCACGAGAGUGUGGUGAG 131 TCTGTACGGTGACAAGGCGUNNNACTNN 1127 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAAAGCCGGCUACGCGCUG GCCACUCCGCAGGAUAAAC 132 TCTGTACGGTGACAAGGCGUNNNACTNN 1128 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAGCCCCUCCUCAGAUG GGAUCCUUGUCCCCACCAT 133 TCTGTACGGTGACAAGGCGUNNNACTNN 1129 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUGUGACAACGGGCUGC GUCACCCCUUCCUUGGCAC 134 TCTGTACGGTGACAAGGCGUNNNACTNN 1130 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGGACAGCAUCGGGAGC GUCGGGAUGGAGAAAGCGA 135 TCTGTACGGTGACAAGGCGUNNNACTNN 1131 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGAACAGGAGCAGCUGCG UCCGGCUGCAAUGAUCAGG 136 TCTGTACGGTGACAAGGCGUNNNACTNN 1132 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCUCCUGUGUGCCCAGA UCCUCAGCUCCCGGUUCUC 137 TCTGTACGGTGACAAGGCGUNNNACTNN 1133 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCCAAGUCCUCCUUGCC UGCUUGGAGUCAGCUGAGG 138 TCTGTACGGTGACAAGGCGUNNNACTNN 1134 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACAGACAGGCUGUGUGC UGGGAUCUCCUUGGGUGCC 139 TCTGTACGGTGACAAGGCGUNNNACTNN 1135 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCUGCCAAGAAGGCCA UGUGUCCACACCUGUGUCC 140 TCTGTACGGTGACAAGGCGUNNNACTNN 1136 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCACAAGUCGGACCCCUA UUGAGCGUGUGAAGACUGC 141 TCTGTACGGTGACAAGGCGUNNNACTNN 1137 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCGGAUCUGGAGGAGCAG UUGCGCUUCUCCUCCUCCT 142 TCTGTACGGTGACAAGGCGUNNNACTNN 1138 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGUGCGGAAGAUUGCCC CCACAUCCACCGAGGCAUT 143 TCTGTACGGTGACAAGGCGUNNNACTNN 1139 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUACACGUUCACGGUGCCC AGUCCUUGCGUGCAUUGUC 144 TCTGTACGGTGACAAGGCGUNNNACTNN 1140 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGAGGAAGCCCAUCGA CAGCGAAUGGGCAGCAUUG 145 TCTGTACGGTGACAAGGCGUNNNACTNN 1141 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGGCUCUUACCGCAAG GACUCGGCCCUGAGUGAUA 146 TCTGTACGGTGACAAGGCGUNNNACTNN 1142 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCCAAGAGUGCCAAGUG CGGCUUUACCUCCAAUGGUG 147 TCTGTACGGTGACAAGGCGUNNNACTNN 1143 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUCGUCUGUCACCCAGG GAGGAUGAGCCUGACCAGUG 148 TCTGTACGGTGACAAGGCGUNNNACTNN 1144 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGACCAGACGGUCUCAGA AAACAGUAGCUUCCCUGGGT 149 TCTGTACGGTGACAAGGCGUNNNACTNN 1145 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCCCCAACCGCACUGAG GUAGCUGACCCUGCCUACCT 150 TCTGTACGGTGACAAGGCGUNNNACTNN 1146 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUGACGGAGGAGCUUGT CUUACCAGGCAAGGCCUUGG 151 TCTGTACGGTGACAAGGCGUNNNACTNN 1147 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGGCACUCAGCAGCAAG AUCAUUUCUGCUGGCGCACA 152 TCTGTACGGTGACAAGGCGUNNNACTNN 1148 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGGUGGCCAUAGGAACG CAUCGUAGACCUGGGUCCCT 153 TCTGTACGGTGACAAGGCGUNNNACTNN 1149 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUAAAACCCAGUGCGUACGCAT GAGUCCACAGUCUGGAAGCG 154 TCTGTACGGTGACAAGGCGUNNNACTNN 1150 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUGAAGAGCACGCCAUG CGGCCCAACACCUUCAUCAT 155 TCTGTACGGTGACAAGGCGUNNNACTNN 1151 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCUGCACGUUUCCUCC GUAGAGUGUGCGUGGCUCUC 156 TCTGTACGGTGACAAGGCGUNNNACTNN 1152 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCACCAGCUCACUGCAC UUGGCUCUGACUGUACCACC 157 TCTGTACGGTGACAAGGCGUNNNACTNN 1153 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCGUGGCCUUGACCUCC UGGCCAUCUACAAGCAGUCA 158 TCTGTACGGTGACAAGGCGUNNNACTNN 1154 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAGCUGGUGGAAGACCT CGCAUCGUGUACUUCCGGAT 159 TCTGTACGGTGACAAGGCGUNNNACTNN 1155 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACGACUCCGUGUUUGCC UCCUUCCUGUCCUCCUAGCA 160 TCTGTACGGTGACAAGGCGUNNNACTNN 1156 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGCUCACAGUCUCCUGGG AGAAGGCGGGAGACAUAUGG 161 TCTGTACGGTGACAAGGCGUNNNACTNN 1157 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAACCUCCGUGAGGACG AAGCCGAAGGUCACAAAGUC 162 TCTGTACGGTGACAAGGCGUNNNACTNN 1158 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGCUGGUGUUGCUGAGGG CAGGUCCUCAAGUCUUCGGG 163 TCTGTACGGTGACAAGGCGUNNNACTNN 1159 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGACAGUGCCCAGGGCUC CAGCUGGCCUUACCAUCCUG 164 TCTGTACGGTGACAAGGCGUNNNACTNN 1160 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCCUGCUCUUCCUUGGG ACACCUGGCCUUCAUACACC 165 TCTGTACGGTGACAAGGCGUNNNACTNN 1161 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUGGGUUUCGAGGCCAAC UUCUUUCUCUUCCGCACCCA 166 TCTGTACGGTGACAAGGCGUNNNACTNN 1162 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGCUUUCCUCCUGCGUC ACACCUGGCCUUCAUACACC 167 TCTGTACGGTGACAAGGCGUNNNACTNN 1163 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUAAUGCUGGGACGCUGCC ACCAGGAAGGACUCCACUUC 168 TCTGTACGGTGACAAGGCGUNNNACTNN 1164 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCACCACCACUUCCCC ACCAUGCCAUAGUCCAUGCC 169 TCTGTACGGTGACAAGGCGUNNNACTNN 1165 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGAGAUCCACGCCUACC ACGGAGACCACUCUUCACGA 170 TCTGTACGGTGACAAGGCGUNNNACTNN 1166 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCGAAGCUUCGAGACCUG AUGAUUUGCAAAGCGCACAC 171 TCTGTACGGTGACAAGGCGUNNNACTNN 1167 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCAGAGGAGGUCGUGGG AUGUCUGUGUGUCCCGUCAA 172 TCTGTACGGTGACAAGGCGUNNNACTNN 1168 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGCAAGCUCCUUCCUG AUGUUGCACAGCCUCCUUGG 173 TCTGTACGGTGACAAGGCGUNNNACTNN 1169 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCCGAGAAGCCAGUCA CAAUCGCGGUAGAGGCUGUC 174 TCTGTACGGTGACAAGGCGUNNNACTNN 1170 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCAACGGAAGCACUGG CAGGUGGAGAAGUUCCUGGT 175 TCTGTACGGTGACAAGGCGUNNNACTNN 1171 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGGAGUGGCAGCAGAAG CCCGUGCCUGUAUUCAAGUG 176 TCTGTACGGTGACAAGGCGUNNNACTNN 1172 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGGAGGAGCAGCUUGA CCGAGGGAAUUCCCACUUUG 177 TCTGTACGGTGACAAGGCGUNNNACTNN 1173 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCCGAGCCAAUCACGGG CCUGGACAGCUUGUGGGAAG 178 TCTGTACGGTGACAAGGCGUNNNACTNN 1174 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACAUCUCCUACGCCCUGG CCUUGUCCCUCCUUCAAGGG 179 TCTGTACGGTGACAAGGCGUNNNACTNN 1175 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCACCUGCUCCUUCCAG CGCCCAGAGUGAAGAUCUCC 180 TCTGTACGGTGACAAGGCGUNNNACTNN 1176 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGACACGGUGGUACUGGC CUCGUACGGUCAGGUUGACG 181 TCTGTACGGTGACAAGGCGUNNNACTNN 1177 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCGAUUGCAGCUCAUGCT CUGACCUAGUGUGAGGGAGG 182 TCTGTACGGTGACAAGGCGUNNNACTNN 1178 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCUGGAAGCCAAGGCAG CUGGACGUUGAUGCCACUGA 183 TCTGTACGGTGACAAGGCGUNNNACTNN 1179 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAUUGGCCAAGGAGUGCC CUUCUUCUCCACCGGGUCUC 184 TCTGTACGGTGACAAGGCGUNNNACTNN 1180 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUGGCGGAGCAGAUGAG GCUCAGCUUGUACUCAGGGC 185 TCTGTACGGTGACAAGGCGUNNNACTNN 1181 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAUACCCGGACCCUGGAG GCUCCUUCAGUUGAGGCUGG 186 TCTGTACGGTGACAAGGCGUNNNACTNN 1182 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGAUCGCCGCCCUCAUT GGGUGUUGGAGUUCAUGGAG 187 TCTGTACGGTGACAAGGCGUNNNACTNN 1183 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCACGCAGCCCAAAUC GGUGACGUUGUGCAAGGAGA 188 TCTGTACGGTGACAAGGCGUNNNACTNN 1184 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACAUCCUGUUGCACCCCA GGUGCACUUCACAACAGGGT 189 TCTGTACGGTGACAAGGCGUNNNACTNN 1185 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCGCCACCUCCAACCAUC GUCAUAGUGGGCUUCAGCCG 190 TCTGTACGGTGACAAGGCGUNNNACTNN 1186 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGUGCGCAAGGUGAAAT GUCUGGACGCCCGAUUCUUC 191 TCTGTACGGTGACAAGGCGUNNNACTNN 1187 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACUUGCUGGAUGGGCCUG UAUAGGUCCGGUGGACAGGG 192 TCTGTACGGTGACAAGGCGUNNNACTNN 1188 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGAAGGAGGGUCACCGC UCUCAGCUGAGGAGAUGGGT 193 TCTGTACGGTGACAAGGCGUNNNACTNN 1189 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUGUGCCAGUAGCCGUG UCUUGAAGGCAUCCACGGAG 194 TCTGTACGGTGACAAGGCGUNNNACTNN 1190 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAUCUGGAGCUCCGUGA UGCCCAAAGCAACCUUCUCC 195 TCTGTACGGTGACAAGGCGUNNNACTNN 1191 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAGAACGUGGUGGGCAT UGUCUUCAGGCUGAUGUUGC 196 TCTGTACGGTGACAAGGCGUNNNACTNN 1192 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUCUGAAGACCGGCCAC UUCUCGCUUCAGCACGAUGT 197 TCTGTACGGTGACAAGGCGUNNNACTNN 1193 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCCCAACAGGCAGGUG UUGUUGAGCACAAGGAGCAG 198 TCTGTACGGTGACAAGGCGUNNNACTNN 1194 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGCAUGGAGUACUUGGC UUUCAGCAUCUUCACGGCCA 199 TCTGTACGGTGACAAGGCGUNNNACTNN 1195 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGCAGUGUCAUGGGCAAG ACCAUUCUGUUCUCUCUGGCA 200 TCTGTACGGTGACAAGGCGUNNNACTNN 1196 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGUGUCUGUCCUGGGAGT GAAUCCUGCUGCCACACAUUG 201 TCTGTACGGTGACAAGGCGUNNNACTNN 1197 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUGCUUUUAGGGCCCACC CUUGGAGCUGGAGCUCUUGUG 202 TCTGTACGGTGACAAGGCGUNNNACTNN 1198 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAAGCCCGCUCAUGAUCAA CAGCAUCCAACAAGGCACUGA 203 TCTGTACGGTGACAAGGCGUNNNACTNN 1199 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGCACUGGGUCAAAGUCT GGAUGCCUGACCAGUUAGAGG 204 TCTGTACGGTGACAAGGCGUNNNACTNN 1200 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCAAGAAUCGCCCGAGCC GGAUGAGGAAGUAGCCUCCCA 205 TCTGTACGGTGACAAGGCGUNNNACTNN 1201 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGAUGGGACCCACUCCAT CUUGGGCACUUGCACAGAGAT 206 TCTGTACGGTGACAAGGCGUNNNACTNN 1202 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCAAAAUGGCCCGAGAC CGUUGAACUCUGACAGCAGGT 207 TCTGTACGGTGACAAGGCGUNNNACTNN 1203 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCAGGGCUUCUUCAGCA AUUCGGACACACUGGCUGUAC 208 TCTGTACGGTGACAAGGCGUNNNACTNN 1204 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCGGGACAUGGACUCAAC CCCUUCUCUGUCUCCCUUGGA 209 TCTGTACGGTGACAAGGCGUNNNACTNN 1205 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAUGUACUGGUCCCGCAT GUCCCGUGAGCACAAUCUCAA 210 TCTGTACGGTGACAAGGCGUNNNACTNN 1206 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGGAAUGCCAACCCAUGGA GCACCUUCAUUGGCUACAAGG 211 TCTGTACGGTGACAAGGCGUNNNACTNN 1207 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUAGGCGAGGAGCUCCAGUC GUUUUUCCCUCAGGCCCUCAT 212 TCTGTACGGTGACAAGGCGUNNNACTNN 1208 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGUGAGGCUCCCCUUUCUT UUCCUACAGUACUCCCCUGCC 213 TCTGTACGGTGACAAGGCGUNNNACTNN 1209 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCCCUCUGACGUCCAUC CACUUCUCACACCGCUGUGUT 214 TCTGTACGGTGACAAGGCGUNNNACTNN 1210 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGUGCCCAUCAAGUGGAT CCCAUGACACACCAUAACUCC 215 TCTGTACGGTGACAAGGCGUNNNACTNN 1211 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCUCCAGCUUCUUCUGCA AACCCUCCUGAUGUACACGGT 216 TCTGTACGGTGACAAGGCGUNNNACTNN 1212 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCGGGCUUGGUUCUGAUGT CUUGCCUUUCUCCCCAACCAG 217 TCTGTACGGTGACAAGGCGUNNNACTNN 1213 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGUCCUGAAGCAGGUCAAC ACCUUCAGCACUCUGCUUGUG 218 TCTGTACGGTGACAAGGCGUNNNACTNN 1214 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGUGAGGGUGUCUCUCUG UUCUAUCGGCAAAGCGGUGUT 219 TCTGTACGGTGACAAGGCGUNNNACTNN 1215 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUAAAUACGGGCCCGACG ACAUUGGGAGCUGAUGAGGAT 220 TCTGTACGGTGACAAGGCGUNNNACTNN 1216 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUCCCCUCCAUUGUGGGC ACUUCCUACAGGAAGCCUCCC 221 TCTGTACGGTGACAAGGCGUNNNACTNN 1217 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAUCCGAAAGCAGUCCAA AGGUGGCACCAAAGCTGTAUT 222 TCTGTACGGTGACAAGGCGUNNNACTNN 1218 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGGCAGGAGUCAAGAUGC AGUCUUCCCCACUUCUGCCUT 223 TCTGTACGGTGACAAGGCGUNNNACTNN 1219 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGGGCCCCUGGAUGGAUA AUGCUUUCAGGAGGCAUCCAG 224 TCTGTACGGTGACAAGGCGUNNNACTNN 1220 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGUAGCAGCCGUCUGUCUC AUUCCGAUGUCAGCACCAAAG 225 TCTGTACGGTGACAAGGCGUNNNACTNN 1221 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUACACACUGCAGCCCAAG CACAGUGAUAGGAGGUGUGGG 226 TCTGTACGGTGACAAGGCGUNNNACTNN 1222 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUACUAUCCCUCGGGAGGC CACCGUUCCACCUGAAAGACT 227 TCTGTACGGTGACAAGGCGUNNNACTNN 1223 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUUUAAGGCCCCAGCGUC CCCCUGCUCUUCAAUACAGCC 228 TCTGTACGGTGACAAGGCGUNNNACTNN 1224 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACCGGAUUCGCAUGUGUG CCCUCAGCUACCAGGAUGUUT 229 TCTGTACGGTGACAAGGCGUNNNACTNN 1225 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCCAGCUCCUCUGACAGC CCUCUUCGAACCUGUCCAUGA 230 TCTGTACGGTGACAAGGCGUNNNACTNN 1226 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCUCCACCCCAGCAAAAC CCUGCUCAGUGUAGCUAGGUT 231 TCTGTACGGTGACAAGGCGUNNNACTNN 1227 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCAUUCAUGCCCCUCCUGG CUACACUUGGCUGGGCAAAGA 232 TCTGTACGGTGACAAGGCGUNNNACTNN 1228 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGAAGUGCAAGGCACUGC CUCCAUCCUGAGUCAUGGCUT 233 TCTGTACGGTGACAAGGCGUNNNACTNN 1229 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUCACGUGCAGCACAUGG CUCCCUCUGGAAAUCCUUCCG 234 TCTGTACGGTGACAAGGCGUNNNACTNN 1230 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGUUUCACGCCACCAACUT CUCGCUGAGAUUGAACUGGAG 235 TCTGTACGGTGACAAGGCGUNNNACTNN 1231 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUUCUGGGCUGGGUGUGA CUGAGUCCUCCUCACCACUGA 236 TCTGTACGGTGACAAGGCGUNNNACTNN 1232 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACGCUGGCCUAUAAGGUGC CUUCGCCUAGCUCCCUUUUCA 237 TCTGTACGGTGACAAGGCGUNNNACTNN 1233 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUGACCUCCCAGACCGAG GAAGACAUGAGCUCGAGUGCT 238 TCTGTACGGTGACAAGGCGUNNNACTNN 1234 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUGGGCAUCACUGUCCUCG GAAUAUGUGGAAGCCCACAGC 239 TCTGTACGGTGACAAGGCGUNNNACTNN 1235 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCUUGAGCAGCAGCUGAG GCAGCAAGUCCAACUGCUAUG 240 TCTGTACGGTGACAAGGCGUNNNACTNN 1236 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAACAGCUCUCUGUGAUGCG GCAGGCUGGACGUACAUUCUT 241 TCTGTACGGTGACAAGGCGUNNNACTNN 1237 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACGACGGGAGGACAAUCUC GCAGUGAUGCCUACCAACUGT 242 TCTGTACGGTGACAAGGCGUNNNACTNN 1238 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGGCUGCAGGACUAUGAGG GGAAUACUCCAGCUCACAGGG 243 TCTGTACGGTGACAAGGCGUNNNACTNN 1239 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCUUGAGCAUCGCAUCCA GGAGCUUGCUCAGCUUGUACT 244 TCTGTACGGTGACAAGGCGUNNNACTNN 1240 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGGGACGUGAACGGAGUG GGGUAGCAGACAAACCUGUGG 245 TCTGTACGGTGACAAGGCGUNNNACTNN 1241 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACACCCCCAGCUCCAGCUC UUUUCCAGGAGAGAGACTCCAGA 246 TCTGTACGGTGACAAGGCGUNNNACTNN 1242 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCUUUCGAGCAGUACUCC GGUGUCUUCAUCCUCGAUGGT 247 TCTGTACGGTGACAAGGCGUNNNACTNN 1243 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACAGUACCCGGCUGUAGA GUGAUCCUUGCCAGGUAAUCC 248 TCTGTACGGTGACAAGGCGUNNNACTNN 1244 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGGCCAUAAAGGGCAACC GUGGUUCGUGGCUCUCUUAUC 249 TCTGTACGGTGACAAGGCGUNNNACTNN 1245 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCAGCCCAGACCAUUCAG UCCCAAAUUCUGCCAGGAAGC 250 TCTGTACGGTGACAAGGCGUNNNACTNN 1246 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGCUCAGGCUACAUCUCGC UCCUUCUCCAAGGCCAGAAUC 251 TCTGTACGGTGACAAGGCGUNNNACTNN 1247 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGACCACGGCAAAGAUG UCUCCACUAGCACCAAGGACA 252 TCTGTACGGTGACAAGGCGUNNNACTNN 1248 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGUGGACGUGGAUUUGGG UGGCCAAGCAAUCUGCGUAUT 253 TCTGTACGGTGACAAGGCGUNNNACTNN 1249 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAUCACAGAGCGAAGCUG UAACGCCUGUUUUCUUUCUGCC 254 TCTGTACGGTGACAAGGCGUNNNACTNN 1250 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUGUUGUGAUCCGCCACT CUGGCCAAGAGUUACGGGAUUC 255 TCTGTACGGTGACAAGGCGUNNNACTNN 1251 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUUCUGGGACUCAUGCCCT AGGAGUGUGUACUCUUGCAUCG 256 TCTGTACGGTGACAAGGCGUNNNACTNN 1252 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCGCGACGACAAGAUCUG GGGACAUUCACCACAUCGACUA 257 TCTGTACGGTGACAAGGCGUNNNACTNN 1253 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUCUACAGCCCAGCCCAG CUCUGAAUCUCUGUGCCCUCAG 258 TCTGTACGGTGACAAGGCGUNNNACTNN 1254 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGGCCAACAUUCAGCAGC CCUUCCUGGUUGGCCGUUAUAT 259 TCTGTACGGTGACAAGGCGUNNNACTNN 1255 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGUUCUCUCCAUCGCCUT UGAACUGCUAGCCUCUGGAUUT 260 TCTGTACGGTGACAAGGCGUNNNACTNN 1256 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCAGCUGCUUCCGUUGCUC GACUUGGUGUCAUGCACCUACC 261 TCTGTACGGTGACAAGGCGUNNNACTNN 1257 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUUCCGAGGCUGGAAUGGA GAAGGGAGUCACUCUGGUUUGG 262 TCTGTACGGTGACAAGGCGUNNNACTNN 1258 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUCAGAAGUCCAGCAGGC CUGAAAUUGGUGUCGGUGCCUA 263 TCTGTACGGTGACAAGGCGUNNNACTNN 1259 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGGCUGUCAGAGCAGGAG AGAUACUGAUCUCGCCAUCGCT 264 TCTGTACGGTGACAAGGCGUNNNACTNN 1260 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGACGAGAUCGCCAACAG CUGGUUGGAGCGAAUCUGCUAG 265 TCTGTACGGTGACAAGGCGUNNNACTNN 1261 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGAGGAAGCCAUGGAGC GAACAUGUGUGAGCACAGCAAC 266 TCTGTACGGTGACAAGGCGUNNNACTNN 1262 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCUGAUGGCUUGAAGGCG UGCCUCUUGCUUCUCUUUUCCT 267 TCTGTACGGTGACAAGGCGUNNNACTNN 1263 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGUGUUUGCUGACGUCCA GUUCUCCAGGUCGAAAGGGUAC 268 TCTGTACGGTGACAAGGCGUNNNACTNN 1264 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUACAACCAGCCCUCCGAC CUGGAUCCUCAGGACUCUGUCT 269 TCTGTACGGTGACAAGGCGUNNNACTNN 1265 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGCCAGAGUCCGUCAUCG CGUUGAAGCACUGGAUCCACUT 270 TCTGTACGGTGACAAGGCGUNNNACTNN 1266 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUGGUACCAGCUCUCCAA CCACAUCCUCUUCCUCAGGAUT 271 TCTGTACGGTGACAAGGCGUNNNACTNN 1267 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCACCUUACUGCCCAGGUG AACGACCAAGUCACCAAGGAUG 272 TCTGTACGGTGACAAGGCGUNNNACTNN 1268 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACCCGCCAGCAUCCUUAG CAGAGUUCAUGGAUGCACUGGA 273 TCTGTACGGTGACAAGGCGUNNNACTNN 1269 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGACUGCUCAGGGUGCC UACUCCACAGUGAGCUCGAUCC 274 TCTGTACGGTGACAAGGCGUNNNACTNN 1270 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCCUGUCAUGAGACCUCC ACAAGGCUGUUUUGGAGAUGGA 275 TCTGTACGGTGACAAGGCGUNNNACTNN 1271 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGCUCUUUCCAGCUGGCUA ACAGCAUACAUGCAUUCCUCAG 276 TCTGTACGGTGACAAGGCGUNNNACTNN 1272 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAACGAGGUUCCGGUGUGUC ACCAUCGGUGUCAUCCUCAUCA 277 TCTGTACGGTGACAAGGCGUNNNACTNN 1273 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUCCCAGGACCUCCACUA AGACUGUCUCGGACUGUAACUC 278 TCTGTACGGTGACAAGGCGUNNNACTNN 1274 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCGACACACUGUAGGCAGT CAAACACUGCCGAGGUGAUUUT 279 TCTGTACGGTGACAAGGCGUNNNACTNN 1275 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCUGGGAACCUACUGUGG CAUCAUUGCUGAUAACGGAGGC 280 TCTGTACGGTGACAAGGCGUNNNACTNN 1276 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUGAAGCUGGACUACCGC CCCAGAGCAAGGAAGUGUUAUC 281 TCTGTACGGTGACAAGGCGUNNNACTNN 1277 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUGGACCUCAGCAGCAUT CCUCCCUCAGGACUGUAACAGA 282 TCTGTACGGTGACAAGGCGUNNNACTNN 1278 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCGUGGCUAUGCCUUCAT CGAGCCCCCUAAAGUGAAGAUC 283 TCTGTACGGTGACAAGGCGUNNNACTNN 1279 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACAGGGAUUCCUCUUCCCC CGCUUCCUUCAGGGUCUUCAUC 284 TCTGTACGGTGACAAGGCGUNNNACTNN 1280 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGGCACGGAACUGAACCA CUUUCAAUGUUGCCACCACACT 285 TCTGTACGGTGACAAGGCGUNNNACTNN 1281 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUGGAGAACCAGGACCUT GACCUUGGCUGCAUGAAGUUUT 286 TCTGTACGGTGACAAGGCGUNNNACTNN 1282 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUUGACCGCAAGCUCCUCC GAGCUUCCCUCUGGAUCUCUCA 287 TCTGTACGGTGACAAGGCGUNNNACTNN 1283 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCUUGCAAGCUGGUCAUT GCAUCGUUUGUGGUUAGUGUCA 288 TCTGTACGGTGACAAGGCGUNNNACTNN 1284 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGGGACUCGUACGAGAA GCCGTCTUCCTCCATCTCAUAG 289 TCTGTACGGTGACAAGGCGUNNNACTNN 1285 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGCAUGACAUGCAGACT GGCUAUCUCCAGGUAGUCUGGG 290 TCTGTACGGTGACAAGGCGUNNNACTNN 1286 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCCCUUAGAGAGCUUGGG GGGUGCUGUAUUCUGCAGGAUC 291 TCTGTACGGTGACAAGGCGUNNNACTNN 1287 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGCAUACCCGCCAUCUUCT GGGUUGUAGUCGGUCAUGAUGG 292 TCTGTACGGTGACAAGGCGUNNNACTNN 1288 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCGGAUACAAAGGCGAC GGUGGUGUUCAAAGAACUUGGA 293 TCTGTACGGTGACAAGGCGUNNNACTNN 1289 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAAAGCUGUGGCUGGAAACA UCCUCCACAGUGAGGUUAGGUG 294 TCTGTACGGTGACAAGGCGUNNNACTNN 1290 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACAUCUGCUCCGGCUUAGC UGAAGAUGACUUCCUUUCUCGC 295 TCTGTACGGTGACAAGGCGUNNNACTNN 1291 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCGACGACUUUAUCUGGGC UUCACCAGCGUCAAGUUGAUGG 296 TCTGTACGGTGACAAGGCGUNNNACTNN 1292 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGUGACTGCUGCCACAAC UUUCUGGCAUUGAUCUCGGCUT 297 TCTGTACGGTGACAAGGCGUNNNACTNN 1293 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGUACAUCCUGGUUGGG AUCUUCAUCACGUUGUCCUCGG 298 TCTGTACGGTGACAAGGCGUNNNACTNN 1294 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAAACCCAACCGUGUGACC CACAAGAACAGUGCAGAGGGUT 299 TCTGTACGGTGACAAGGCGUNNNACTNN 1295 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCAAGCCUGUCACCGUAG CUGUUUCUGGGAAACUCCCAUUT 300 TCTGTACGGTGACAAGGCGUNNNACTNN 1296 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACGGCACACCCUACGUUA GUGCUGGAAGCCUUUGUCUAUGA 301 TCTGTACGGTGACAAGGCGUNNNACTNN 1297 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAGUGCCACAACCUCCUG UUCCAGACCAGGGUGUUGUUUUC 302 TCTGTACGGTGACAAGGCGUNNNACTNN 1298 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAUGGCUCCCAGCUUCCT ACAGCAAAGCAGAAACUCACAUC 303 TCTGTACGGTGACAAGGCGUNNNACTNN 1299 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGGAUCCUCACAGAGCT UUAGAGGGACUCUUCCCAAUGGA 304 TCTGTACGGTGACAAGGCGUNNNACTNN 1300 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGACGAAGUGAGUCCCACA CUGAUAAAGCACCCUCCAUCGUT 305 TCTGTACGGTGACAAGGCGUNNNACTNN 1301 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAACGGGAAGCCCUCAUGUC AUGACGGAAUAUAAGCUGGUGGT 306 TCTGTACGGTGACAAGGCGUNNNACTNN 1302 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGACUCUGGAUCCCAGAAG CCCAAGCCUGGGACCUCUAUUAT 307 TCTGTACGGTGACAAGGCGUNNNACTNN 1303 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCUCCUUCUGGCCACCAUG CAUCUGCAUGGUACUCUGUCUCG 308 TCTGTACGGTGACAAGGCGUNNNACTNN 1304 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUGCUGGACACGACAACAA CCUCAUUUCUCCUCCAUCCUCAG 309 TCTGTACGGTGACAAGGCGUNNNACTNN 1305 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGACCCUGAAGGAUGCCAGT CAACCUUGUCCUAACCUCUCUCC 310 TCTGTACGGTGACAAGGCGUNNNACTNN 1306 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGAUCGUUUGCAACCUGCUC CUGGUUUACAGAGAAACCCACCA 311 TCTGTACGGTGACAAGGCGUNNNACTNN 1307 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGACAGGCUAUGUCCUCGUG ACAUCAGAGAAAGGGACCCUAGT 312 TCTGTACGGTGACAAGGCGUNNNACTNN 1308 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCACAAGAGGCCCUAGAUT GUUGCCACUUUCUCAACUUUCCC 313 TCTGTACGGTGACAAGGCGUNNNACTNN 1309 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCUACCUGACCGACGUUGA UUUUUCCUCUCACUGGCUUCUCC 314 TCTGTACGGTGACAAGGCGUNNNACTNN 1310 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGACCAGCUCUUUCGGAAC ACUGCUGUUCCUUCAUACACUUC 315 TCTGTACGGTGACAAGGCGUNNNACTNN 1311 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGUGAAGGUGCUUGGAUCUG AUACCCCAGCUCAGAUCUUCUCC 316 TCTGTACGGTGACAAGGCGUNNNACTNN 1312 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUUCAGCAGGAAGUACCGT GCAUGUUUGUUGGUGAUUCCAAG 317 TCTGTACGGTGACAAGGCGUNNNACTNN 1313 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGAGGUGGAAGAGACAGGC AAAUGUGUAAAUUGCCGAGCACG 318 TCTGTACGGTGACAAGGCGUNNNACTNN 1314 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGAGGAGCUCUUCAAGCUG AAUGCUUAUUCAUGGCAGGACCA 319 TCTGTACGGTGACAAGGCGUNNNACTNN 1315 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAAGACCCAAGCUGCCUGAC AGAUGAUGAUCUCCAGGUACAGG 320 TCTGTACGGTGACAAGGCGUNNNACTNN 1316 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCUGUUGUGAAAAGGACGG AGGUCUGUCCUCAAGGAAUGGAT 321 TCTGTACGGTGACAAGGCGUNNNACTNN 1317 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUGCUACAUACGGGCUGAA CAUCACCACGAAAUCCUUGGUCT 322 TCTGTACGGTGACAAGGCGUNNNACTNN 1318 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGCCAUUGGCUCUAUGGAA CAUCAGGAGUCUGUUGGACCUUG 323 TCTGTACGGTGACAAGGCGUNNNACTNN 1319 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGGCUAUCACAAGCUGCAC CCAAACUGCUCCAGGUAAUCCAC 324 TCTGTACGGTGACAAGGCGUNNNACTNN 1320 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAUGUCUGGCUGUGAUGCT CCAUCCUUCAUAGCUGUAUGCAC 325 TCTGTACGGTGACAAGGCGUNNNACTNN 1321 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGACGUACCAAACAGGCAC CCCAAGAAAUCGAACUCCACAAG 326 TCTGTACGGTGACAAGGCGUNNNACTNN 1322 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCGGUUCCCACUGAUGACA CCUCUUUGAGGUCUUGUCCAGUC 327 TCTGTACGGTGACAAGGCGUNNNACTNN 1323 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCAUUCAGCACCAGAGGCA CGAUUCCUGGCUUUUCAUCUCUT 328 TCTGTACGGTGACAAGGCGUNNNACTNN 1324 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGCUGCUCAGUUACAGCAG CUGACACCAGAUCAGAAAGGUCT 329 TCTGTACGGTGACAAGGCGUNNNACTNN 1325 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAAAUCUCUGGCCAACUCCG CUGAGGAUUUCCAGCAAAUAGGG 330 TCTGTACGGTGACAAGGCGUNNNACTNN 1326 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAUGCAGAAUGCCACCAAG GGUGAACUCCUGCAUGUCAUCAG 331 TCTGTACGGTGACAAGGCGUNNNACTNN 1327 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCACUCCUUGGAGCAAAAGC GUAACAAUACCAGUGAAGACCCG 332 TCTGTACGGTGACAAGGCGUNNNACTNN 1328 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUGUUGGCCUGGCAGAAAA GUAGUAGUGGUUGUGGCACUUGG 333 TCTGTACGGTGACAAGGCGUNNNACTNN 1329 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGAAGGAGAUUGCCCUGCT GUCACAUUCAGGAUGUGCUUUCG 334 TCTGTACGGTGACAAGGCGUNNNACTNN 1330 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCACAGUUUGAGGCACAGG GUUCCUCAGAUCAUUCUCCAGCT 335 TCTGTACGGTGACAAGGCGUNNNACTNN 1331 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCUCUCAUUGACCGGAACC UACAGCUUCUCCCAGUAAGCAUC 336 TCTGTACGGTGACAAGGCGUNNNACTNN 1332 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCUCUCAUCGGCCAAUCA UAUGGAGGCCAAUGCUCUCUUCA 337 TCTGTACGGTGACAAGGCGUNNNACTNN 1333 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUUCUGGACCAAGACGACT UCUACAUUUGUAGGUGUGGCUGT 338 TCTGTACGGTGACAAGGCGUNNNACTNN 1334 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCCAUCCAGACCUACUCUG UGACAGGAAGACCUUGAGGUAGA 339 TCTGTACGGTGACAAGGCGUNNNACTNN 1335 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUGCCGCUAAAGAAGGGUC UGGUUGAGGACUGUGAGACAGUT 340 TCTGTACGGTGACAAGGCGUNNNACTNN 1336 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGCAUCUCUCGCUGGUUT UUAUCCUUAAGGAGCCCUGUGUG 341 TCTGTACGGTGACAAGGCGUNNNACTNN 1337 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGUGUCAUCCAGCCUUAGC UUCAACACAGCUGUUGGUUUCUC 342 TCTGTACGGTGACAAGGCGUNNNACTNN 1338 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAUACCAGAGGCAAUCCGCA CAGACGUCACUUUCAAACGUGUAT 343 TCTGTACGGTGACAAGGCGUNNNACTNN 1339 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACAGCCGGAGGUCAUACUG UCUCUUGGAAACUCCCAUCUUGAG 344 TCTGTACGGTGACAAGGCGUNNNACTNN 1340 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGGAUAGUGGAUCCCAACGG AGUGACAGAAAGGUAAAGAGGAGC 345 TCTGTACGGTGACAAGGCGUNNNACTNN 1341 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAGCAGAGGCAUAAGGUUC UGGAGUUUGUCUGCUGAAUGAACC 346 TCTGTACGGTGACAAGGCGUNNNACTNN 1342 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAAAACGCCUGUGUUCCACC GUCCUUCUCUUCCAGAGACUUCAG 347 TCTGTACGGTGACAAGGCGUNNNACTNN 1343 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCCGGCAAAUCACAGAUCG CUGUGCCAGGGACCUUACCUUAUA 348 TCTGTACGGTGACAAGGCGUNNNACTNN 1344 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCUCCGGUGUGGAGUUCUG UUGCCAUCAUUGUCCAACAAAGUC 349 TCTGTACGGTGACAAGGCGUNNNACTNN 1345 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCAACAUUGAAAGCCUCGT UUGUUAACCUUGCAGAAUGGUCGA 350 TCTGTACGGTGACAAGGCGUNNNACTNN 1346 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACACAAGGGAGGUCCUCAA UUUUUCAGCAUUAACAUGCGUGCT 351 TCTGTACGGTGACAAGGCGUNNNACTNN 1347 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGACGACGAGGAUGAGGAUG GGCCAUGAAUUCGUCAGCUAGUUT 352 TCTGTACGGTGACAAGGCGUNNNACTNN 1348 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCGAACAGAAACCCCUCCUC GGUGACUGGAUCCACAACCAAAAT 353 TCTGTACGGTGACAAGGCGUNNNACTNN 1349 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCUGCAUCCAAUGGAUGCT CUUGCAGCCAUGAUCCAAUUCUCA 354 TCTGTACGGTGACAAGGCGUNNNACTNN 1350 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUCUCUUCAUGGCCAGUGC CUCCCAGAAUUACCAAGUGAGUCC 355 TCTGTACGGTGACAAGGCGUNNNACTNN 1351 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAUGGAGAGGCUGAAGCAG GAAAGAGAAGUGCAUGUGCAAGAC 356 TCTGTACGGTGACAAGGCGUNNNACTNN 1352 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGAAGCCAUCAAACAGCUGC GUGCCUUUAAAAAUUUGCCCCGAT 357 TCTGTACGGTGACAAGGCGUNNNACTNN 1353 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUUACAUACCCAGCACCGA AGUGCCACUGGUCUAUAAUCCAGA 358 TCTGTACGGTGACAAGGCGUNNNACTNN 1354 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCUUGUGUCAAUGGAGGCA UAAGGCCUGCUGAAAAUGACUGAA 359 TCTGTACGGTGACAAGGCGUNNNACTNN 1355 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACAGCAUCAAGGAUGUGCA GAUCAUUGUUCCUUCCCCUCAGAC 360 TCTGTACGGTGACAAGGCGUNNNACTNN 1356 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCAAUACCUGCAGCUUCUG AUCUGAUCCUAAAACCCAGCCUCT 361 TCTGTACGGTGACAAGGCGUNNNACTNN 1357 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACUACCAGGAUUGCCAACC UUACAGCCCUGGAUUUGUCAAGUT 362 TCTGTACGGTGACAAGGCGUNNNACTNN 1358 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGAUGGAAACUUUGCUGCT GCCGUUGUACACUCAUCUUCCUAG 363 TCTGTACGGTGACAAGGCGUNNNACTNN 1359 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUUGGAGCCCAUUCAGAGC UGCAGUUGGUGGAACCAUUAACUC 364 TCTGTACGGTGACAAGGCGUNNNACTNN 1360 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCGCUCACCUGGAUGACAA CUUCACCUUUAACACCUCCAGUCC 365 TCTGTACGGTGACAAGGCGUNNNACTNN 1361 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGAGGAGUACGUGGAGGUG AAAAACUAUGAUGGUGACGUGCAG 366 TCTGTACGGTGACAAGGCGUNNNACTNN 1362 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUCUCCUUGGCCUCUCCUG GUGAUGAUUGGGAGAUUCCUGAUG 367 TCTGTACGGTGACAAGGCGUNNNACTNN 1363 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGCCCAACACUGUACCUCAG AGACCCAAAGGGCAGUAAGAUAGG 368 TCTGTACGGTGACAAGGCGUNNNACTNN 1364 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCGGGCAGGAAUCUGAUGAC AAUAAGGUUCACAUCAGGAAGGGT 369 TCTGTACGGTGACAAGGCGUNNNACTNN 1365 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAGGGCAGCAACAUCUUUG AAUAUGCUCAGACCAGUCAUCUGC 370 TCTGTACGGTGACAAGGCGUNNNACTNN 1366 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCUGCAACAGCAGCACAAA AAUCUCCCAAUCAUCACUCGAGUC 371 TCTGTACGGTGACAAGGCGUNNNACTNN 1367 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCUGCAAUUCCUCGAACG AGCAUCAAAUUUGCGCUGGAUUUC 372 TCTGTACGGTGACAAGGCGUNNNACTNN 1368 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGGCCUCACUAAACUGUUGG CAUCAUCUCCAUCUCAGACACCAG 373 TCTGTACGGTGACAAGGCGUNNNACTNN 1369 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGAAGGAGCUGGAGAAGCA CAUUUUGAGAUGCUUGCAAUUGCC 374 TCTGTACGGTGACAAGGCGUNNNACTNN 1370 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGAGGAAAAGGUCGCCUC CCCAGGUUUAUUAAAUUUCGCAGC 375 TCTGTACGGTGACAAGGCGUNNNACTNN 1371 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAAUUUAGAAGGGCUGGUGGC CUCCUUCUCCGCACAUUUUACAAG 376 TCTGTACGGTGACAAGGCGUNNNACTNN 1372 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAAACCCCCUACAGAUGGC CUCUUUGUCGGUGGUAUUAACUCC 377 TCTGTACGGTGACAAGGCGUNNNACTNN 1373 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACCAGUGGGAGGGUCUUAT CUGGUCCAACUUCAUUUUCUGAGA 378 TCTGTACGGTGACAAGGCGUNNNACTNN 1374 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACAUCUGCAACAGCAAGCAC GAGUCCAUUAUGAUGCUCCAGGUG 379 TCTGTACGGTGACAAGGCGUNNNACTNN 1375 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUACAAUGUCCUCCUGACAGC GCCAAUUCACUGUGGUUUAAGUGC 380 TCTGTACGGTGACAAGGCGUNNNACTNN 1376 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUGAAGACAGGCCCAACUT GCCAGAGUCAUAGCUGGAGUAACT 381 TCTGTACGGTGACAAGGCGUNNNACTNN 1377 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACGAGGCUGCAAGAGAGAUC GGACAUCAGUGGUACUGAGCAAUA 382 TCTGTACGGTGACAAGGCGUNNNACTNN 1378 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGCACCCGAGGCAUUAUUT GGUCUAUUCCUGUUGAAGCAGCAA 383 TCTGTACGGTGACAAGGCGUNNNACTNN 1379 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGAGAAUGAGUACGGCAGCA GGUGGCUAAUAGCUUCUUCUGUUC 384 TCTGTACGGTGACAAGGCGUNNNACTNN 1380 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGGACUCUCCCAUCACUCUG GUCACAGCUGCAGUUGAAAAAGUT 385 TCTGTACGGTGACAAGGCGUNNNACTNN 1381 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGCUGAAGGAAGGACACA GUUUUCCUUCCUUUAUCCCAGGUG 386 TCTGTACGGTGACAAGGCGUNNNACTNN 1382 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCAUGAGACUCAGUGCAGA UAGCAGGUCAAAAGUGAACUGAUG 387 TCTGTACGGTGACAAGGCGUNNNACTNN 1383 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGACUCUGCUUCGCUGCAT UAUCUCUUCCAUAGGCUCCUGCUG 388 TCTGTACGGTGACAAGGCGUNNNACTNN 1384 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGGAUAGCCUCCACCACCT UAUGCUAUCUGAGCCGUCUAGACT 389 TCTGTACGGTGACAAGGCGUNNNACTNN 1385 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGUGAAUUAGGGACCGGGA UCAGUCUCCAUGAUAGUGGUCCAG 390 TCTGTACGGTGACAAGGCGUNNNACTNN 1386 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCUCAAGGAGCCCUUUCCA UGGACUUCCAUGUGCAAACACUAC 391 TCTGTACGGTGACAAGGCGUNNNACTNN 1387 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAACCCCCAGUACUUCCGUCA UGUGCUGUCCAUUUUCACUUUCUG 392 TCTGTACGGTGACAAGGCGUNNNACTNN 1388 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGAGUGCUACAACCUCAGCC UUACCAAAAGGCAAAAUCCCACCA 393 TCTGTACGGTGACAAGGCGUNNNACTNN 1389 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAUUCAGCCCAGAGCCUUUG UUCACUUCCAAUAUUCUCUGCUGC 394 TCTGTACGGTGACAAGGCGUNNNACTNN 1390 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAUCUGAAAGGCAGAGCAGG UUCUGGAUUUCAGCUUUGGAAAGT 395 TCTGTACGGTGACAAGGCGUNNNACTNN 1391 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUACCUACUCCCUCUCCGUGA UUGCAGAAGGAACACCUAUUCGUT 396 TCTGTACGGTGACAAGGCGUNNNACTNN 1392 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCACUGCUGUGUCUGUAAACG GCACACCAGAAAAGUCUUAGUAACC 397 TCTGTACGGTGACAAGGCGUNNNACTNN 1393 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCUCUGCGCAUUCAGGAGUG UGUUUCCAAAUGACAACCAGGACAA 398 TCTGTACGGTGACAAGGCGUNNNACTNN 1394 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGUACCAGAUGGAUGUGAACC UCUUUGUGAUCCGACCAUGAGUAAG 399 TCTGTACGGTGACAAGGCGUNNNACTNN 1395 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGGACCUCCGGUCAGAAAAC UGGUGAAACCUGUUUGUUGGACAUA 400 TCTGTACGGTGACAAGGCGUNNNACTNN 1396 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCACACGCAACUGUCUAGUGG GCAAAUGUAAUCUACCAGGCUUUGG 401 TCTGTACGGTGACAAGGCGUNNNACTNN 1397 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCUACAGAUUGCGAGAGAGC GAGCCAUAGUGGAGAGCUGUAAAUT 402 TCTGTACGGTGACAAGGCGUNNNACTNN 1398 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUUCCUGUGCAUGAAAGCACT ACAUGUAUGCCAGCUGUUAGAGAUT 403 TCTGTACGGTGACAAGGCGUNNNACTNN 1399 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCUCUGUCACCAGGACAUUC CACCCCAGCAAAGCAUUUUAAGAUC 404 TCTGTACGGTGACAAGGCGUNNNACTNN 1400 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACUUGGCAGCCAGAAACAUC UACAUCAUGAGAGGAAUGCAGGAAT 405 TCTGTACGGTGACAAGGCGUNNNACTNN 1401 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACCACGUGACCUUGAAGCUC CACUUAAUUUGGAUUGUGGCACAGA 406 TCTGTACGGTGACAAGGCGUNNNACTNN 1402 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCGUGUUCUUCAUUCGGCAC CGGUGUCAGCCUCCACT 407 TCTGTACGGTGACAAGGCGUNNNACTNN 1403 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGUUCUGGAUCAGCUGGAUG ACUUUGCGUGGUGUAGAUAUGAUCA 408 TCTGTACGGTGACAAGGCGUNNNACTNN 1404 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACACUCUUGAGGGCCACAAA CUCUCCUUCCUCCUGUAGUUUCAGA 409 TCTGTACGGTGACAAGGCGUNNNACTNN 1405 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUCCUCAGGAGUCUCCACAT CUCAGGACUUAGCAAGAAGUUAUGG 410 TCTGTACGGTGACAAGGCGUNNNACTNN 1406 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGAUACUUACGCGCCACAGAG UAUCACAGAAUUCCUCCAGGCUUCT 411 TCTGTACGGTGACAAGGCGUNNNACTNN 1407 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUGAUGAGCAGCAGCGAAAG CACGGGAAAGUGGUGAAGAUAUGUG 412 TCTGTACGGTGACAAGGCGUNNNACTNN 1408 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCAAGCCCUCCAACAUCCUA UGUGGGUCCUGAAUUGGAGGAAUAT 413 TCTGTACGGTGACAAGGCGUNNNACTNN 1409 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACUGACAACCACCCUUAACCC CACCUGGAACUUGGUCUCAAAGAUT 414 TCTGTACGGTGACAAGGCGUNNNACTNN 1410 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUACCCUCUCAGCGUACCCUUG AACCAUAUCAAAUUCACACACUGGC 415 TCTGTACGGTGACAAGGCGUNNNACTNN 1411 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUUUGCUGGCUGCAAGAAGAT GCUUUUCCAUCUUUUCUGUGUUGGT 416 TCTGTACGGTGACAAGGCGUNNNACTNN 1412 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCACUCACCAUGUGUUCCAUG CCCAGUUGUGGGUACCUUUAGAUUC 417 TCTGTACGGTGACAAGGCGUNNNACTNN 1413 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUCGUACAUGACCACACCCA AAAGAGAUCAUUUGCCCCAUCAAUT 418 TCTGTACGGTGACAAGGCGUNNNACTNN 1414 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAACGUUAGGUGGGACAGUAC AAGAUCUAUGUCAUAAAAGCAGGGC 419 TCTGTACGGTGACAAGGCGUNNNACTNN 1415 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCAAGAGGCAGUUUCUGGCA ACGGCGAUAUUUUGUCUGAUGUAGG 420 TCTGTACGGTGACAAGGCGUNNNACTNN 1416 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUUAGUCACUGGCAGCAACA ACUAUCUGCAGGUUUCAUCUGAAUG 421 TCTGTACGGTGACAAGGCGUNNNACTNN 1417 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACAACGUGAUGAAGAUCGCA ACUGCAUGCAAUUUCUUUUCCAUCT 422 TCTGTACGGTGACAAGGCGUNNNACTNN 1418 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUCUGCCUCUUCUUCUCCAG AGUUGGUUGAACAGUUAUUUCUGCA 423 TCTGTACGGTGACAAGGCGUNNNACTNN 1419 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCUUUAGCCAUGGCAAGGUC CAAGACCUCUCAGGUAUUGUAAGGG 424 TCTGTACGGTGACAAGGCGUNNNACTNN 1420 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCCACGGAGUGUAUGACCAC CAAGCUCAGAUAUUUGGGCUUCAAG 425 TCTGTACGGTGACAAGGCGUNNNACTNN 1421 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUCAGUCACUGGGAGAAGAA CAGUGCUGUAUCAUCCCAAAUGUCA 426 TCTGTACGGTGACAAGGCGUNNNACTNN 1422 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCGGCUUUACACCAAAAGC CAUUCAUCAGCUGUGUGUUCUGAAT 427 TCTGTACGGTGACAAGGCGUNNNACTNN 1423 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUCCCUGCACUCUCAUCGCT CCAGUCCCCAGGUAAUGUAAAUGUA 428 TCTGTACGGTGACAAGGCGUNNNACTNN 1424 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAUCCAACCAAUGGUGGACA CCUUCUAGUAAUUUGGGAAUGCCUG 429 TCTGTACGGTGACAAGGCGUNNNACTNN 1425 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUUUAAUAACCCAGCCACGG CUAGGUUUCAUGCUCAUAUCCGGUC 430 TCTGTACGGTGACAAGGCGUNNNACTNN 1426 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAAGUCCUCUCGGAAGGUAGC CUGAUCCUCAGUGGUUUGAACAGUC 431 TCTGTACGGTGACAAGGCGUNNNACTNN 1427 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAAGAAGCAACUGAGAGCUG GAUCGUCUCCUCUGAAAUGUCAUUC 432 TCTGTACGGTGACAAGGCGUNNNACTNN 1428 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAGCUCCCAGAAGUUGACAG GCCAUCUCUUUAUCGGAGUCUCUUT 433 TCTGTACGGTGACAAGGCGUNNNACTNN 1429 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUCAGGCAUUGCUACUCUGG GGAAGUCAAAUAUUUGCCUCUCCAG 434 TCTGTACGGTGACAAGGCGUNNNACTNN 1430 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGUAGUAGACAUCACUCGCAC UAAGGCAUUUCGCUCAACACUUUUC 435 TCTGTACGGTGACAAGGCGUNNNACTNN 1431 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCAUCUAGUCUUUCCGCUUC UCAUAUGGCUAUCCCUUUGCAAUUC 436 TCTGTACGGTGACAAGGCGUNNNACTNN 1432 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUAUGGCACAAUCAGAGCUGT UCCAUACUGCUCAACCUCUGCAAUA 437 TCTGTACGGTGACAAGGCGUNNNACTNN 1433 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAAGAUCAUGUGGCCUCAGT UCCAUUUCUGAGAUCAGGUCUGACA 438 TCTGTACGGTGACAAGGCGUNNNACTNN 1434 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUGCUUUGGAGCAGAAGAAGG UCUAGCUGUAGCACAAAAUCUUCGT 439 TCTGTACGGTGACAAGGCGUNNNACTNN 1435 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUUGCAAAGACACAAGUGGG UGACACCAACAUCUUUACUGCAGAA 440 TCTGTACGGTGACAAGGCGUNNNACTNN 1436 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCGGAACCUUUCUUCCCCUG GUUUGGAUGAAUGGAGGUGAGGAAUT 441 TCTGTACGGTGACAAGGCGUNNNACTNN 1437 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCAACGAAAAGAGCUACCGC CUUGCGCUUGUUAUACUCUUUAGUGC 442 TCTGTACGGTGACAAGGCGUNNNACTNN 1438 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCCUGACUUCCAGAAAACCA AAAAGACUCGGAUGAUGUACCUAUGG 443 TCTGTACGGTGACAAGGCGUNNNACTNN 1439 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCACUGCUCUCAGUGAGAAG CCUGACCCAAGAUGAAAUAAAACGUC 444 TCTGTACGGTGACAAGGCGUNNNACTNN 1440 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGAUUAUGGGCAUCCCAGAAG AGAGCCUAAACAUCCCCUUAAAUUGG 445 TCTGTACGGTGACAAGGCGUNNNACTNN 1441 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAAAUAUUGGGCCCUUCCUG GGUGUGAAAUGACUGAGUACAAACUG 446 TCTGTACGGTGACAAGGCGUNNNACTNN 1442 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAACUGAAGCUGUCAGGACAGA GCUCACAGAAAUGUCUGCUAUACUGA 447 TCTGTACGGTGACAAGGCGUNNNACTNN 1443 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUUGGCUACCUUGGGACAUC AGACUGCUAAGGCAUAGGAAUUUUCG 448 TCTGTACGGTGACAAGGCGUNNNACTNN 1444 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUGCAUCUCUUGUCGCAGGUT GGUAAUAGUCGGUGCUGUAGAUAUCC 449 TCTGTACGGTGACAAGGCGUNNNACTNN 1445 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAACUGUGAGGAUGUGGCUGA GUUCAAAUGAGUAGACACAGCUUGAG 450 TCTGTACGGTGACAAGGCGUNNNACTNN 1446 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUAAUCAAGCAGCAGCCAGA UACCAGAUAGAACAGACACAGCUACT 451 TCTGTACGGTGACAAGGCGUNNNACTNN 1447 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUAUUGGGACUCCUCUGCCCUG CAAAGAUGCAGAGCUCUGAGUAGAAC 452 TCTGTACGGTGACAAGGCGUNNNACTNN 1448 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAAGCUGGUUUUGAAGUCGC CUGCUUGAAGAUCAGAAGUUCCAAUG 453 TCTGTACGGTGACAAGGCGUNNNACTNN 1449 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCAGAGAGAGCAGCUUUGUG CAUAGGCAAGAAGAUGGAACAGAUGA 454 TCTGTACGGTGACAAGGCGUNNNACTNN 1450 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAUUCAGCUCCUCUGUGUUT AGAUGGAGAUGAUGAAGAUGAUUGGG 455 TCTGTACGGTGACAAGGCGUNNNACTNN 1451 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUUGAAGAGAUUGGCUGGUC AAGAGAAAAGGAGAUUACAGCUUCCC 456 TCTGTACGGTGACAAGGCGUNNNACTNN 1452 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUACAACUGCUACCAUGAGGGC AGAAACCUGUCUCUUGGAUAUUCUCG 457 TCTGTACGGTGACAAGGCGUNNNACTNN 1453 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGUGGGAACGUGAAACAUCT CCCAAAUAUCCCCAGUUUCCAGAAUC 458 TCTGTACGGTGACAAGGCGUNNNACTNN 1454 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUCACAUCUUCAGGUGCCUC AUCUACUUCCAUCUUGUCAGGAGGAC 459 TCTGTACGGTGACAAGGCGUNNNACTNN 1455 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAUCUACAAGAAAGCCCCCA GAUCUUCUCAAAGUCGUCAUCCUUCA 460 TCTGTACGGTGACAAGGCGUNNNACTNN 1456 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAGGUACCACCUUAUCCACA CUCACAGAGUUCAAGCUGAAGAAGAT 461 TCTGTACGGTGACAAGGCGUNNNACTNN 1457 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUACCUGGACAAGCACAUGGAG GCUGAAACAAAAAGCACUCUUCUGUC 462 TCTGTACGGTGACAAGGCGUNNNACTNN 1458 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACAGUCUCUUGCAAUCGGCUA ACAUGAUGGAUGUCACGUUCUCAAAG 463 TCTGTACGGTGACAAGGCGUNNNACTNN 1459 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCCGGGAAUUUCUUCGAAAA CUUGUGAGUGGAUGGGUAAAACCUAT 464 TCTGTACGGTGACAAGGCGUNNNACTNN 1460 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAACUUCAGUGGGCAUCGAGAT CACAGCAGUCUUUCUUUCCCAUGUAA 465 TCTGTACGGTGACAAGGCGUNNNACTNN 1461 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCACAGACUGUUUCCACUCCT AGCCUCUUGCUCAGUUUUAUCUAAGG 466 TCTGTACGGTGACAAGGCGUNNNACTNN 1462 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUAGAGGAUGCCGAGGAGAA UCUCUUUAGGGAGCUUCUCUUCUUCC 467 TCTGTACGGTGACAAGGCGUNNNACTNN 1463 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCUGUGAUCGCACUGACAC GCCAGAGAAAAGAGAGUUACUCACAC 468 TCTGTACGGTGACAAGGCGUNNNACTNN 1464 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGCAUCCUUGGCAGAAAGUG ACACCUUGUCUUGAUUUUACUUUCCC 469 TCTGTACGGTGACAAGGCGUNNNACTNN 1465 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAACAACCUGUUGGAGCACAT ACUAAUGAAUUCUUCUUCCUGCUCAG 470 TCTGTACGGTGACAAGGCGUNNNACTNN 1466 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCAGUGCAAGACUGAGACUC AGUGAUCAGAGGUCUUGACAUAUUGG 471 TCTGTACGGTGACAAGGCGUNNNACTNN 1467 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCUCCAUCAGUGACCUGAAG AUAAAUCAGGGAGUCAGAUGGAGUGG 472 TCTGTACGGTGACAAGGCGUNNNACTNN 1468 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGAGGCCUUCAUGGAAGGAA CACUGACGGAAGUUCUCAUAAACGUC 473 TCTGTACGGTGACAAGGCGUNNNACTNN 1469 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGACUUCCACCAGGACUGUG CACUUUGACCAAAGUCUCACUGACAA 474 TCTGTACGGTGACAAGGCGUNNNACTNN 1470 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUGACCAGUGCUACGUUUCCT CAUCUUCAAAGUUGCAGUAAAAACCC 475 TCTGTACGGTGACAAGGCGUNNNACTNN 1471 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCACAUGGCGGAGAGUUUUA CCUUUCACGAAUUCAUUUUCUUUGCG 476 TCTGTACGGTGACAAGGCGUNNNACTNN 1472 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUACUGUGCCACUUCAGUGUGC CUAUCACAUUGUUCUCUCCAAUGCAG 477 TCTGTACGGTGACAAGGCGUNNNACTNN 1473 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUUCAGUGCCAUCAUCCUGG CUCGUACAAGUCACAAAGUGUAUCCA 478 TCTGTACGGTGACAAGGCGUNNNACTNN 1474 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCCCUUCCACAGACGUCACT GACAGACUUCUCUCACACAUUGUGUC 479 TCTGTACGGTGACAAGGCGUNNNACTNN 1475 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUAACCGGAGCCUGGACCAUAG GAGAGUGCAGUAUCAAGAAUCUUGUC 480 TCTGTACGGTGACAAGGCGUNNNACTNN 1476 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAACGCUCUGGAGUCUCUCUCC GAGAUAGUUUCACUUUCUUCCCAGCT 481 TCTGTACGGTGACAAGGCGUNNNACTNN 1477 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUAGAGCAAAUCCAUCCCCACA GCCAUCUCCUCUUGCAUAAACAAGUT 482 TCTGTACGGTGACAAGGCGUNNNACTNN 1478 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCGAGCCACCAAUUUCAUAGGC GGUGGAAAGUAAUAGUCAAUGGGCAA 483 TCTGTACGGTGACAAGGCGUNNNACTNN 1479 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCCAACCAAGCUCUCUUGAG GUCUUCCCAACAAAUUUUGGGUGAAA 484 TCTGTACGGTGACAAGGCGUNNNACTNN 1480 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGUAUUCGAUGAUCCCUGUGG UCAUCAUCAUCAUCAUCAUCCUCCGA 485 TCTGTACGGTGACAAGGCGUNNNACTNN 1481 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCCCCAAUGACCUGCUGAAAT UGAUGCUUUGUUAAUGCGAAGUUCUG 486 TCTGTACGGTGACAAGGCGUNNNACTNN 1482 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGAAGCAUCUCACCGAAAUCC UGUUGUACACUUUGAGGAGUGAUCUG 487 TCTGTACGGTGACAAGGCGUNNNACTNN 1483 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUAUGGUGGUGCCGACUACAAG UUUUGUGAACAGUUCUUCUGGAUCAG 488 TCTGTACGGTGACAAGGCGUNNNACTNN 1484 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUCUACCAGCUCACCAAGCUC AACCAGACAGAAAAUUUCCACAUAAGC 489 TCTGTACGGTGACAAGGCGUNNNACTNN 1485 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACCCCCACUGAACCUCUCUUA UGGGACACAAUUUGACAAAUAUGACCA 490 TCTGTACGGTGACAAGGCGUNNNACTNN 1486 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCAAUCCCCACACCAAGUAUCA UAGCACAGUUUAAAAAUGAGGCCUACT 491 TCTGTACGGTGACAAGGCGUNNNACTNN 1487 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGCCUGAAGAUCCUACCUGAG GAUUCUUAUAAAGUGCAGCUUCUGCAT 492 TCTGTACGGTGACAAGGCGUNNNACTNN 1488 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGCAAUCCGGAACCAGAUCAUA UUGUGUGGAAGAUCCAAUCCAUUUUUG 493 TCTGTACGGTGACAAGGCGUNNNACTNN 1489 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGACUAGGCGUGGGAUGUUUUT UGAAACUAAAAAUCCUUUGCAGGACUG 494 TCTGTACGGTGACAAGGCGUNNNACTNN 1490 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACUCCACACGCAAAUUUCCUUC ACCAUACUCUACCACAUAUAGGUCCUT 495 TCTGTACGGTGACAAGGCGUNNNACTNN 1491 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUGCAGCAAAGACUGGUUCUCA GCUUCUUUGAGUUUGUAUCUUGGAUGC 496 TCTGTACGGTGACAAGGCGUNNNACTNN 1492 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGAAUAACCAGCUGUCCUCCT UGUGGAGUAUUUGGAUGACAGAAACAC 497 TCTGTACGGTGACAAGGCGUNNNACTNN 1493 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGGUAUUCUCGGAGGUUGCCUT CAUGAACCGUUCUGAGAUGAAUUAGGA 498 TCTGTACGGTGACAAGGCGUNNNACTNN 1494 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUUCCCUCGGGAAAAACUGAC CUGAUCUACAGAGUUCCAAAAGUGACA 499 TCTGTACGGTGACAAGGCGUNNNACTNN 1495 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCAAGCACAUGGAUCAGUGUT CUUGAUUUCUUUUACUGACCCUUCUGC 500 TCTGTACGGTGACAAGGCGUNNNACTNN 1496 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAAGUACAAUUGCAGGCUGAACG GAAGAUUUUCAAUCUCCUCUUGGGUUG 501 TCTGTACGGTGACAAGGCGUNNNACTNN 1497 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUAAGCCCACAUAUCAGGACCGA GAUCUUUGUGCUUACUCCUUCCUAGUT 502 TCTGTACGGTGACAAGGCGUNNNACTNN 1498 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACACCUGGACACCUUGUUAGAT GGAAAUGUUUCCUAGACAAACUCGUCA 503 TCTGTACGGTGACAAGGCGUNNNACTNN 1499 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCUGGAUCUGCAGCUCUAUGG GUGGAAUUGGAAUGGAUUUUGAAGGAG 504 TCTGTACGGTGACAAGGCGUNNNACTNN 1500 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCUACAGAGACACAACCCAUT UGGAAGAUCUUAACUUCCCUUUCAAGA 505 TCTGTACGGTGACAAGGCGUNNNACTNN 1501 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAAUCGCAAGAGAAGCACCUT UUCUGGUUGAGAGAUUUGGUAUUUGGT 506 TCTGTACGGTGACAAGGCGUNNNACTNN 1502 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCGGCUCUUUCCACUAAACCAG GUGUACGUUUGUCAGUUAUUAUAGUGCC 507 TCTGTACGGTGACAAGGCGUNNNACTNN 1503 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGCAGUGUUUAGCAUUCUUGGG AAAAUCUCCAGGCCUAACAUAAUUUCAG 508 TCTGTACGGTGACAAGGCGUNNNACTNN 1504 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCAAAACUACUGUAGAGCCCA ACACAUGAAGCCAUCGUAUAUAUUCACA 509 TCTGTACGGTGACAAGGCGUNNNACTNN 1505 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCCUUUUGCUCCUGGUGGAAC CAGCUCAGAAUUAACCAUAAAACUGGUG 510 TCTGTACGGTGACAAGGCGUNNNACTNN 1506 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACAUGUUGGAUGUGAAGGAGC UCAUACCUACCUCUGCAAUUAAAUUUGG 511 TCTGTACGGTGACAAGGCGUNNNACTNN 1507 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUCCACCAAAGUCACCAGAGGG AUUGAUUGUUUCUAAUAGAGCAGCCAGA 512 TCTGTACGGTGACAAGGCGUNNNACTNN 1508 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGUCUUAUAGCGGAAGAGGCAGA UGUAGACUUGGAAUCUACUGAUAUCCCT 513 TCTGTACGGTGACAAGGCGUNNNACTNN 1509 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAGCCAUGGACACACUCAAGA AAAUAAAGGACCCAUUAGAACCAACUCC 514 TCTGTACGGTGACAAGGCGUNNNACTNN 1510 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUCUUCUCCAUCGUCCAUGAC UAGAAUGCCAGUUAAUGAAAACAGAACG 515 TCTGTACGGTGACAAGGCGUNNNACTNN 1511 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCAGAUUCCUCAUGGUCAUGGG UGAAGACAGAUGGCUCAUUCAUAGGAUA 516 TCTGTACGGTGACAAGGCGUNNNACTNN 1512 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAAGAACUAGUCCAGCUUCGA CAAUUCCUCUUGACUAUUCUACAGCAAA 517 TCTGTACGGTGACAAGGCGUNNNACTNN 1513 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAACCUGCGCAAACUCUUUGUUC ACAAGAAUGAAAAGUCUUCAACACUUGG 518 TCTGTACGGTGACAAGGCGUNNNACTNN 1514 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCAAGUUGGUGAAAAGGCUUGG CCAGAAAUGUUUUGGUAACAGAAAACAA 519 TCTGTACGGTGACAAGGCGUNNNACTNN 1515 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAAGUUGACCCUGGGUCUGAUC AAGCAUCAGCAUUUGACUUUACCUUAUC 520 TCTGTACGGTGACAAGGCGUNNNACTNN 1516 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGAGGAAAAGAGGAUGCUGGAG GAAUCUCCAUUUUAGCACUUACCUGUGA 521 TCTGTACGGTGACAAGGCGUNNNACTNN 1517 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAACGUAAAAUGUGUCGCUCC AGAGUUUUUCCAAGAACCAAGUUCUUCC 522 TCTGTACGGTGACAAGGCGUNNNACTNN 1518 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAUGUGCUGAAAAUCCGAAGUG AUCUUCCACCUUAAAUUCUGGUUCUGUA 523 TCTGTACGGTGACAAGGCGUNNNACTNN 1519 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUUAAUGCCUCAGAAACCACA CAUCAACUCAUGAAUUAGCUGGUUUCGA 524 TCTGTACGGTGACAAGGCGUNNNACTNN 1520 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACUUCUUGGCCAAGAGGAAGAC GAUCUUCAAUGGCUUUAGUCUGUUCCAA 525 TCTGTACGGTGACAAGGCGUNNNACTNN 1521 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUUGGAGAUGGUUUCACAGCAC UGGAGAGAGAACAAAUAAAUGGUUACCUG 526 TCTGTACGGTGACAAGGCGUNNNACTNN 1522 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGAAUCUCCCAGGCGGUAUUUG UAUUUUCAGCCUUCUACUAGUCGAAAGCG 527 TCTGTACGGTGACAAGGCGUNNNACTNN 1523 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCGCACUGCCCCAAGUUUUACUA AAAAUCCAAAUCAUAUACCAAAGCAUCCA 528 TCTGTACGGTGACAAGGCGUNNNACTNN 1524 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAAGACGAAAACUCUGCGGAAG ACUUUUAACACUUCACCUUUAACUGCUUC 529 TCTGTACGGTGACAAGGCGUNNNACTNN 1525 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGAUCCUCUUCCCUCAGCUUCC CGUUGAUGAUUUCUAACCUUUUCUGGUUT 530 TCTGTACGGTGACAAGGCGUNNNACTNN 1526 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAGAUCACUGAUGACCUGCACT CUGGUUUCUGUAGAAUUCCAUGAGUAGUT 531 TCTGTACGGTGACAAGGCGUNNNACTNN 1527 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCUUCAAUGCACUGAUACACA GCUCUGGUAGAAUUGACAUAUCUCAACAC 532 TCTGTACGGTGACAAGGCGUNNNACTNN 1528 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUAUGUCAGCGUUUGGCUUAACA GGAGAUAUUUCACCUGACUUGAUUCAAGG 533 TCTGTACGGTGACAAGGCGUNNNACTNN 1529 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCACCAUAUACAGGAGCUCAGA GUUUUUCUGGAUAAAAAGAGCCACUGUUC 534 TCTGTACGGTGACAAGGCGUNNNACTNN 1530 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGUCUUUGGAACCACACCAGAA ACAACCCACUGAGGUAUAUGUAUAGGUAUT 535 TCTGTACGGTGACAAGGCGUNNNACTNN 1531 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUGAUAGCUGCACUGAGUGUCA AGAAAAUCAAAGCAUUCUUACCUUACUACA 536 TCTGTACGGTGACAAGGCGUNNNACTNN 1532 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACCUGGAUCCACAGGAAAGAA UCCCAGAGAACAAAUUAAAAGAGUUAAGGA 537 TCTGTACGGTGACAAGGCGUNNNACTNN 1533 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGACUUGCUUCUGCACUAGACA GCUUCUUUAAAUAGUUCAUGCUUUAUGGUT 538 TCTGTACGGTGACAAGGCGUNNNACTNN 1534 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGAUGACCUGGAAGAUGGAGUCT UCCGAAUAUAGAGAACCUCAAUCUCUUUGT 539 TCTGTACGGTGACAAGGCGUNNNACTNN 1535 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCUGGAAGAAGCUGAAAAAGC CAAUGCUUUUAAAUAUGUCAUUGUGGGCAT 540 TCTGTACGGTGACAAGGCGUNNNACTNN 1536 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAGAGAACGGUUGCAAAACUG GUACAACAGAUUAUCUCUGAAUUAGAGCGA 541 TCTGTACGGTGACAAGGCGUNNNACTNN 1537 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGCUACAGUGAUGCCCACUACA UAGAUAAUGCUUAAUAUUCACUUCCCCGUG 542 TCTGTACGGTGACAAGGCGUNNNACTNN 1538 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCUCAAACAGAACGGUCCAGUC UUUUUCCAGUUUAUUGUAUUUGCAUAGCACA 543 TCTGTACGGTGACAAGGCGUNNNACTNN 1539 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUCAGCUAGAAGAGAAGCAGC GAUCUACUGUUUUCCUUUACUUACUACACCT 544 TCTGTACGGTGACAAGGCGUNNNACTNN 1540 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGGAGUGAUUUGCGCCAUCAUC AAAAUAUAGAACCUAAUGGAAGGAUUUGGUG 545 TCTGTACGGTGACAAGGCGUNNNACTNN 1541 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCCCCUGAUAGCAGAUUUGAT GGGUAUGGCAUAUAUCCAAGAGAAAAGAUUT 546 TCTGTACGGTGACAAGGCGUNNNACTNN 1542 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUACCAGCUGAAGAGCGACAAG ACCUUGCUAAGAGAUAUUCAUCUGUCUUUUC 547 TCTGTACGGTGACAAGGCGUNNNACTNN 1543 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAAACAUUCGUCUCGGAAACCC AUUCUGAUCUGGUUGAACUAUUACUUUUCCA 548 TCTGTACGGTGACAAGGCGUNNNACTNN 1544 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUGGUGAUUUUGGCAUGAGCAG CCCUUCUUAAAUUGCUCCUGUAUCAUUGAUT 549 TCTGTACGGTGACAAGGCGUNNNACTNN 1545 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCCGAGAUUGGAGCCUAACAGT AAAAGAAUAUGAAAAGAUGAUUUGAGAUGGUG 550 TCTGTACGGTGACAAGGCGUNNNACTNN 1546 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCAGCAAGAAUAUUCCCCUGGCA GGUUAGUAUGUUAUCAUUUGGGAAACCAAAUT 551 TCTGTACGGTGACAAGGCGUNNNACTNN 1547 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUCUCAUUUGCCUGGCAGAUCUC AAAAUCUGUUUUCCAAUAAAUUCUCAGAUCCA 552 TCTGTACGGTGACAAGGCGUNNNACTNN 1548 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGACAUCAGCAAAGACCUGGAGA CUAGAUAUGGUUAAGAAAACUGUUCCAAUACA 553 TCTGTACGGTGACAAGGCGUNNNACTNN 1549 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGAACUUGCUGGUGAAAAUCGG AGAAUAGGAUAUUGUAUCAUACCAAUUUCUCG 554 TCTGTACGGTGACAAGGCGUNNNACTNN 1550 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUUCAUCCUGCACGAACAGAAAGA GAAUUAAACACACAUCACAUACAUACAAGUCA 555 TCTGTACGGTGACAAGGCGUNNNACTNN 1551 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCCAGGCACUUGAUGAUACUCAC UGUCUGUGUAAUCAAACAAGUUUAUAUUUCCC 556 TCTGTACGGTGACAAGGCGUNNNACTNN 1552 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCCUCUCUCUCUUGUCACGUAGC UUCCCUUUUGUACUGAAUUUUAGAUUACUGAT 557 TCTGTACGGTGACAAGGCGUNNNACTNN 1553 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGGCCAUUUCUGUUUUCCUGUAGC CUGGAAGCUUUAACUUCUUUAUUAAGUUCUUC 558 TCTGTACGGTGACAAGGCGUNNNACTNN 1554 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCUUCGCCUGUCCUCAUGUAUUGG CUGUUCAAGAACUUCUGAAUUUAAAACAGUCT 559 TCTGTACGGTGACAAGGCGUNNNACTNN 1555 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCCGGGCUUUACGCAAAUAAGT UAGUAAGUAUGAAACUUGUUUCUGGUAUCCAA 560 TCTGTACGGTGACAAGGCGUNNNACTNN 1556 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGGAUUUGACCCUCCAUGAUCAG UCUUUGGCACAAUAUUAACUAGUCUAUUGUAG 561 TCTGTACGGTGACAAGGCGUNNNACTNN 1557 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAUCUGUACAGCAUGAAGUGCAAG UGUCUGAUAUUCUUUCUCAUAUUUCUUCAGCT 562 TCTGTACGGTGACAAGGCGUNNNACTNN 1558 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUAGUCGUCAGCCUGAACAUAACAT UUGCUCUUUUGAUUCUUUAAAUACAUCAAAGT 563 TCTGTACGGTGACAAGGCGUNNNACTNN 1559 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUUGCUUCUCAGAUGAAACCACCAG GUUAUAUUGAAAAUGAUUAACAUGUAGAAGGGC 564 TCTGTACGGTGACAAGGCGUNNNACTNN 1560 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUGCUGCACCUUGACUUUAAGUGAG UUAAGUGACAUACCAAUUUGUACAACAGUUAUC 565 TCTGTACGGTGACAAGGCGUNNNACTNN 1561 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCCGAGAAUGGUCAUAAAUGUGCA CAACAUGCUGAUUCUUUUCAACGUUUUAUUUUC 566 TCTGTACGGTGACAAGGCGUNNNACTNN 1562 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUCACUAUGGAGCUCUCACAUGUGG GUGGUAUUCUGUCUUUAAUUGUAAGAUAUGCAA 567 TCTGTACGGTGACAAGGCGUNNNACTNN 1563 TGACAAGGCGTAGTCACGGUNNNACTNNNTGAU NTGAUACCCGAAGAAAGAGACUCUGGAA UGUUCCUGUGUCAACUUAAUCAUUUGUUUGAUA 568 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCUCACAUUGCCCCUGACAACAUA 569 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUAAGGGACCAGGGUCUAUGAAGC 570 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGUGUCCUUUCAGGAUGGUGGAUG 571 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUACAGGAAGAGCACAGUCACUUUG 572 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGAUGCCCCCAAGAAUCCUAGUAG 573 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUCCUCAACCCUCUUCUCAUCAGG 574 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUUCUUUGAGGUGAAGCCAAACCT 575 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUCCCCUACCUAGACCCUCCUAAC 576 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGCUCCAGAAGCCCUGUUUGAUAG 577 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUCAUUCCUGUGUCGUCUAGCCUT 578 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGGUUAUUAUGAGGAAGCUGUGCC 579 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCUUUGAACUCCAAGCUGCUCAAG 580 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUACGUCAUGGAGUAUAUGUGUGGG 581 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAACUACCACCUGUCCUACACCUG 582 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGUUGGUAUCCCUUCAGGACUAGG 583 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCUCAGCAGACAAUAUCGGAUCGA 584 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUACUUGGAGAAGCUGAGAGAAAAC 585 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUCCAGGUCAUGAAGGAGUACUUG 586 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGACCUUCAUGAGCUGCAAUCUCA 587 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUGUUUCAGUAUCCCUGCUCCAAA 588 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAAGAUGUCAUCAUCAACCAAGCA 589 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUACUCCAUGUUCUUGGCCAUGCUA 590 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGGAGCUGGUUCACAUGAUCAACT 591 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAUAUUUCUUCCGCAAGUGUGUCC 592 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAAACUCGAACUGAUUUCUCCUGG 593 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGGCGCUGUCAACAGAAAGAAAAA 594 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCCAACGUUCAAGCAGUUGGUAGA 595 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUAACCAAGAGGAAGUUGGAGGUG 596 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGGUAGAGGAGGUGUUUGAUGUUC 597 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGAUCCUCCUUGCUUACCACACAC 598 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGCCCUUCGAGAGCAAGUUUAAGA 599 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCAAGUGACUCUUCAGAUCCCUGC 600 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUACAUGAAAGGGAGUUUGGUUCUG 601 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUGCUAAAAGAGAGGGAGAGUGAT 602 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGGAGGAACUGGACUUCCAGAAGA 603 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUGGGAUCUUCGUAGCAUCAGUUG 604 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGCAGAACCAUCCACCAACAUAAG 605 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAGAGUUAAAUGCCCUCAAGUCGA 606 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUGGGUUUUUCCUGUGGCUGAAAA 607 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAGGACUGGGUGAAUGCUAUUGAG 608 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUACCAGGGAUGAGCAGAAUGAAGA 609 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAAGACGGUCCGUAAACUGAAAAA 610 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCAGGGAUAUAUCCCCCAAAGGAT 611 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGGUUAUUAAGGAGCUUCGCAAGG 612 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGCAUGUCCAGAGAUGUCUACAGC 613 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGCCGUAUUUGAAGCCUCAGGAAC 614 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUCCAGAAGUCCAGAGCUGAGAAG 615 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCUAGACAUCUUCUCCCUCCCUUG 616 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUAUCGCAGGAGAGACUGUGAUUC 617 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCAGCAGAUGAAUCACCUUUCGUT 618 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCUGAGGAUGCUCAAAGGGUUUUT 619 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAGGCUCCUGAGACCUUUGAUAAC 620 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGGAUGAGCAAGACCUAAAUGAGC 621 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCUAUUGUAAGCAGGCGAUGUUGT 622 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCCUUAGCUGUUGAAGGAAAACGA 623 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUGAAUUUCCUGAAGAACGUUGGG 624 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUACGUGAAGGAUGACAUCUUCCG 625 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGUGCCUUUGAAAAUCAACGACAA 626 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGACCUAAAGACCAUUGCACUUCG 627 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUCUUGUCAGGGAACAGGAAGAAUT 628 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAAUAAAACUUUGCUGCCACCUGT 629 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAACAACAGGAGUUGCCAUUCCAT 630 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGUGAUCCUAGUUUCUGGGCUCAA 631 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAUCAGGAAGAGGAAGAGUCCACA 632 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUAAAGAGGGACUGCCAUAACAUUC 633 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUACUGCCUUCUGAAAGGUGGAAUC 634 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGUGGGAAUUGACAAAGACAAGCC 635 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUACAGCCCAAAGAUGAGAGUGAUT 636 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUGGUUUCAGACGCUGAAGGAUUUT 637 TCTGTACGGTGACAAGGCGUNNNACTNN NTGAUUGAUGUGGACUGGAUAGUCACUG 638 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU AUUAACUCCGAGCACUUAGCGA 639 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU AUCUUCUAGCUCUCUGCCUACC 640 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG ACAGCCAUCAUCAAAGAGAUCG 641 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU UGUGAAGAUCUGUGACUUUGGC 642 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GCGAAUUCCUUUGGAAAACCUG 643 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA UCCAGUGUGCCCACUACAUUGA 644 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU CUUUUUCAGAGUGCAACCAGCA 645 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU UGCAAGCAAAAAGUUUGUCCAC 646 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UUGGUGUAGCACUGACAUUCAT 647 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU UGGGUCACUGUAUGGGAUGUAG 648 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UGAUUUGCCAAGUUGCUCUCUT 649 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU UUUCUGUCCACCAGGGAGUAAC 650 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UACUGCCAUCGACUUACAUUGG 651 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GAUAGUGGUGAAGGACAAUGGC 652 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU CCUCAUGUACUGGUCCCUCAUT 653 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU GAAUUAGCUGUAUCGUCAAGGC 654 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCG AUGCUGAGAACCAAUACCAGAC 655 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU CUGCUGGAUCAUGUGAGACAAC 656 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA UCUGGAUACAUGCCCAUGAACC 657 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU CAGAAUCUUGUUGGCUGCAUUG 658 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AGAAUGUGAAAAUUCCAGUGGC 659 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU GAGUGUAUCCUGGAGGUUGUUG 660 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU GACCAUGUGGACAUUAGGUGUG 661 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UGAAGAAGACCUUUGACUCUGT 662 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GGAGGAGGAUGAGAUUCUUCCA 663 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU CCUAGAAGACUCCAAGGGAGUA 664 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG GACGACAUAUACCUGUGUGCUA 665 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA UGCUACGAAGUGGGAAUGAUGA 666 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC AGGCUACCAUUAUGGAGUCUGG 667 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UUACAAUGGCAGGACCAUUCUG 668 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GGAAGUGGUCAUUUCAGAUGUG 669 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA GAGAUGCGCCAAUUGUAAACAA 670 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA UUUCUCCUUCAGACAAUGCAGT 671 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC UCUUCCAGCUUAAGAAUGAACC 672 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU ACAGAAGCUGAUGGGCCAGAUA 673 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC AGAAUUACCAAGCUAGGGAAGC 674 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC GUUAAAGUCUCUCUUCACCCUG 675 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC CCCAUCUAUGAGUUCAAGAUCA 676 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC GAGUGGCGGAAAGCAAUAAAAT 677 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG ACAAAGGGUGGAUGAAAUUGAT 678 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC AGUGAUGAUCUCAAUGGGCAAT 679 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCG AGGUGUUUUUACCACCAAGACT 680 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU AAAUGACUGUGUCCAGCAAGUT 681 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC AGCUGCCUACAUAAAGGAAUGG 682 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UUGCAAGAUGAAAGGAGAAGGG 683 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC ACUGGAAAGGAAGAGAUUCAUG 684 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA CUGGAGGAGAUGGUCAAGAAUC 685 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GUACACAUGUACAAUGCCCAAT 686 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC ACUUUUUGGAUACUUUGUGCCT 687 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCG CAAUUUAUGUUUUCCAAGCCAC 688 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC UCCCUGGAUAUUCUUAGUAGCG 689 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AGCUCGAAUUCCAGAAUGAUGA 690 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU UCAGCGAGGAAGCUACACUUUT 691 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC AUCAAGUCCUUUGACAGUGCAT 692 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC AGAAGUGGUUUCCUUUCUCACC 693 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA GUUUCGGACAGUACAAAGAACG 694 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AGUCCAAGUUGCUUCUCAGUCT 695 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC UUGGAGCAAGAAAAGGAAUUGC 696 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC CAAUCCAGAAAACCUUCCAUCG 697 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GUGUGCCAGAUACCAUUGAUGA 698 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC AUCAUUAUUCUGGCUGGAGCAA 699 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU GUAGGCUUUUGUUUCGUUUGUG 700 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU GGCAACAAACAAGAUACUGGUG 701 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC GUGGCUUUUGACAAUAUCUCCA 702 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AAUAACUCCUCGGUUCUAGGGC 703 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UCUGAGUAUGAGCUUCCCGAAG 704 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC GUCCAUCUUUUUAAGGGAUUGC 705 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU CAUUACGUCAACGCAACGUCUA 706 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC CACACAUAAACGGCAGUGUUAA 707 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GAAAAGCCUGUUUACCAAGGAG 708 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AGAUCUUCACCUAUGGAAAGCA 709 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCG UGUUGUGGGAGAUUUUCACCUA 710 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC UGACUUUUACUCCAGGCUAACUT 711 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG UCCUGGUCAUUUAUAGAAACCGA 712 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG UUCGUGGGCUUGUUUUGUAUCAA 713 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG UUGAAUGUAAGGCUUACAACGAT 714 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU GGUUCUGGAUUAGCUGGAUUGUC 715 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU GUGCCUCCUUCAGGAAUUCAAUC 716 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA CCAAGUUCUUUCUUUUGCACAGG 717 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GUGGGCUACAAGAACUACCGAUA 718 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA CCUCACCAUAGCUAAUCUUGGGA 719 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC AGCACUUCUGCAUUGGAACUAUT 720 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GCAUUGUGUGUUUUUGACCACUG 721 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC CUCAUUCCUUUUUCCUCUGUGUA 722 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC CAGCCAAGUAGAAUGUGAAAGAC 723 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UUUUCCUCCUACUCACCAUCCUG 724 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UCAAAUUGUUGCCAUUUCAGGGT 725 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GCCUGUUUUGUGUCUACUGUUCT 726 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG ACCAGAGCUUCAAGACUGUUUAG 727 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC CUCCUCCUCUUCCCUAGAUAACT 728 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA UCAUUCUUGAGGAGGAAGUAGCG 729 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA CUCUACCUCCAGCACAGAAUUUG 730 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UUAGACAACUACCUUUCUACGGA 731 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC CUUGUUGGUGUCCAUUUUCUUGT 732 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC UCCUCUUCAGAGGAGAAAGAAAC 733 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG ACUAAGAAUGGGAAGGAGUCACC 734 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC CUGUUCCUCCCAGUUUAAGAUUT 735 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC CAACACAAGAGAAAAUAUUUGCT 736 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC AUCUCAUUAAUGACAAUCAGCCA 737 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA GCAGAGGCAUCUGUAAAGUCAUG 738 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG CAGUUGAAAAACUCCUAGAAGCC 739 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GCAGUACACUACCAACAGAUCAA 740 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UUACCAGCUUUGACAAUACAGGA 741 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC CUCUGAGAAGUAUGUCUGAUCCA 742 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AAAGUACCAAUCAGAAGGACGUG 743 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU CAGAGCCAGAAUUUUGCAGAAGA 744 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC AACCAGAUGCAGUAUGAGUACAC 745 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC CAAGUCUUAUGGUUCUGGAUCAA 746 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AGUGAAACUGUGUGAGAAGAUGG 747 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU GUCUAACUCGGGAGACUAUGAAA 748 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AAAGAAACUCUUUCAUCUGCUGC 749 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU CUGGCGUUGGUGUUUUCAAAAUA 750 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG UGAAUAACAACUUGAGUGACGAG 751 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AGAUGCUGAAAUCCAGAAGCUGA 752 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA CUAGCUGCCAAGUACUUGGAUAA 753 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU AAUGCUGUUUCCUUUACCUGGGA 754 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG GUCAAAGAAUAUGGCCAGAAGAG 755 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU AAACCAACAGCUCACAAAGGAGA 756 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GAAGAGCAUCAACAAGAAGACCA 757 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU UGAAAUCCGCCUGAAUGAACAAG 758 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UUAAGGUUGAAGUGUGGUUCAGG 759 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU UUCUUUCUCAGAAAGCAGAGGCT 760 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG UAUCAACAUCACGGACAUCUCAA 761 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UCUAAAGAUCAAAACACCCCUGT 762 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA GAACGAGUAAAUCUGUCUGCAGC 763 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC AUCGUGAUUCAGGAGACAAUUCT 764 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG CUGUUUCUGGUGUUAUCAGUGAC 765 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA CAUGGCACUAGAAGAACGCUUAG 766 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC AAAGACAAAUGUGAAAUUGUGGG 767 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA CACAUUCAUUCAUAACACUGGGA 768 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU UAAUCAGCAAGCUUUCUCUGCUG 769 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GAUGCAAGCAGUUAUUGAUGCAA 770 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU AGCAAGAAGGAAGUGCCUAUCCA 771 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC CCACAGCUAAUUUGGACCAAAAG 772 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UUCUUCGUCUUAUCUUUGGGACC 773 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GGAAGCCAGAGUUUAUUAACUGC 774 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AUGAGAAGAAGCACCAUGACAAT 775 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AGGGUAAAGUUCACAAAAGACCA 776 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC CAAAAAUGUGCAUACUCACAGAG 777 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG UAUCAUCUCCUGAAGCAACAUCT 778 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UGGAUAAUGAAAGACUCCUUCCC 779 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC AGAUAGCAUACAAGAGACCAUGC 780 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AAGACCAAGAAGAACUUACUCCCT 781 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU GAUCUAUUUUUCCCUUUCUCCCCA 782 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG CAAGAGGCUUUGGAGUAUUUCAUG 783 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC AAAUGCUGAAAGCUGUACCAUACC 784 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC UAGGUGAAUACUGUUCGAGAGGUT 785 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU CCAUGCCUUUGAGAACCUAGAAAT 786 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU CAAAAGGAAGUAUCUUGGCCUCCA 787 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA ACGCUGUGCCAAUUUUGUAAAUGT 788 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA AUCAUGUUGCAGCAAUUCACUGUA 789 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA CUUUACCCUGUAAUAAUCCGUGCT 790 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GUGAUGAGAGUGACAUGUACUGUT 791 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GUCCCAACCAUGUCAAAAUUACAG 792 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU UGCCAACAUGACUUACUUGAUCCC 793 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU ACCCUCUUCAGCUCAGUUUCUUUC 794 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG UGAGAUCCAUUGACCUCAAUUUUG 795 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG UGGACCCCAAGCUUUAGUAAAUAT 796 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AUACCCCCUCCAUCAACUUCUUCA 797 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU CCAAAGAUCAAAGAGACGAAGUCT 798 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU UAGAGAACUACCCUGGAAUGACCC 799 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UUGCUUACCUGAGGAACUUAUUCA 800 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC ACAUUACAUACUUACCAUGCCACT 801 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG GAAGCUGUCCAUCAGUAUACAUUC 802 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG UCUAUAUCCAUCUCCAUGUCCUCT 803 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA UUAUUGUGGCCUGUUUGACUCUGT 804 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG ACUCUUUACUUCAAACUCUGAGCC 805 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU CGUCUUCGGAAAUGUUAUGAAGCA 806 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GAGAGUACUGAAUUCUUGCAGCAG 807 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC UUCAAAAUCAAGUUUGCUGAGACT 808 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC AAUUCACUAACAAGAAAACAGGGA 809 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AUACACAGACAAACUCCAGAAAGC 810 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU ACUGUUUGCUCCUAACUUGCUCUT 811 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GAGAGGAAAGUCCCUUAUUGAUUG 812 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG AGUGUGGUGGAGUUCAGUUUCUAT 813 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA GACCUUGCAGAAAUAGGAAUUGCT 814 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AGAAAAUGAAAAGGAGUUAGCAGC 815 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GUAACACAUCUUCUCAACCAGGAC 816 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG GAUUUUUCUUACCACAACAUGACA 817 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU UUCAGUUUGCUGAAGUCAAGGAGG 818 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AUUUCUUCUGAUGGUAGCUUUUGT 819 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GUCUACAAAAAGACCUGCUAGAGC 820 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU GUGGAUGAAACUUUGAUGUGUUCA 821 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AAUUAUGGACCAGACUCAGUGCCT 822 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCG GGAGGAAUUCAUCAUAUUCAACAG 823 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AAAGACAUGGAUGAAAGACGACGA 824 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG UAGGACUGUAGACAGUGAAACUUG 825 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU AUUGGGAUAUCCUUUCACUCUGCA 826 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU GAUCGGGAAACACAAAAACAUCAT 827 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU CCUAGCUGAAUGCUAUAACCUCUG 828 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU CCUGGUUAUAGGAAAUUACACUGGC 829 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU CCAAGCAAUUCUAUGCUAUACACAC 830 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA CAAAGAUUUGUGAUUUUGGUCUAGC 831 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU GACCAACUUUUCCCAGUUUCUCAAT 832 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC CUUUCCUCUGGAGUAUCUACAUGAA 833 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA CAGCAUCAAGCUAUGUACGUAGUUC 834 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AUUUCUUGUUACUUUUUCCCCAGAC 835 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA CUGUUGUUUCACAAGAUGAUGUUUG 836 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UUGACAGUUAAAGGCAUUUCCUGUG 837 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC CUUCGGCUUUUUCAACCCUUUUUAA 838 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AAACAACAUUCAACUCCCUACUUUG 839 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AUCAUCAACAUCAACAUUGCAGACT 840 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA UGGCUGAUCUUGAAGGUUUACACUT 841 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA AGUAUUACAAUAGAGCUGGGAUGGA 842 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AGGAUCCUGUAAUUAUUGAAAGAGC 843 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA GAAGACUUGACUGGUCUUACAUUGC 844 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG GAAGAAGCAGAUCAGAUACGAAAAA 845 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA CAGUAAAGAGAUUGUGGCUAUCAGC 846 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCG UAUACAAAGGAAACUCAGACUCCAG 847 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA UGAAUCAUUUGGAGGUGGAUUUGCT 848 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UCCACUUGUCAGUGAAGUUCAAAUA 849 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AGACUUGGAUCGAAUUCUCACUCUC 850 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AGGGAUCUUCCAGUAUGACUACCAT 851 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU AACGAAACAGACAGUCUUACAGAAG 852 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GAAACACUCAGAAAAACAGUUGAGG 853 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU AGAGGAAGAGUUAAGAAAGGCCAAC 854 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC AGAACAGGAUAUAACUACCUUGGAG 855 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA CAGUGAGAGACUUCAGUAUGAAAAA 856 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AUUAUGAGACCUACUGAUGUCCCUG 857 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU UCCUCAGGGAAUACUUUGAGAGGUT 858 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU UUGCAAGCUGAUAAUGAUUUCACCA 859 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UGCUCCAGCACUAAGUGUAUUUAAT 860 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UCACUUUCAAUAUCACGAAGACCAT 861 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AGAAACCACUGGAUGGAGAAUAUUT 862 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AUCGGUAGCCAAGCUGGAAAAGACA 863 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG GUUACUAGUUUAGAAGAAUCCCUGA 864 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GUUAUCCAAGUUCCCAACACAGAUC 865 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG UGGAAAAAGAUUUAGCAGGCUAGAC 866 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA GAAUGAAUCUGGCACAUGGAUUCAG 867 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC CGUGAUAGAAAAUAUACAGCGAGAA 868 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG UGGCUCAUAAAGCAUUUCUGAAAAA 869 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG CCUAUCAUAGUCAUUCAGUGAUUGUT 870 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA GUAGCUCCAAAUUAAUGAAUGUGCAT 871 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UCAUGUCUGAACUGAAGAUAAUGACT 872 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA CCCAAAUUGCUUCUGUCUGUUAAAUG 873 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA AAUGGUUUUCUUUUCUCCUCCAACCT 874 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU AGUGAUUAGUAAAGGAGCCCAAGAAT 875 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA UUAACUUACUUGCCACUGAAAAGUUG 876 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC GUGAAGAUCCCAUUGUCUAUGAAAUT 877 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC CUUCCUAGAGAGUUAGAGUAACUUCA 878 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU GUCUUUAUAUUCAUGACCUACUGGCA 879 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU GACCCCUUCCCAUCAAAAUUUUAUCT 880 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU CCCUUUGGGUUAUAAAUAGUGCACUC 881 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU CUUGACAAAGCAAAUAAAGACAAAGC 882 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU AAGGGAAAAUGACAAAGAACAGCUCA 883 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG GAAGAAAAGUGUUUUGAAAUGUGUUT 884 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA AAUCUUUUCUCAAUGAUGCUUGGCUC 885 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA GGAACUGUGUGCAAAAUCUUCAAUUG 886 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA AGAAUAAAAUGUCUAGCAGCAAGAAG 887 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AUCAGAUCUGGACUAUAUUAGGUCCC 888 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AACAGAUAUCCAGAACUAGUGAACUT 889 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG UGAAGAACUUAAAACUGUGACAGAGA 890 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UGAAAACCAAAUACGAUGAAGAAACT 891 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU GUUGACAACUAUGAUGACAUCAGAAC 892 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA UGAAGACUUCCUAGAGAAUUCACAUC 893 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU AAAGGACAAGGUAAGAAGAAGACAAG 894 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA ACUGGAGAAGAUGAUGACUAUGUUGA 895 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC CUGUGAAGAAAAUGUGUGUUGAUUUT 896 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU CAACAAACAGGACUAAGGAAAGGAAA 897 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UACUCAGCUGAAAAGCAGAGUUAAAA 898 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG GUUCUCACCCAUAUAUUGAUUUUCGT 899 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GAAAAUGAAGAGUUUGUUGAAGUGGG 900 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC AGUUCCUAGCAGAUUUAAUAGACGAG 901 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG GAAUUGGCUAUUCUUUACAACUGUAC 902 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AUUUCAAAGUGUUACCUCAAGAAGCA 903 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG ACAGAAUUGAAUCAGGGAGAUAUGAA 904 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA UAUAGUGAUCAGAGAUUAAGGCCAAG 905 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC AUAAAAUUCACAGGAAAUCAGAUCCA 906 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU UUUCAGGAGGUGUAAAACAAGAAAAA 907 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GAAAAAUGGCAAAGAAUUCAAACCUG 908 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UGUUCAAUUUUGUUGAGCUUCUGAAUT 909 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG AUCGGGAAGCAUAAGAAUAUCAUCAAC 910 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU AUUUAUUGGUCUCUCAUUCUCCCAUCC 911 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC CAAGUACAUAUCCUGUAAGACCAGAAT 912 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AGCCUAAUCUUUCAUUAUUACUGGGAA 913 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA CGGGUUAUUAACAUAUUUCAGAGCAAC 914 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA AAGCAGGGAUUUCAUUCAUCAUUAAGA 915 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UGUAAAUACGAAUCUUUCCAAAGGAGA 916 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GAAAGCGUUUGAGAAUCUUUUAGGACA 917 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA GUUGAAGAUUUACCACUGAAACUGACA 918 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UUUUUGGAAACAUACAGGAUAUCUACC 919 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC CAAUACUUCAGAAGACAAAUGUGAAAA 920 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA UUGAAGAAGCAUACAUGACAAAAUGUG 921 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG AUUUGGAUUUUCCUGCCUUAAGAAAAA 922 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG UACAAACAUUUCAAGAAGACAAAAGAT 923 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG UGAUAAUUUGCAACAUAGUAAGAAGGG 924 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC AGUCAGAAUAUUCCUGUUCCUACUACA 925 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU CUCAAAGUAAACUAUUGUUAGCAACCAT 926 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA AUGCAAAUUAGUUUCUUGCAAGAGAAAA 927 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG AUAAACUUCAGAAAGAACUCAAUGUACT 928 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA CUGGAGAGAUAUGUCAAGUCUUGUUUAC 929 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA UGACAAAAAGCUUCAGAGUUCUCUAAAA 930 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU GAGAAAGAAGAAGAAUUCCUCACUAAUG 931 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG AAAAGAACAAGAGAUGAAUUGAUAGAGT 932 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA UGCAAAUUUCACAGAGCCUCAGUUUUAT 933 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA AUACCAAAAGUUACCAAAACUGCAGACA 934 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AGAAGACCUUUCUGUGGAAAUAGAUGAC 935 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUU GGAAAUUAUGGAAAUCAAGCAACUUCAA 936 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU GGAAAAGGAGCACUUAAAUAAGGUUCAG 937 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC CUUUCUUGAAAAUAAUCUUGAACAGCUC 938 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GCUUAAAGUUGAUAAAGAGAAGUGGUUA 939 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA CCGGCAAAUUAAAGCAAUUAUGAAAGAA 940 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GCUACAUCAAUCCUUGAGUAUCCUAUUG 941 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG ACUGCACUUUUAUUCAUCAAUUCAUAGA 942 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA CAAGAUAAAGUGAUUUCAGGAAUAGCAA 943 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AAAGGAAAAUCUGCAAAGAACUUUCCUG 944 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AAGGAAUUAGAGAAUGCAAAUGACCUUC 945 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AAAUGCAGUCAGAUAUGGAGAAAAUCCA 946 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UACUACGAAAUUCUUAAUUCCCCUGACC 947 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG UUCCUAAUAUGUAUUGGGAUGUUGGUAA 948 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UCUCUUCGUCAUGAUCAACAAAUAUGGT 949 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC AGAAAUGGUUUCAAAUGAAUCUGUAGACT 950 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG AUCAUAUUCACUAAGCGCUACUAGAAACA 951 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA CAUGUUCAUGCUGUGUAUGUAAUAGAAUG 952 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU CAUCUCUAAGGUAUCUUCUAGAUCCAACA 953 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AAGCUUUAAAUGCACUAAAUAACCUGAGT 954 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AUAUGAUCAACUCCUGAAAGAACACUCUG 955 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GUUUACUCCAGUAAAAAUUGAAGGUUAUG 956 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA UAUUUGCGAUUAUUGAAGCUGCUUAAUGT 957 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC ACAGUUAAUAUGCCAGAAAAAGAAAGAAA 958 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA UCUGUGCUCAAUAAUCAGUUGUUAGAAAT 959 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUG GAUUUGUUUCUCAUUCUCAUAUUUCACCA 960 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AAUAAUUCUGUGGGAUCAUGAUCUGAAUC 961 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU CCGGGUAUAAUAAUGAAGUUAAAAGAGCA 962 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC UCAUAUUCUACUUCAUUCAGAAGAUCAGG 963 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC CGAUUUAAUUCACAUUUAUAAAGGCUUUG 964 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU AACUAAAUUGGAGAAAAGCAUUGAUGACT 965 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGU UUUCGAAUUUCUCGAACUAAUGUAUAGAAG 966 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA AAACAAAGUGGACAACUAGAAAGAUUUUGA 967 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UUCCUAAGUGCAAAAGAUAACUUUAUAUCA 968 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA CAUAACAGUUAUGAUUUUGCAGAAAACAGA 969 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UUUCAGAAAUUUCUUCAAAUAAACAGAACC 970 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG AAGAAUGACAAAGAUAAGAAGAUAGCUGAG 971 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA UGUAGAUUUUAAUCUGAACUUUGAACCAUC 972 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG GAGGAACUCUUUACUAUGAAGUUAAUAGAA 973 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGG AGAAGACAUCAACCAAUUAAUCAUAAAUAC 974 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAU UAUUUUCAUGCUUUGGAGAUUGGAUAUAGG 975 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AUCCUUAUCAAUCAUCAAUGAAAAAGUACC 976 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA UGAUUUACUUGGAGAAGAUUUGCUAUCUGG 977 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GGAAGAAAAUCAUCAAUUACGAAGUGAAAA 978 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG GAAGAAAUCAAGAUUCUUACUGAUAAACUC 979 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA GAACCAAUGAGAGACUAUCUCAAGAACUUG 980 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUA UGAUGAGACAGAUCCAUUUAUUGAUAACUC 981 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAA GAACUUAAACGAAAAUUGAACAUUCUGACT 982 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG CAAGCUGGUAUUUUCAUACAAAUUCUUCUA 983 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UAGCUACACUGAAAAAUUAUAAUGAAGUAGG 984 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GUAAACUGACUCUAAACUUAAAAUCUUACCT 985 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA GAUAUUUAUCCAAACAUUAUUGCUAUGGGAT 986 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAC UAAAUAGUUUAAGAUGAGUCAUAUUUGUGGG 987 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUUC UCAUCUCUAAAGGAUUUAAUUACAAAGAUGC 988 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU CUAUGUAGUCUCUGAAAAUGGAAGAAAAUAT 989 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA ACAAGAUAGAAGAUUUGGAGCAAGAAAUAAA 990 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCA UGCAACUUACUGAAAAAUACUAUAAAUGACC 991 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UUAUUAAAGAACUUUCUAAAGUAAUUCGAGC 992 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCU CAGGACUCAUUAUUUUAACAUUUGGGAGAAA 993 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGC CCUAUAUUUGCAUUAAAAUGGAAUAAGAAAG 994 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUGA AUUAAAUGCCCACAUAAAACUUUCUAAUUUG 995 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUAG UUGCUAUAUUUACACUGAUGGUAGAAAUAAA 996 TCTGTACGGTGACAAGGCGUNNNACTNNNTGAUCC UAUAUUACAGAUUCUAUUCAUGAACAAUGCT Each N independently is A, C, G or T 

1-20. (canceled)
 21. A composition for a single stream multiplex determination of actionable oncology biomarkers in a sample, the composition comprising a plurality of sets of primer pair reagents directed to a plurality of target sequences to detect low level targets in the sample, wherein the target genes consist of the following functions: DNA hotspot mutation genes, copy number variation (CNV) genes, inter-genetic fusion genes, and intra-genetic fusion genes; and wherein the plurality of sets of primer pair reagents comprise two or more primers of any of SEQ ID NO: 1-SEQ ID NO:
 1563. 22. The composition of claim 21, wherein the one or more actionable target genes in a sample determines a change in oncology activity in the sample indicative of a potential diagnosis, prognosis, candidate therapeutic regimen, and/or adverse event.
 23. The composition of claim 21, wherein the target genes comprise one or more of AKT1, AKT2, AKT3, ALK, AR, ARAF, BRAF, CDK4, CD274, CDKN2A, CHEK2, CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MET, MTOR, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, RSPO2, RSPO3, SMO, and TP53.
 24. The composition of claim 21, wherein the target genes comprise AKT1, AKT2, AKT3, ALK, AR, ARAF, BRAF, CDK4, CD274, CDKN2A, CHEK2, CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MET, MTOR, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, RSPO2, RSPO3, SMO, and TP53.
 25. The composition of claim 21, wherein the plurality of target sequences comprise one or more of the amplicon sequences detected by the primers of SEQ ID NO: 1-SEQ ID NO:
 1563. 26. The composition of claim 21, wherein the plurality of target sequences comprise each of the amplicon sequences detected by the primers of SEQ ID NO: 1-SEQ ID NO:
 1563. 27. The composition of claim 21, wherein the plurality of sets of primer pair reagents comprise the primers of SEQ ID NO: 1-SEQ ID NO:
 1563. 28. The composition of claim 21, wherein the plurality of sets of primer pair reagents consist of each of the primers of SEQ ID NO: 1-SEQ ID NO:
 1563. 29. A multiplex assay comprising the composition of claim
 25. 30. A test kit comprising the composition of claim
 25. 31. A method for determining the presence of one or more actionable oncology biomarkers in a biological sample, comprising: multiplex amplification of a plurality of target oncology sequences from the biological sample, wherein amplifying comprises contacting at least a portion of the sample with the composition of claim 21 and a polymerase under amplification conditions, thereby producing amplified target oncology sequences; detecting each of the plurality of target oncology sequences, wherein detection of one or more actionable oncology biomarkers as compared with a control sample determines a change in oncology activity in the sample indicative of a potential diagnosis, prognosis, candidate therapeutic regimen, and/or adverse event.
 32. The method of claim 31, wherein target genes are selected from the group consisting of DNA hotspot mutation genes, copy number variation (CNV) genes, inter-genetic fusion genes, and intra-genetic fusion genes.
 33. The method of claim 31, wherein the target genes comprise one or more of AKT1, AKT2, AKT3, ALK, AR, ARAF, BRAF, CDK4, CD274, CDKN2A, CHEK2, CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MET, MTOR, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, RSPO2, RSPO3, SMO, and TP53.
 34. The method of claim 31, wherein the target genes comprise AKT1, AKT2, AKT3, ALK, AR, ARAF, BRAF, CDK4, CD274, CDKN2A, CHEK2, CTNNB1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MET, MTOR, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, RSPO2, RSPO3, SMO, and TP53.
 35. The method of claim 31, wherein the plurality of target sequences comprise one or more of the amplicon sequences detected by the primers of SEQ ID NO: 1-SEQ ID NO:
 1563. 36. The method of claim 31, wherein the plurality of target sequences comprise each of the amplicon sequences detected by the primers of SEQ ID NO: 1-SEQ ID NO:
 1563. 37. The method of claim 31, wherein the plurality of sets of primer pair reagents comprise the primers of SEQ ID NO: 1-SEQ ID NO:
 1563. 38. The method of claim 31, wherein the plurality of sets of primer pair reagents consist of each of the primers of SEQ ID NO: 1-SEQ ID NO:
 1563. 39. The method of claim 31, wherein the biological sample comprises a tumor and/or tissue surrounding a tumor.
 40. The method of claim 31, wherein the biological sample and the control sample are from the same individual. 